Samples for study ST001237
Species: Homo sapiens (Factor headings shown in green)mb_sample_id | Subject name | Sample name | Time point | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS) | CRF_MSKCC_Risk_Group | Treatment | Prior antiangiogenic regimens (≥2) | Sample_Data:OS (Overall Survival, months) | Trial | Region | Derived_Age_at_Consent | Sex | Race | raw file name |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SA089172 | CA209025-1-1048 | CA209025-1-1048_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 38.275 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0227_Marios_PD1_Inhib2_HP-AF439758-9.raw |
SA089186 | CA209025-1-110 | CA209025-1-110_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 34.793 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0726_Marios_PD1_Inhib2_HP-AD424475-8.raw |
SA089174 | CA209025-114-56 | CA209025-114-56_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 52.403 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | F | WHITE | 0603_Marios_PD1_Inhib2_HP-E9123054-7.raw |
SA089179 | CA209025-11-481 | CA209025-11-481_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 29.339 | Phase III_RCC_CA209025 | US/CANADA | 55 | M | WHITE | 0637_Marios_PD1_Inhib2_HP-AD604107-7.raw |
SA089182 | CA209025-12-216 | CA209025-12-216_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 35.647 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | F | WHITE | 1161_Marios_PD1_Inhib2_HP-E9108720-7.raw |
SA089185 | CA209025-12-275 | CA209025-12-275_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 48.296 | Phase III_RCC_CA209025 | WESTERN EUROPE | 56 | M | WHITE | 0228_Marios_PD1_Inhib2_HP-EA000634-7.raw |
SA089187 | CA209025-135-434 | CA209025-135-434_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 46.949 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | F | WHITE | 0782_Marios_PD1_Inhib2_HP-L1366488-10.raw |
SA089201 | CA209025-139-224 | CA209025-139-224_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 48.230 | Phase III_RCC_CA209025 | US/CANADA | 55 | M | WHITE | 0335_Marios_PD1_Inhib2_HP-AE052725-7.raw |
SA089203 | CA209025-139-227 | CA209025-139-227_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 46.883 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 1188_Marios_PD1_Inhib2_HP-AE052720-7.raw |
SA089188 | CA209025-139-827 | CA209025-139-827_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 43.138 | Phase III_RCC_CA209025 | US/CANADA | 69 | F | WHITE | 0554_Marios_PD1_Inhib2_HP-AE913730-7.raw |
SA089173 | CA209025-141-667 | CA209025-141-667_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 28.583 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0362_Marios_PD1_Inhib2_HP-AE462180-7.raw |
SA089170 | CA209025-141-730 | CA209025-141-730_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 34.793 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0712_Marios_PD1_Inhib2_HP-AD780394-7.raw |
SA089202 | CA209025-14-943 | CA209025-14-943_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 41.429 | Phase III_RCC_CA209025 | US/CANADA | 75 | F | WHITE | 0929_Marios_PD1_Inhib2_HP-AE902415-7.raw |
SA089171 | CA209025-154-1019 | CA209025-154-1019_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 39.754 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | OTHER | 0707_Marios_PD1_Inhib2_HP-S4107199-9.raw |
SA089190 | CA209025-154-125 | CA209025-154-125_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 34.168 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | M | OTHER | 0835_Marios_PD1_Inhib2_HP-S3470295-7.raw |
SA089207 | CA209025-158-182 | CA209025-158-182_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 49.774 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | OTHER | 0224_Marios_PD1_Inhib2_HP-S3473954-7.raw |
SA089206 | CA209025-159-812 | CA209025-159-812_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 43.400 | Phase III_RCC_CA209025 | REST OF WORLD | 68 | M | OTHER | 1205_Marios_PD1_Inhib2_HP-S4005764-7.raw |
SA089184 | CA209025-159-994 | CA209025-159-994_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 24.476 | Phase III_RCC_CA209025 | REST OF WORLD | 60 | F | OTHER | 0319_Marios_PD1_Inhib2_HP-S4199733-8.raw |
SA089169 | CA209025-160-157 | CA209025-160-157_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 50.201 | Phase III_RCC_CA209025 | REST OF WORLD | 71 | M | OTHER | 0390_Marios_PD1_Inhib2_HP-S3474788-7.raw |
SA089183 | CA209025-174-235 | CA209025-174-235_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 32.953 | Phase III_RCC_CA209025 | REST OF WORLD | 72 | M | OTHER | 1053_Marios_PD1_Inhib2_HP-S3733281-7.raw |
SA089181 | CA209025-180-937 | CA209025-180-937_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 27.860 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | M | WHITE | 0878_Marios_PD1_Inhib2_HP-E9784760-7.raw |
SA089176 | CA209025-1-96 | CA209025-1-96_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 51.384 | Phase III_RCC_CA209025 | US/CANADA | 54 | M | WHITE | 1086_Marios_PD1_Inhib2_HP-AD185795-7.raw |
SA089178 | CA209025-20-946 | CA209025-20-946_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 41.298 | Phase III_RCC_CA209025 | US/CANADA | 55 | M | WHITE | 0558_Marios_PD1_Inhib2_HP-AF002811-9.raw |
SA089177 | CA209025-2-210 | CA209025-2-210_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 31.967 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | OTHER | 0881_Marios_PD1_Inhib2_HP-E9657513-7.raw |
SA089180 | CA209025-2-792 | CA209025-2-792_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 25.331 | Phase III_RCC_CA209025 | WESTERN EUROPE | 68 | F | WHITE | 1218_Marios_PD1_Inhib2_HP-E9618949-7.raw |
SA089175 | CA209025-39-133 | CA209025-39-133_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 39.951 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | F | WHITE | 0239_Marios_PD1_Inhib2_HP-E9204601-7.raw |
SA089205 | CA209025-42-441 | CA209025-42-441_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 47.606 | Phase III_RCC_CA209025 | US/CANADA | 65 | F | WHITE | 0720_Marios_PD1_Inhib2_HP-AE155083-7.raw |
SA089200 | CA209025-43-787 | CA209025-43-787_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 26.809 | Phase III_RCC_CA209025 | US/CANADA | 61 | F | WHITE | 0446_Marios_PD1_Inhib2_HP-AE794300-7.raw |
SA089198 | CA209025-50-281 | CA209025-50-281_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 29.963 | Phase III_RCC_CA209025 | WESTERN EUROPE | 61 | M | WHITE | 0965_Marios_PD1_Inhib2_HP-E9721147-7.raw |
SA089204 | CA209025-65-579 | CA209025-65-579_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 45.733 | Phase III_RCC_CA209025 | WESTERN EUROPE | 86 | M | WHITE | 1222_Marios_PD1_Inhib2_HP-EA048754-7.raw |
SA089196 | CA209025-82-690 | CA209025-82-690_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 44.419 | Phase III_RCC_CA209025 | WESTERN EUROPE | 41 | M | WHITE | 0926_Marios_PD1_Inhib2_HP-EA305476-7.raw |
SA089195 | CA209025-82-745 | CA209025-82-745_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 44.090 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 0080_Marios_PD1_Inhib2_HP-EA305477-7.raw |
SA089197 | CA209025-84-861 | CA209025-84-861_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 27.466 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | WHITE | 0608_Marios_PD1_Inhib2_HP-L1381828-7.raw |
SA089194 | CA209025-87-548 | CA209025-87-548_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 46.554 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | F | WHITE | 0723_Marios_PD1_Inhib2_HP-E9774328-7.raw |
SA089193 | CA209025-89-33 | CA209025-89-33_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 37.027 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | M | WHITE | 0589_Marios_PD1_Inhib2_HP-E9073345-7.raw |
SA089191 | CA209025-92-806 | CA209025-92-806_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 27.236 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | WHITE | 1020_Marios_PD1_Inhib2_HP-E9123073-7.raw |
SA089192 | CA209025-93-212 | CA209025-93-212_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 35.877 | Phase III_RCC_CA209025 | WESTERN EUROPE | 47 | F | WHITE | 1038_Marios_PD1_Inhib2_HP-E9123037-7.raw |
SA089199 | CA209025-93-274 | CA209025-93-274_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 48.493 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 0617_Marios_PD1_Inhib2_HP-E9791865-7.raw |
SA089189 | CA209025-9-649 | CA209025-9-649_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | FALSE | 26.152 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 1171_Marios_PD1_Inhib2_HP-AE556393-6.raw |
SA089214 | CA209025-103-747 | CA209025-103-747_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 43.992 | Phase III_RCC_CA209025 | REST OF WORLD | 81 | M | WHITE | 0148_Marios_PD1_Inhib2_HP-E9648565-7.raw |
SA089215 | CA209025-1-1056 | CA209025-1-1056_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 22.801 | Phase III_RCC_CA209025 | US/CANADA | 76 | M | WHITE | 0200_Marios_PD1_Inhib2_HP-AF439757-9.raw |
SA089219 | CA209025-111-657 | CA209025-111-657_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 25.692 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | F | WHITE | 0582_Marios_PD1_Inhib2_HP-EA003798-7.raw |
SA089218 | CA209025-138-699 | CA209025-138-699_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 43.532 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0139_Marios_PD1_Inhib2_HP-AE428477-7.raw |
SA089216 | CA209025-139-741 | CA209025-139-741_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 27.368 | Phase III_RCC_CA209025 | US/CANADA | 67 | F | WHITE | 0869_Marios_PD1_Inhib2_HP-AE861577-7.raw |
SA089213 | CA209025-139-775 | CA209025-139-775_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 43.598 | Phase III_RCC_CA209025 | US/CANADA | 73 | M | WHITE | 0490_Marios_PD1_Inhib2_HP-AE645250-7.raw |
SA089211 | CA209025-158-77 | CA209025-158-77_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 35.220 | Phase III_RCC_CA209025 | REST OF WORLD | 60 | M | OTHER | 0225_Marios_PD1_Inhib2_HP-S3473953-7.raw |
SA089220 | CA209025-2-67 | CA209025-2-67_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 33.380 | Phase III_RCC_CA209025 | WESTERN EUROPE | 61 | M | OTHER | 0160_Marios_PD1_Inhib2_HP-E9130936-7.raw |
SA089217 | CA209025-41-455 | CA209025-41-455_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 36.928 | Phase III_RCC_CA209025 | US/CANADA | 69 | M | OTHER | 0636_Marios_PD1_Inhib2_HP-AD604542-7.raw |
SA089212 | CA209025-44-464 | CA209025-44-464_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 27.959 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 0577_Marios_PD1_Inhib2_HP-AE002908-7.raw |
SA089209 | CA209025-47-1037 | CA209025-47-1037_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 40.476 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0567_Marios_PD1_Inhib2_HP-AF016166-10.raw |
SA089221 | CA209025-58-162 | CA209025-58-162_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 50.858 | Phase III_RCC_CA209025 | WESTERN EUROPE | 57 | M | OTHER | 0038_Marios_PD1_Inhib2_HP-E9425615-7.raw |
SA089210 | CA209025-86-735 | CA209025-86-735_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 44.090 | Phase III_RCC_CA209025 | WESTERN EUROPE | 51 | M | WHITE | 0350_Marios_PD1_Inhib2_HP-E9164126-7.raw |
SA089208 | CA209025-87-229 | CA209025-87-229_baseline | baseline | 1 | FAVORABLE | EVEROLIMUS | TRUE | 33.643 | Phase III_RCC_CA209025 | WESTERN EUROPE | 61 | M | WHITE | 0623_Marios_PD1_Inhib2_HP-E9103644-7.raw |
SA089258 | CA209025-101-142 | CA209025-101-142_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 51.187 | Phase III_RCC_CA209025 | WESTERN EUROPE | 73 | M | WHITE | 0634_Marios_PD1_Inhib2_HP-E9123031-7.raw |
SA089256 | CA209025-118-255 | CA209025-118-255_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 49.380 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | F | WHITE | 0412_Marios_PD1_Inhib2_HP-E9712824-7.raw |
SA089246 | CA209025-13-181 | CA209025-13-181_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.234 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 0466_Marios_PD1_Inhib2_HP-AD827408-7.raw |
SA089245 | CA209025-138-734 | CA209025-138-734_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.682 | Phase III_RCC_CA209025 | US/CANADA | 62 | F | WHITE | 1189_Marios_PD1_Inhib2_HP-AE428478-7.raw |
SA089243 | CA209025-139-1006 | CA209025-139-1006_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 39.589 | Phase III_RCC_CA209025 | US/CANADA | 46 | M | WHITE | 0920_Marios_PD1_Inhib2_HP-AF003923-9.raw |
SA089252 | CA209025-154-929 | CA209025-154-929_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 42.481 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | M | OTHER | 1155_Marios_PD1_Inhib2_HP-S4107200-9.raw |
SA089253 | CA209025-156-1017 | CA209025-156-1017_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 39.918 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | OTHER | 1050_Marios_PD1_Inhib2_HP-S4124106-9.raw |
SA089251 | CA209025-15-773 | CA209025-15-773_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.090 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0331_Marios_PD1_Inhib2_HP-AE562609-7.raw |
SA089250 | CA209025-15-99 | CA209025-15-99_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 51.515 | Phase III_RCC_CA209025 | US/CANADA | 51 | M | WHITE | 0734_Marios_PD1_Inhib2_HP-AD267739-7.raw |
SA089254 | CA209025-161-577 | CA209025-161-577_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 45.339 | Phase III_RCC_CA209025 | REST OF WORLD | 46 | M | OTHER | 0287_Marios_PD1_Inhib2_HP-S3672131-7.raw |
SA089249 | CA209025-161-974 | CA209025-161-974_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.936 | Phase III_RCC_CA209025 | REST OF WORLD | 69 | F | OTHER | 0517_Marios_PD1_Inhib2_HP-S4103669-8.raw |
SA089248 | CA209025-162-171 | CA209025-162-171_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.037 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | F | OTHER | 1174_Marios_PD1_Inhib2_HP-S3475115-7.raw |
SA089242 | CA209025-169-660 | CA209025-169-660_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.419 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 0842_Marios_PD1_Inhib2_HP-S3606414-7.raw |
SA089257 | CA209025-170-221 | CA209025-170-221_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.201 | Phase III_RCC_CA209025 | REST OF WORLD | 45 | M | OTHER | 0777_Marios_PD1_Inhib2_HP-S3474749-7.raw |
SA089244 | CA209025-17-1044 | CA209025-17-1044_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 39.524 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0378_Marios_PD1_Inhib2_HP-AE613960-7.raw |
SA089263 | CA209025-173-757 | CA209025-173-757_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 22.111 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | M | OTHER | 0496_Marios_PD1_Inhib2_HP-S3575912-7.raw |
SA089241 | CA209025-174-1010 | CA209025-174-1010_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.049 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | OTHER | 0982_Marios_PD1_Inhib2_HP-S4107168-9.raw |
SA089247 | CA209025-17-928 | CA209025-17-928_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 42.283 | Phase III_RCC_CA209025 | US/CANADA | 77 | M | WHITE | 1057_Marios_PD1_Inhib2_HP-AF015796-9.raw |
SA089264 | CA209025-18-954 | CA209025-18-954_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 41.922 | Phase III_RCC_CA209025 | US/CANADA | 43 | M | OTHER | 0678_Marios_PD1_Inhib2_HP-AF008928-9.raw |
SA089265 | CA209025-2-10 | CA209025-2-10_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 53.848 | Phase III_RCC_CA209025 | WESTERN EUROPE | 71 | F | WHITE | 0253_Marios_PD1_Inhib2_HP-E9064309-7.raw |
SA089266 | CA209025-21-1027 | CA209025-21-1027_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 34.267 | Phase III_RCC_CA209025 | US/CANADA | 69 | F | WHITE | 0934_Marios_PD1_Inhib2_HP-AF063577-9.raw |
SA089260 | CA209025-21-1039 | CA209025-21-1039_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 31.803 | Phase III_RCC_CA209025 | US/CANADA | 59 | F | WHITE | 0892_Marios_PD1_Inhib2_HP-AF063576-9.raw |
SA089261 | CA209025-21-849 | CA209025-21-849_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.312 | Phase III_RCC_CA209025 | US/CANADA | 52 | F | WHITE | 0783_Marios_PD1_Inhib2_HP-AE622889-10.raw |
SA089259 | CA209025-22-1000 | CA209025-22-1000_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.969 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 0439_Marios_PD1_Inhib2_HP-AE302092-6.raw |
SA089262 | CA209025-23-8 | CA209025-23-8_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 12.485 | Phase III_RCC_CA209025 | US/CANADA | 46 | M | WHITE | 1002_Marios_PD1_Inhib2_HP-AD195648-7.raw |
SA089255 | CA209025-24-840 | CA209025-24-840_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 42.842 | Phase III_RCC_CA209025 | US/CANADA | 23 | F | WHITE | 0538_Marios_PD1_Inhib2_HP-AE003497-7.raw |
SA089223 | CA209025-29-1002 | CA209025-29-1002_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.674 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0482_Marios_PD1_Inhib2_HP-AF127960-9.raw |
SA089224 | CA209025-39-147 | CA209025-39-147_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.201 | Phase III_RCC_CA209025 | WESTERN EUROPE | 56 | M | WHITE | 1018_Marios_PD1_Inhib2_HP-E9432885-6.raw |
SA089222 | CA209025-41-979 | CA209025-41-979_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 41.035 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | OTHER | 0583_Marios_PD1_Inhib2_HP-AE525980-7.raw |
SA089226 | CA209025-43-248 | CA209025-43-248_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 28.780 | Phase III_RCC_CA209025 | US/CANADA | 79 | M | WHITE | 0595_Marios_PD1_Inhib2_HP-AD452609-7.raw |
SA089240 | CA209025-43-743 | CA209025-43-743_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 22.965 | Phase III_RCC_CA209025 | US/CANADA | 44 | M | WHITE | 1076_Marios_PD1_Inhib2_HP-AE586111-7.raw |
SA089236 | CA209025-43-941 | CA209025-43-941_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 22.012 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | WHITE | 0599_Marios_PD1_Inhib2_HP-AF003942-9.raw |
SA089235 | CA209025-44-643 | CA209025-44-643_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 45.043 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0721_Marios_PD1_Inhib2_HP-AE002907-7.raw |
SA089227 | CA209025-65-329 | CA209025-65-329_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 48.066 | Phase III_RCC_CA209025 | WESTERN EUROPE | 83 | F | WHITE | 0070_Marios_PD1_Inhib2_HP-EA048756-7.raw |
SA089237 | CA209025-6-586 | CA209025-6-586_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 45.273 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0745_Marios_PD1_Inhib2_HP-E9125345-7.raw |
SA089238 | CA209025-72-394 | CA209025-72-394_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 47.934 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 0624_Marios_PD1_Inhib2_HP-E9145479-7.raw |
SA089239 | CA209025-73-511 | CA209025-73-511_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 46.324 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | M | OTHER | 1115_Marios_PD1_Inhib2_HP-E9717900-7.raw |
SA089234 | CA209025-75-112 | CA209025-75-112_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 51.220 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | M | WHITE | 0668_Marios_PD1_Inhib2_HP-E9479164-6.raw |
SA089233 | CA209025-82-338 | CA209025-82-338_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 47.901 | Phase III_RCC_CA209025 | WESTERN EUROPE | 68 | M | WHITE | 0586_Marios_PD1_Inhib2_HP-E9703898-7.raw |
SA089230 | CA209025-89-174 | CA209025-89-174_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.398 | Phase III_RCC_CA209025 | WESTERN EUROPE | 48 | M | WHITE | 0115_Marios_PD1_Inhib2_HP-E9073344-7.raw |
SA089232 | CA209025-89-725 | CA209025-89-725_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 43.926 | Phase III_RCC_CA209025 | WESTERN EUROPE | 45 | M | WHITE | 0342_Marios_PD1_Inhib2_HP-E9656487-7.raw |
SA089229 | CA209025-90-105 | CA209025-90-105_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.727 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | F | WHITE | 0646_Marios_PD1_Inhib2_HP-E9103086-7.raw |
SA089231 | CA209025-9-756 | CA209025-9-756_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 43.302 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0512_Marios_PD1_Inhib2_HP-AE679322-8.raw |
SA089225 | CA209025-97-765 | CA209025-97-765_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.058 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | F | WHITE | 0261_Marios_PD1_Inhib2_HP-S4008627-7.raw |
SA089228 | CA209025-9-892 | CA209025-9-892_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | FALSE | 43.072 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | WHITE | 1199_Marios_PD1_Inhib2_HP-AF002738-2.raw |
SA089271 | CA209025-111-299 | CA209025-111-299_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 47.639 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | WHITE | 0996_Marios_PD1_Inhib2_HP-EA003794-7.raw |
SA089270 | CA209025-114-813 | CA209025-114-813_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 43.926 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | M | WHITE | 0348_Marios_PD1_Inhib2_HP-EA341118-7.raw |
SA089273 | CA209025-139-1036 | CA209025-139-1036_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 38.571 | Phase III_RCC_CA209025 | US/CANADA | 72 | M | WHITE | 0767_Marios_PD1_Inhib2_HP-AF003924-9.raw |
SA089272 | CA209025-139-610 | CA209025-139-610_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 44.649 | Phase III_RCC_CA209025 | US/CANADA | 58 | F | WHITE | 0977_Marios_PD1_Inhib2_HP-AE052721-7.raw |
SA089274 | CA209025-161-518 | CA209025-161-518_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 45.667 | Phase III_RCC_CA209025 | REST OF WORLD | 69 | F | OTHER | 0284_Marios_PD1_Inhib2_HP-S3672129-7.raw |
SA089275 | CA209025-17-154 | CA209025-17-154_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 51.055 | Phase III_RCC_CA209025 | US/CANADA | 40 | M | WHITE | 0732_Marios_PD1_Inhib2_HP-AD577685-7.raw |
SA089276 | CA209025-17-94 | CA209025-17-94_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 51.220 | Phase III_RCC_CA209025 | US/CANADA | 75 | F | WHITE | 0485_Marios_PD1_Inhib2_HP-AD577686-7.raw |
SA089277 | CA209025-2-401 | CA209025-2-401_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 46.719 | Phase III_RCC_CA209025 | WESTERN EUROPE | 29 | M | WHITE | 0796_Marios_PD1_Inhib2_HP-E9618951-7.raw |
SA089278 | CA209025-33-466 | CA209025-33-466_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 47.146 | Phase III_RCC_CA209025 | WESTERN EUROPE | 57 | M | WHITE | 0524_Marios_PD1_Inhib2_HP-E9811934-7.raw |
SA089279 | CA209025-65-340 | CA209025-65-340_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 47.672 | Phase III_RCC_CA209025 | WESTERN EUROPE | 45 | F | WHITE | 0295_Marios_PD1_Inhib2_HP-EA048757-7.raw |
SA089269 | CA209025-93-836 | CA209025-93-836_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 42.743 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 0770_Marios_PD1_Inhib2_HP-EA214037-7.raw |
SA089268 | CA209025-95-167 | CA209025-95-167_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 49.807 | Phase III_RCC_CA209025 | REST OF WORLD | 53 | M | WHITE | 0870_Marios_PD1_Inhib2_HP-S3447247-7.raw |
SA089267 | CA209025-97-264 | CA209025-97-264_baseline | baseline | 1 | FAVORABLE | NIVOLUMAB | TRUE | 48.197 | Phase III_RCC_CA209025 | REST OF WORLD | 56 | M | WHITE | 0206_Marios_PD1_Inhib2_HP-S3708672-7.raw |
SA089296 | CA209025-104-911 | CA209025-104-911_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 18.924 | Phase III_RCC_CA209025 | REST OF WORLD | 79 | M | WHITE | 0999_Marios_PD1_Inhib2_HP-E9649574-7.raw |
SA089295 | CA209025-1-1023 | CA209025-1-1023_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 40.214 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 0909_Marios_PD1_Inhib2_HP-AE471828-6.raw |
SA089283 | CA209025-111-738 | CA209025-111-738_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 27.335 | Phase III_RCC_CA209025 | REST OF WORLD | 67 | M | WHITE | 0109_Marios_PD1_Inhib2_HP-EA003796-7.raw |
SA089284 | CA209025-118-151 | CA209025-118-151_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 35.844 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | M | WHITE | 0017_Marios_PD1_Inhib2_HP-E9314437-7.raw |
SA089280 | CA209025-118-164 | CA209025-118-164_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 49.938 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 0076_Marios_PD1_Inhib2_HP-E9655432-7.raw |
SA089286 | CA209025-118-242 | CA209025-118-242_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 49.216 | Phase III_RCC_CA209025 | WESTERN EUROPE | 56 | M | WHITE | 1158_Marios_PD1_Inhib2_HP-E9655430-7.raw |
SA089292 | CA209025-118-768 | CA209025-118-768_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 44.189 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | M | WHITE | 1101_Marios_PD1_Inhib2_HP-E9712821-13.raw |
SA089293 | CA209025-1-1 | CA209025-1-1_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 39.557 | Phase III_RCC_CA209025 | US/CANADA | 47 | M | WHITE | 0800_Marios_PD1_Inhib2_HP-AD185796-7.raw |
SA089290 | CA209025-125-637 | CA209025-125-637_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 45.437 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | M | WHITE | 0326_Marios_PD1_Inhib2_HP-L1384311-7.raw |
SA089294 | CA209025-126-298 | CA209025-126-298_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 23.491 | Phase III_RCC_CA209025 | WESTERN EUROPE | 72 | F | WHITE | 1118_Marios_PD1_Inhib2_HP-E9755278-7.raw |
SA089288 | CA209025-131-1043 | CA209025-131-1043_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 40.312 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | F | WHITE | 0506_Marios_PD1_Inhib2_HP-EA720987-9.raw |
SA089291 | CA209025-131-939 | CA209025-131-939_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 18.628 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | WHITE | 0590_Marios_PD1_Inhib2_HP-E9786648-7.raw |
SA089287 | CA209025-139-144 | CA209025-139-144_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 50.103 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0018_Marios_PD1_Inhib2_HP-AD585852-7.raw |
SA089285 | CA209025-139-271 | CA209025-139-271_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 48.657 | Phase III_RCC_CA209025 | US/CANADA | 50 | M | WHITE | 0831_Marios_PD1_Inhib2_HP-AE052724-7.raw |
SA089282 | CA209025-139-895 | CA209025-139-895_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 25.396 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0773_Marios_PD1_Inhib2_HP-AF048311-9.raw |
SA089281 | CA209025-14-1070 | CA209025-14-1070_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 38.505 | Phase III_RCC_CA209025 | US/CANADA | 59 | F | WHITE | 1176_Marios_PD1_Inhib2_HP-AE902414-7.raw |
SA089289 | CA209025-149-672 | CA209025-149-672_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 37.815 | Phase III_RCC_CA209025 | REST OF WORLD | 67 | M | WHITE | 0622_Marios_PD1_Inhib2_HP-EA039695-7.raw |
SA089317 | CA209025-155-156 | CA209025-155-156_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 50.201 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | OTHER | 0565_Marios_PD1_Inhib2_HP-S3578237-7.raw |
SA089316 | CA209025-160-158 | CA209025-160-158_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 35.154 | Phase III_RCC_CA209025 | REST OF WORLD | 75 | M | OTHER | 0010_Marios_PD1_Inhib2_HP-S3474786-7.raw |
SA089315 | CA209025-162-614 | CA209025-162-614_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 44.977 | Phase III_RCC_CA209025 | REST OF WORLD | 68 | F | OTHER | 0955_Marios_PD1_Inhib2_HP-S3667126-7.raw |
SA089314 | CA209025-163-382 | CA209025-163-382_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 31.310 | Phase III_RCC_CA209025 | REST OF WORLD | 68 | M | OTHER | 0014_Marios_PD1_Inhib2_HP-S3675225-7.raw |
SA089319 | CA209025-165-850 | CA209025-165-850_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 43.039 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | OTHER | 0060_Marios_PD1_Inhib2_HP-S4035311-7.raw |
SA089297 | CA209025-17-556 | CA209025-17-556_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 15.212 | Phase III_RCC_CA209025 | US/CANADA | 43 | M | WHITE | 0437_Marios_PD1_Inhib2_HP-AE522913-7.raw |
SA089318 | CA209025-2-180 | CA209025-2-180_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 37.224 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | M | WHITE | 0924_Marios_PD1_Inhib2_HP-E9657508-7.raw |
SA089312 | CA209025-21-927 | CA209025-21-927_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 37.782 | Phase III_RCC_CA209025 | US/CANADA | 72 | F | WHITE | 1137_Marios_PD1_Inhib2_HP-AF063579-9.raw |
SA089320 | CA209025-2-290 | CA209025-2-290_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 30.160 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | M | WHITE | 0357_Marios_PD1_Inhib2_HP-E9657510-7.raw |
SA089302 | CA209025-23-536 | CA209025-23-536_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 46.029 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0779_Marios_PD1_Inhib2_HP-AE070739-7.raw |
SA089303 | CA209025-25-202 | CA209025-25-202_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 49.380 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0428_Marios_PD1_Inhib2_HP-AD775403-7.raw |
SA089301 | CA209025-38-430 | CA209025-38-430_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 37.980 | Phase III_RCC_CA209025 | WESTERN EUROPE | 53 | M | WHITE | 0054_Marios_PD1_Inhib2_HP-E9133654-7.raw |
SA089298 | CA209025-43-931 | CA209025-43-931_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 33.643 | Phase III_RCC_CA209025 | US/CANADA | 57 | F | WHITE | 0129_Marios_PD1_Inhib2_HP-AF003943-9.raw |
SA089300 | CA209025-4-533 | CA209025-4-533_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 28.452 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | F | WHITE | 0075_Marios_PD1_Inhib2_HP-E9099272-7.raw |
SA089299 | CA209025-65-300 | CA209025-65-300_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 29.470 | Phase III_RCC_CA209025 | WESTERN EUROPE | 49 | M | WHITE | 0645_Marios_PD1_Inhib2_HP-EA002604-7.raw |
SA089304 | CA209025-65-608 | CA209025-65-608_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 30.324 | Phase III_RCC_CA209025 | WESTERN EUROPE | 80 | F | WHITE | 0463_Marios_PD1_Inhib2_HP-E9778361-7.raw |
SA089305 | CA209025-65-848 | CA209025-65-848_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 0.493 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | F | WHITE | 0391_Marios_PD1_Inhib2_HP-EA399862-7.raw |
SA089310 | CA209025-75-262 | CA209025-75-262_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 43.269 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | F | WHITE | 0923_Marios_PD1_Inhib2_HP-E9104439-7.raw |
SA089311 | CA209025-8-177 | CA209025-8-177_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 33.380 | Phase III_RCC_CA209025 | WESTERN EUROPE | 49 | M | WHITE | 1215_Marios_PD1_Inhib2_HP-E9125191-7.raw |
SA089309 | CA209025-84-390 | CA209025-84-390_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 12.386 | Phase III_RCC_CA209025 | REST OF WORLD | 77 | F | WHITE | 0662_Marios_PD1_Inhib2_HP-L1357307-7.raw |
SA089313 | CA209025-84-454 | CA209025-84-454_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 30.292 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | WHITE | 0655_Marios_PD1_Inhib2_HP-L1371960-10.raw |
SA089308 | CA209025-85-683 | CA209025-85-683_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 17.019 | Phase III_RCC_CA209025 | REST OF WORLD | 53 | F | WHITE | 1035_Marios_PD1_Inhib2_HP-L1361776-11.raw |
SA089307 | CA209025-95-408 | CA209025-95-408_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 47.934 | Phase III_RCC_CA209025 | REST OF WORLD | 60 | M | WHITE | 1197_Marios_PD1_Inhib2_HP-S3792617-7.raw |
SA089306 | CA209025-9-896 | CA209025-9-896_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 42.842 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0420_Marios_PD1_Inhib2_HP-AF002778-9.raw |
SA089324 | CA209025-104-900 | CA209025-104-900_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | TRUE | 18.924 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | WHITE | 0709_Marios_PD1_Inhib2_HP-E9649573-7.raw |
SA089322 | CA209025-158-654 | CA209025-158-654_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | TRUE | 32.493 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 0381_Marios_PD1_Inhib2_HP-S3746241-7.raw |
SA089326 | CA209025-166-287 | CA209025-166-287_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | TRUE | 31.310 | Phase III_RCC_CA209025 | REST OF WORLD | 78 | M | OTHER | 1060_Marios_PD1_Inhib2_HP-S3508689-7.raw |
SA089325 | CA209025-185-805 | CA209025-185-805_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | TRUE | 31.113 | Phase III_RCC_CA209025 | US/CANADA | 49 | M | WHITE | 1105_Marios_PD1_Inhib2_HP-AE722161-7.raw |
SA089323 | CA209025-20-81 | CA209025-20-81_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | TRUE | 33.840 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0429_Marios_PD1_Inhib2_HP-AD452648-7.raw |
SA089321 | CA209025-33-250 | CA209025-33-250_baseline | baseline | 1 | INTERMEDIATE | EVEROLIMUS | TRUE | 35.581 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | M | WHITE | 0053_Marios_PD1_Inhib2_HP-E9101787-7.raw |
SA089365 | CA209025-108-362 | CA209025-108-362_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 48.427 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | F | WHITE | 0504_Marios_PD1_Inhib2_HP-E9563929-7.raw |
SA089364 | CA209025-111-778 | CA209025-111-778_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.992 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | WHITE | 0219_Marios_PD1_Inhib2_HP-EA003799-7.raw |
SA089359 | CA209025-11-687 | CA209025-11-687_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 45.602 | Phase III_RCC_CA209025 | US/CANADA | 43 | M | WHITE | 0012_Marios_PD1_Inhib2_HP-AE487819-7.raw |
SA089367 | CA209025-125-855 | CA209025-125-855_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.762 | Phase III_RCC_CA209025 | REST OF WORLD | 54 | M | WHITE | 0992_Marios_PD1_Inhib2_HP-L1392382-7.raw |
SA089366 | CA209025-12-64 | CA209025-12-64_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 51.745 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | M | WHITE | 0580_Marios_PD1_Inhib2_HP-E9124673-7.raw |
SA089369 | CA209025-137-503 | CA209025-137-503_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.949 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | F | WHITE | 1062_Marios_PD1_Inhib2_HP-E9106225-7.raw |
SA089360 | CA209025-138-700 | CA209025-138-700_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 3.844 | Phase III_RCC_CA209025 | US/CANADA | 72 | M | WHITE | 0822_Marios_PD1_Inhib2_HP-AE428476-7.raw |
SA089361 | CA209025-139-1049 | CA209025-139-1049_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 38.637 | Phase III_RCC_CA209025 | US/CANADA | 50 | M | WHITE | 0082_Marios_PD1_Inhib2_HP-AF438543-9.raw |
SA089368 | CA209025-139-152 | CA209025-139-152_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 50.234 | Phase III_RCC_CA209025 | US/CANADA | 48 | M | WHITE | 1065_Marios_PD1_Inhib2_HP-AD783000-7.raw |
SA089373 | CA209025-139-554 | CA209025-139-554_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.062 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0039_Marios_PD1_Inhib2_HP-AD782999-7.raw |
SA089372 | CA209025-139-776 | CA209025-139-776_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.138 | Phase III_RCC_CA209025 | US/CANADA | 73 | M | WHITE | 0410_Marios_PD1_Inhib2_HP-AE913731-7.raw |
SA089371 | CA209025-143-679 | CA209025-143-679_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 44.452 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 1144_Marios_PD1_Inhib2_HP-AE602890-7.raw |
SA089370 | CA209025-144-372 | CA209025-144-372_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 47.770 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 0203_Marios_PD1_Inhib2_HP-AD829005-7.raw |
SA089358 | CA209025-1-516 | CA209025-1-516_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.095 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 0396_Marios_PD1_Inhib2_HP-AD709258-7.raw |
SA089345 | CA209025-153-718 | CA209025-153-718_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 44.682 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 0003_Marios_PD1_Inhib2_HP-AE613290-7.raw |
SA089336 | CA209025-155-1020 | CA209025-155-1020_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 39.951 | Phase III_RCC_CA209025 | REST OF WORLD | 46 | M | OTHER | 0179_Marios_PD1_Inhib2_HP-S4103681-8.raw |
SA089335 | CA209025-157-237 | CA209025-157-237_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 4.403 | Phase III_RCC_CA209025 | REST OF WORLD | 79 | F | OTHER | 1123_Marios_PD1_Inhib2_HP-S3510222-7.raw |
SA089337 | CA209025-157-436 | CA209025-157-436_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.324 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 0533_Marios_PD1_Inhib2_HP-S3510221-9.raw |
SA089334 | CA209025-159-777 | CA209025-159-777_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.598 | Phase III_RCC_CA209025 | REST OF WORLD | 73 | M | OTHER | 1095_Marios_PD1_Inhib2_HP-S3681809-7.raw |
SA089340 | CA209025-163-1012 | CA209025-163-1012_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 40.411 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | OTHER | 0970_Marios_PD1_Inhib2_HP-S4211190-9.raw |
SA089339 | CA209025-163-425 | CA209025-163-425_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 47.606 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 0264_Marios_PD1_Inhib2_HP-S3675226-7.raw |
SA089341 | CA209025-167-1011 | CA209025-167-1011_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 39.819 | Phase III_RCC_CA209025 | REST OF WORLD | 69 | F | OTHER | 0596_Marios_PD1_Inhib2_HP-S4110168-9.raw |
SA089331 | CA209025-174-203 | CA209025-174-203_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 49.840 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | M | OTHER | 1131_Marios_PD1_Inhib2_HP-S3486353-7.raw |
SA089362 | CA209025-1-82 | CA209025-1-82_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 51.581 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0840_Marios_PD1_Inhib2_HP-AD176329-7.raw |
SA089363 | CA209025-1-961 | CA209025-1-961_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 41.725 | Phase III_RCC_CA209025 | US/CANADA | 69 | M | WHITE | 0270_Marios_PD1_Inhib2_HP-AF002674-9.raw |
SA089327 | CA209025-20-116 | CA209025-20-116_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 50.858 | Phase III_RCC_CA209025 | US/CANADA | 88 | F | WHITE | 0322_Marios_PD1_Inhib2_HP-AD612900-7.raw |
SA089330 | CA209025-20-753 | CA209025-20-753_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.696 | Phase III_RCC_CA209025 | US/CANADA | 83 | M | WHITE | 0019_Marios_PD1_Inhib2_HP-AE331983-7.raw |
SA089332 | CA209025-21-1065 | CA209025-21-1065_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 38.932 | Phase III_RCC_CA209025 | US/CANADA | 55 | M | WHITE | 0658_Marios_PD1_Inhib2_HP-AF002695-9.raw |
SA089328 | CA209025-2-356 | CA209025-2-356_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.456 | Phase III_RCC_CA209025 | WESTERN EUROPE | 71 | F | WHITE | 1208_Marios_PD1_Inhib2_HP-E9657511-7.raw |
SA089333 | CA209025-23-953 | CA209025-23-953_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 41.363 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 1120_Marios_PD1_Inhib2_HP-AE886502-6.raw |
SA089357 | CA209025-26-491 | CA209025-26-491_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.423 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0172_Marios_PD1_Inhib2_HP-AD775604-6.raw |
SA089329 | CA209025-29-988 | CA209025-29-988_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 40.772 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0007_Marios_PD1_Inhib2_HP-AF127961-9.raw |
SA089338 | CA209025-35-674 | CA209025-35-674_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 45.175 | Phase III_RCC_CA209025 | WESTERN EUROPE | 50 | M | WHITE | 1068_Marios_PD1_Inhib2_HP-E9103731-7.raw |
SA089356 | CA209025-38-624 | CA209025-38-624_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 45.207 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | F | WHITE | 0545_Marios_PD1_Inhib2_HP-EA295652-7.raw |
SA089352 | CA209025-55-172 | CA209025-55-172_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 50.858 | Phase III_RCC_CA209025 | WESTERN EUROPE | 73 | M | WHITE | 0738_Marios_PD1_Inhib2_HP-E9096030-7.raw |
SA089351 | CA209025-56-791 | CA209025-56-791_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.696 | Phase III_RCC_CA209025 | WESTERN EUROPE | 37 | M | WHITE | 0405_Marios_PD1_Inhib2_HP-E9106980-7.raw |
SA089353 | CA209025-66-488 | CA209025-66-488_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.883 | Phase III_RCC_CA209025 | WESTERN EUROPE | 44 | M | WHITE | 0324_Marios_PD1_Inhib2_HP-E9241872-7.raw |
SA089354 | CA209025-70-405 | CA209025-70-405_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 47.869 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | WHITE | 0351_Marios_PD1_Inhib2_HP-EA088438-7.raw |
SA089342 | CA209025-71-635 | CA209025-71-635_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 45.667 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | WHITE | 0403_Marios_PD1_Inhib2_HP-E9337921-7.raw |
SA089350 | CA209025-76-507 | CA209025-76-507_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.456 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0259_Marios_PD1_Inhib2_HP-AE442046-7.raw |
SA089349 | CA209025-79-465 | CA209025-79-465_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.456 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | WHITE | 1107_Marios_PD1_Inhib2_HP-L1381836-7.raw |
SA089344 | CA209025-79-982 | CA209025-79-982_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 17.840 | Phase III_RCC_CA209025 | REST OF WORLD | 67 | M | WHITE | 0694_Marios_PD1_Inhib2_HP-L1443409-9.raw |
SA089343 | CA209025-82-208 | CA209025-82-208_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 50.103 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | F | WHITE | 1192_Marios_PD1_Inhib2_HP-E9172457-7.raw |
SA089346 | CA209025-84-1041 | CA209025-84-1041_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 39.031 | Phase III_RCC_CA209025 | REST OF WORLD | 57 | M | WHITE | 0487_Marios_PD1_Inhib2_HP-L1443422-9.raw |
SA089355 | CA209025-84-535 | CA209025-84-535_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 5.520 | Phase III_RCC_CA209025 | REST OF WORLD | 50 | M | WHITE | 0166_Marios_PD1_Inhib2_HP-L1381809-7.raw |
SA089347 | CA209025-85-986 | CA209025-85-986_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 41.035 | Phase III_RCC_CA209025 | REST OF WORLD | 71 | M | WHITE | 0824_Marios_PD1_Inhib2_HP-L1497970-10.raw |
SA089348 | CA209025-9-589 | CA209025-9-589_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 45.536 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0563_Marios_PD1_Inhib2_HP-AE556394-6.raw |
SA089375 | CA209025-126-31 | CA209025-126-31_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 53.947 | Phase III_RCC_CA209025 | WESTERN EUROPE | 46 | F | WHITE | 1080_Marios_PD1_Inhib2_HP-E9123119-7.raw |
SA089380 | CA209025-139-143 | CA209025-139-143_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 50.366 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 1026_Marios_PD1_Inhib2_HP-AD783004-7.raw |
SA089383 | CA209025-14-1057 | CA209025-14-1057_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 39.129 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 0301_Marios_PD1_Inhib2_HP-AF015784-9.raw |
SA089382 | CA209025-142-593 | CA209025-142-593_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 46.029 | Phase III_RCC_CA209025 | US/CANADA | 69 | M | WHITE | 0752_Marios_PD1_Inhib2_HP-AD744030-7.raw |
SA089379 | CA209025-156-606 | CA209025-156-606_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 45.207 | Phase III_RCC_CA209025 | REST OF WORLD | 73 | M | OTHER | 0029_Marios_PD1_Inhib2_HP-S3877148-7.raw |
SA089381 | CA209025-17-496 | CA209025-17-496_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 0.953 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 0944_Marios_PD1_Inhib2_HP-AE302154-9.raw |
SA089374 | CA209025-20-1059 | CA209025-20-1059_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 38.899 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0906_Marios_PD1_Inhib2_HP-AF002810-9.raw |
SA089384 | CA209025-29-1045 | CA209025-29-1045_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 38.735 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0474_Marios_PD1_Inhib2_HP-AF360064-9.raw |
SA089376 | CA209025-44-944 | CA209025-44-944_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 41.265 | Phase III_RCC_CA209025 | US/CANADA | 54 | F | WHITE | 0125_Marios_PD1_Inhib2_HP-AF016216-9.raw |
SA089378 | CA209025-49-66 | CA209025-49-66_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 52.074 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 1178_Marios_PD1_Inhib2_HP-AD193616-7.raw |
SA089377 | CA209025-84-384 | CA209025-84-384_baseline | baseline | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 47.244 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | F | WHITE | 0587_Marios_PD1_Inhib2_HP-L1357306-7.raw |
SA089386 | CA209025-20-913 | CA209025-20-913_baseline | baseline | 1 | POOR | EVEROLIMUS | FALSE | 25.593 | Phase III_RCC_CA209025 | US/CANADA | 61 | F | WHITE | 0131_Marios_PD1_Inhib2_HP-AE710606-7.raw |
SA089387 | CA209025-20-976 | CA209025-20-976_baseline | baseline | 1 | POOR | EVEROLIMUS | FALSE | 23.688 | Phase III_RCC_CA209025 | US/CANADA | 75 | F | WHITE | 0036_Marios_PD1_Inhib2_HP-AE710609-7.raw |
SA089388 | CA209025-21-1064 | CA209025-21-1064_baseline | baseline | 1 | POOR | EVEROLIMUS | FALSE | 27.006 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 1138_Marios_PD1_Inhib2_HP-AF002696-9.raw |
SA089385 | CA209025-79-1061 | CA209025-79-1061_baseline | baseline | 1 | POOR | EVEROLIMUS | FALSE | 24.246 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | WHITE | 1130_Marios_PD1_Inhib2_HP-L1478148-8.raw |
SA089389 | CA209025-89-415 | CA209025-89-415_baseline | baseline | 1 | POOR | EVEROLIMUS | FALSE | 30.029 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | F | WHITE | 1064_Marios_PD1_Inhib2_HP-E9656486-7.raw |
SA089390 | CA209025-151-363 | CA209025-151-363_baseline | baseline | 1 | POOR | EVEROLIMUS | TRUE | 47.869 | Phase III_RCC_CA209025 | REST OF WORLD | 81 | M | WHITE | 0937_Marios_PD1_Inhib2_HP-E9540924-7.raw |
SA089393 | CA209025-12-428 | CA209025-12-428_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 46.982 | Phase III_RCC_CA209025 | WESTERN EUROPE | 78 | M | WHITE | 0176_Marios_PD1_Inhib2_HP-E9108718-6.raw |
SA089400 | CA209025-131-640 | CA209025-131-640_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 3.680 | Phase III_RCC_CA209025 | REST OF WORLD | 48 | M | WHITE | 0761_Marios_PD1_Inhib2_HP-E9786646-7.raw |
SA089395 | CA209025-139-324 | CA209025-139-324_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 11.006 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0827_Marios_PD1_Inhib2_HP-AE052723-7.raw |
SA089397 | CA209025-141-666 | CA209025-141-666_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 43.959 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0832_Marios_PD1_Inhib2_HP-AE630786-7.raw |
SA089396 | CA209025-165-758 | CA209025-165-758_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 44.616 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | OTHER | 0267_Marios_PD1_Inhib2_HP-S3717262-7.raw |
SA089399 | CA209025-25-396 | CA209025-25-396_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 47.376 | Phase III_RCC_CA209025 | US/CANADA | 51 | M | WHITE | 0137_Marios_PD1_Inhib2_HP-AD775404-7.raw |
SA089394 | CA209025-28-951 | CA209025-28-951_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 41.429 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0163_Marios_PD1_Inhib2_HP-AE477279-7.raw |
SA089398 | CA209025-29-921 | CA209025-29-921_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 42.053 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 0046_Marios_PD1_Inhib2_HP-AF008965-9.raw |
SA089401 | CA209025-39-467 | CA209025-39-467_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 46.982 | Phase III_RCC_CA209025 | WESTERN EUROPE | 53 | M | WHITE | 0015_Marios_PD1_Inhib2_HP-E9493856-7.raw |
SA089402 | CA209025-4-26 | CA209025-4-26_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 53.980 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 0547_Marios_PD1_Inhib2_HP-E9108954-7.raw |
SA089392 | CA209025-4-468 | CA209025-4-468_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 47.310 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | M | WHITE | 1182_Marios_PD1_Inhib2_HP-E9108953-7.raw |
SA089391 | CA209025-9-1055 | CA209025-9-1055_baseline | baseline | 1 | POOR | NIVOLUMAB | FALSE | 39.097 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | OTHER | 1069_Marios_PD1_Inhib2_HP-AF002780-9.raw |
SA089403 | CA209025-13-360 | CA209025-13-360_baseline | baseline | 1 | POOR | NIVOLUMAB | TRUE | 47.212 | Phase III_RCC_CA209025 | US/CANADA | 75 | M | WHITE | 1084_Marios_PD1_Inhib2_HP-AE059520-7.raw |
SA089404 | CA209025-9-870 | CA209025-9-870_baseline | baseline | 1 | POOR | NIVOLUMAB | TRUE | 43.039 | Phase III_RCC_CA209025 | US/CANADA | 73 | M | WHITE | 0716_Marios_PD1_Inhib2_HP-AE556391-9.raw |
SA088696 | CA209025-108-737 | CA209025-108-737_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 23.557 | Phase III_RCC_CA209025 | REST OF WORLD | 69 | M | WHITE | 0306_Marios_PD1_Inhib2_HP-EA175142-7.raw |
SA088686 | CA209025-111-296 | CA209025-111-296_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 26.612 | Phase III_RCC_CA209025 | REST OF WORLD | 45 | M | WHITE | 0776_Marios_PD1_Inhib2_HP-EA003800-7.raw |
SA088678 | CA209025-118-427 | CA209025-118-427_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 30.850 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 0610_Marios_PD1_Inhib2_HP-E9712822-7.raw |
SA088684 | CA209025-121-463 | CA209025-121-463_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 35.680 | Phase III_RCC_CA209025 | REST OF WORLD | 67 | M | WHITE | 0336_Marios_PD1_Inhib2_HP-L1370586-6.raw |
SA088666 | CA209025-1-27 | CA209025-1-27_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 28.977 | Phase III_RCC_CA209025 | US/CANADA | 72 | M | WHITE | 1023_Marios_PD1_Inhib2_HP-AD185798-7.raw |
SA088676 | CA209025-138-550 | CA209025-138-550_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 19.548 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0257_Marios_PD1_Inhib2_HP-AE428479-7.raw |
SA088668 | CA209025-139-153 | CA209025-139-153_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 15.869 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 0847_Marios_PD1_Inhib2_HP-AD585850-7.raw |
SA088674 | CA209025-139-712 | CA209025-139-712_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 8.476 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | WHITE | 0141_Marios_PD1_Inhib2_HP-AD783003-7.raw |
SA088693 | CA209025-139-990 | CA209025-139-990_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 15.047 | Phase III_RCC_CA209025 | US/CANADA | 67 | F | WHITE | 0632_Marios_PD1_Inhib2_HP-AF337223-9.raw |
SA088679 | CA209025-144-487 | CA209025-144-487_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 42.185 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0358_Marios_PD1_Inhib2_HP-AE506717-7.raw |
SA088677 | CA209025-144-717 | CA209025-144-717_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 19.680 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0925_Marios_PD1_Inhib2_HP-AE673799-7.raw |
SA088698 | CA209025-154-655 | CA209025-154-655_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 25.725 | Phase III_RCC_CA209025 | REST OF WORLD | 57 | M | OTHER | 1054_Marios_PD1_Inhib2_HP-S3704162-7.raw |
SA088708 | CA209025-158-244 | CA209025-158-244_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 18.957 | Phase III_RCC_CA209025 | REST OF WORLD | 72 | M | OTHER | 0117_Marios_PD1_Inhib2_HP-S3653085-7.raw |
SA088709 | CA209025-161-973 | CA209025-161-973_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 32.526 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | OTHER | 0760_Marios_PD1_Inhib2_HP-S4144269-9.raw |
SA088683 | CA209025-172-651 | CA209025-172-651_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 21.848 | Phase III_RCC_CA209025 | REST OF WORLD | 77 | F | OTHER | 0805_Marios_PD1_Inhib2_HP-S3670414-7.raw |
SA088681 | CA209025-1-948 | CA209025-1-948_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 12.550 | Phase III_RCC_CA209025 | US/CANADA | 71 | M | WHITE | 1149_Marios_PD1_Inhib2_HP-AF002675-9.raw |
SA088665 | CA209025-20-1040 | CA209025-20-1040_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 2.431 | Phase III_RCC_CA209025 | US/CANADA | 51 | F | WHITE | 0337_Marios_PD1_Inhib2_HP-AF252764-9.raw |
SA088669 | CA209025-20-232 | CA209025-20-232_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 17.610 | Phase III_RCC_CA209025 | US/CANADA | 46 | M | WHITE | 0503_Marios_PD1_Inhib2_HP-AD612901-7.raw |
SA088692 | CA209025-2-11 | CA209025-2-11_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 21.355 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | M | WHITE | 0508_Marios_PD1_Inhib2_HP-E9064308-7.raw |
SA088688 | CA209025-21-319 | CA209025-21-319_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 26.021 | Phase III_RCC_CA209025 | US/CANADA | 72 | F | WHITE | 0084_Marios_PD1_Inhib2_HP-AD601338-7.raw |
SA088690 | CA209025-21-907 | CA209025-21-907_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 14.292 | Phase III_RCC_CA209025 | US/CANADA | 56 | F | WHITE | 0093_Marios_PD1_Inhib2_HP-AE622887-10.raw |
SA088680 | CA209025-22-345 | CA209025-22-345_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 34.793 | Phase III_RCC_CA209025 | US/CANADA | 71 | F | WHITE | 0687_Marios_PD1_Inhib2_HP-AE198221-7.raw |
SA088682 | CA209025-23-54 | CA209025-23-54_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 8.049 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0074_Marios_PD1_Inhib2_HP-AD362184-7.raw |
SA088664 | CA209025-23-952 | CA209025-23-952_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 12.255 | Phase III_RCC_CA209025 | US/CANADA | 76 | M | WHITE | 0110_Marios_PD1_Inhib2_HP-AE886504-6.raw |
SA088671 | CA209025-2-801 | CA209025-2-801_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 12.255 | Phase III_RCC_CA209025 | WESTERN EUROPE | 38 | M | WHITE | 0928_Marios_PD1_Inhib2_HP-EA495435-7.raw |
SA088670 | CA209025-2-839 | CA209025-2-839_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 18.103 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | F | WHITE | 0697_Marios_PD1_Inhib2_HP-EA495437-7.raw |
SA088685 | CA209025-30-419 | CA209025-30-419_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 25.758 | Phase III_RCC_CA209025 | US/CANADA | 50 | F | WHITE | 0974_Marios_PD1_Inhib2_HP-AD810796-7.raw |
SA088689 | CA209025-30-639 | CA209025-30-639_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 32.756 | Phase III_RCC_CA209025 | US/CANADA | 66 | F | WHITE | 0806_Marios_PD1_Inhib2_HP-AD810797-6.raw |
SA088687 | CA209025-33-670 | CA209025-33-670_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 19.088 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | F | WHITE | 1087_Marios_PD1_Inhib2_HP-E9811936-7.raw |
SA088667 | CA209025-42-45 | CA209025-42-45_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 43.368 | Phase III_RCC_CA209025 | US/CANADA | 74 | M | WHITE | 0703_Marios_PD1_Inhib2_HP-AD452685-7.raw |
SA088691 | CA209025-42-962 | CA209025-42-962_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 24.279 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0274_Marios_PD1_Inhib2_HP-AF126070-9.raw |
SA088699 | CA209025-43-605 | CA209025-43-605_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 19.943 | Phase III_RCC_CA209025 | US/CANADA | 56 | F | WHITE | 0142_Marios_PD1_Inhib2_HP-AE427606-7.raw |
SA088710 | CA209025-43-897 | CA209025-43-897_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 14.916 | Phase III_RCC_CA209025 | US/CANADA | 63 | F | WHITE | 1116_Marios_PD1_Inhib2_HP-AE586110-7.raw |
SA088713 | CA209025-44-1009 | CA209025-44-1009_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 4.074 | Phase III_RCC_CA209025 | US/CANADA | 23 | M | WHITE | 0065_Marios_PD1_Inhib2_HP-AF016218-9.raw |
SA088697 | CA209025-48-502 | CA209025-48-502_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 30.390 | Phase III_RCC_CA209025 | WESTERN EUROPE | 82 | F | WHITE | 0073_Marios_PD1_Inhib2_HP-E9782205-7.raw |
SA088703 | CA209025-50-426 | CA209025-50-426_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 8.345 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | M | WHITE | 1125_Marios_PD1_Inhib2_HP-E9721146-7.raw |
SA088695 | CA209025-5-662 | CA209025-5-662_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 19.023 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | M | WHITE | 0426_Marios_PD1_Inhib2_HP-E9108658-7.raw |
SA088712 | CA209025-6-138 | CA209025-6-138_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 26.908 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | F | WHITE | 0275_Marios_PD1_Inhib2_HP-E9125344-7.raw |
SA088706 | CA209025-62-727 | CA209025-62-727_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 23.655 | Phase III_RCC_CA209025 | WESTERN EUROPE | 61 | M | WHITE | 0927_Marios_PD1_Inhib2_HP-EA039957-7.raw |
SA088694 | CA209025-66-625 | CA209025-66-625_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 35.450 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | F | WHITE | 1037_Marios_PD1_Inhib2_HP-EA239331-7.raw |
SA088705 | CA209025-69-297 | CA209025-69-297_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 17.249 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | F | WHITE | 1122_Marios_PD1_Inhib2_HP-E9483501-7.raw |
SA088702 | CA209025-75-3 | CA209025-75-3_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 21.224 | Phase III_RCC_CA209025 | WESTERN EUROPE | 76 | F | WHITE | 0095_Marios_PD1_Inhib2_HP-E9064316-18.raw |
SA088701 | CA209025-79-1062 | CA209025-79-1062_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 3.647 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | F | WHITE | 0364_Marios_PD1_Inhib2_HP-L1443408-8.raw |
SA088704 | CA209025-80-120 | CA209025-80-120_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 27.795 | Phase III_RCC_CA209025 | WESTERN EUROPE | 48 | M | WHITE | 0059_Marios_PD1_Inhib2_HP-E9433498-6.raw |
SA088700 | CA209025-80-439 | CA209025-80-439_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 20.271 | Phase III_RCC_CA209025 | WESTERN EUROPE | 82 | M | WHITE | 0978_Marios_PD1_Inhib2_HP-E9134599-7.raw |
SA088707 | CA209025-84-495 | CA209025-84-495_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 3.581 | Phase III_RCC_CA209025 | REST OF WORLD | 58 | M | WHITE | 1075_Marios_PD1_Inhib2_HP-L1371961-10.raw |
SA088711 | CA209025-89-173 | CA209025-89-173_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 12.747 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | F | WHITE | 1074_Marios_PD1_Inhib2_HP-E9103840-7.raw |
SA088714 | CA209025-90-720 | CA209025-90-720_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 22.702 | Phase III_RCC_CA209025 | WESTERN EUROPE | 46 | M | WHITE | 0890_Marios_PD1_Inhib2_HP-E9665085-7.raw |
SA088672 | CA209025-93-558 | CA209025-93-558_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 11.795 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | F | WHITE | 0453_Marios_PD1_Inhib2_HP-EA214039-7.raw |
SA088673 | CA209025-95-168 | CA209025-95-168_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 13.470 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | WHITE | 0315_Marios_PD1_Inhib2_HP-S3447248-7.raw |
SA088675 | CA209025-97-260 | CA209025-97-260_baseline | baseline | - | FAVORABLE | EVEROLIMUS | FALSE | 6.439 | Phase III_RCC_CA209025 | REST OF WORLD | 60 | F | WHITE | 0433_Marios_PD1_Inhib2_HP-S3447034-7.raw |
SA088719 | CA209025-13-228 | CA209025-13-228_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 19.318 | Phase III_RCC_CA209025 | US/CANADA | 43 | M | WHITE | 1025_Marios_PD1_Inhib2_HP-AD452591-7.raw |
SA088722 | CA209025-138-872 | CA209025-138-872_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 25.856 | Phase III_RCC_CA209025 | US/CANADA | 58 | F | WHITE | 1093_Marios_PD1_Inhib2_HP-AE726342-7.raw |
SA088727 | CA209025-139-431 | CA209025-139-431_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 23.327 | Phase III_RCC_CA209025 | US/CANADA | 54 | F | OTHER | 0187_Marios_PD1_Inhib2_HP-AD783002-7.raw |
SA088726 | CA209025-148-879 | CA209025-148-879_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 1.446 | Phase III_RCC_CA209025 | REST OF WORLD | 72 | M | WHITE | 0479_Marios_PD1_Inhib2_HP-E9541294-7.raw |
SA088724 | CA209025-149-256 | CA209025-149-256_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 24.345 | Phase III_RCC_CA209025 | REST OF WORLD | 73 | M | WHITE | 0544_Marios_PD1_Inhib2_HP-E9540031-7.raw |
SA088731 | CA209025-168-424 | CA209025-168-424_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 30.719 | Phase III_RCC_CA209025 | REST OF WORLD | 43 | M | OTHER | 0321_Marios_PD1_Inhib2_HP-S3700181-7.raw |
SA088721 | CA209025-17-95 | CA209025-17-95_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 17.216 | Phase III_RCC_CA209025 | US/CANADA | 44 | M | WHITE | 0633_Marios_PD1_Inhib2_HP-AD577684-6.raw |
SA088715 | CA209025-184-352 | CA209025-184-352_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 42.218 | Phase III_RCC_CA209025 | US/CANADA | 23 | F | WHITE | 0836_Marios_PD1_Inhib2_HP-AE142419-7.raw |
SA088730 | CA209025-20-659 | CA209025-20-659_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 26.579 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | WHITE | 0087_Marios_PD1_Inhib2_HP-AE710610-7.raw |
SA088717 | CA209025-20-88 | CA209025-20-88_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 13.733 | Phase III_RCC_CA209025 | US/CANADA | 44 | F | WHITE | 0434_Marios_PD1_Inhib2_HP-AD452647-7.raw |
SA088718 | CA209025-28-584 | CA209025-28-584_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 18.694 | Phase III_RCC_CA209025 | US/CANADA | 77 | M | WHITE | 0101_Marios_PD1_Inhib2_HP-AE477281-7.raw |
SA088732 | CA209025-29-4 | CA209025-29-4_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 16.099 | Phase III_RCC_CA209025 | US/CANADA | 54 | M | WHITE | 0045_Marios_PD1_Inhib2_HP-AD185902-7.raw |
SA088720 | CA209025-31-421 | CA209025-31-421_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 13.832 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0369_Marios_PD1_Inhib2_HP-AD452581-6.raw |
SA088729 | CA209025-62-602 | CA209025-62-602_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 11.828 | Phase III_RCC_CA209025 | WESTERN EUROPE | 73 | M | WHITE | 0915_Marios_PD1_Inhib2_HP-EA297782-7.raw |
SA088733 | CA209025-64-663 | CA209025-64-663_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 6.472 | Phase III_RCC_CA209025 | WESTERN EUROPE | 41 | F | WHITE | 1085_Marios_PD1_Inhib2_HP-E9485321-6.raw |
SA088723 | CA209025-69-696 | CA209025-69-696_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 2.103 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | WHITE | 0960_Marios_PD1_Inhib2_HP-E9483502-7.raw |
SA088725 | CA209025-85-880 | CA209025-85-880_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 3.285 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | WHITE | 0178_Marios_PD1_Inhib2_HP-L1361774-10.raw |
SA088728 | CA209025-87-402 | CA209025-87-402_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 31.901 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | F | WHITE | 0665_Marios_PD1_Inhib2_HP-E9774329-7.raw |
SA088716 | CA209025-87-899 | CA209025-87-899_baseline | baseline | - | FAVORABLE | EVEROLIMUS | TRUE | 5.585 | Phase III_RCC_CA209025 | WESTERN EUROPE | 53 | M | WHITE | 0334_Marios_PD1_Inhib2_HP-E9774330-7.raw |
SA088788 | CA209025-1-1004 | CA209025-1-1004_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 32.657 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0415_Marios_PD1_Inhib2_HP-AF002677-9.raw |
SA088769 | CA209025-1-1030 | CA209025-1-1030_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 23.951 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 0397_Marios_PD1_Inhib2_HP-AE663607-7.raw |
SA088766 | CA209025-1-117 | CA209025-1-117_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 10.875 | Phase III_RCC_CA209025 | US/CANADA | 37 | F | WHITE | 1019_Marios_PD1_Inhib2_HP-AD424474-7.raw |
SA088758 | CA209025-111-811 | CA209025-111-811_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 11.302 | Phase III_RCC_CA209025 | REST OF WORLD | 34 | F | WHITE | 1039_Marios_PD1_Inhib2_HP-E9720046-7.raw |
SA088771 | CA209025-11-240 | CA209025-11-240_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 38.768 | Phase III_RCC_CA209025 | US/CANADA | 51 | M | WHITE | 0435_Marios_PD1_Inhib2_HP-AD604108-7.raw |
SA088757 | CA209025-113-669 | CA209025-113-669_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 6.604 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0991_Marios_PD1_Inhib2_HP-E9717741-7.raw |
SA088763 | CA209025-118-207 | CA209025-118-207_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 19.778 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 1112_Marios_PD1_Inhib2_HP-E9314448-7.raw |
SA088765 | CA209025-11-910 | CA209025-11-910_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 8.674 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0470_Marios_PD1_Inhib2_HP-AE330680-6.raw |
SA088789 | CA209025-1-205 | CA209025-1-205_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 29.865 | Phase III_RCC_CA209025 | US/CANADA | 45 | M | WHITE | 0189_Marios_PD1_Inhib2_HP-AD424473-7.raw |
SA088761 | CA209025-121-272 | CA209025-121-272_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 31.836 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | WHITE | 1043_Marios_PD1_Inhib2_HP-L1305560-7.raw |
SA088762 | CA209025-12-838 | CA209025-12-838_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 20.567 | Phase III_RCC_CA209025 | WESTERN EUROPE | 35 | M | WHITE | 0025_Marios_PD1_Inhib2_HP-EA000635-7.raw |
SA088774 | CA209025-135-450 | CA209025-135-450_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 17.971 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | WHITE | 0298_Marios_PD1_Inhib2_HP-L1366487-10.raw |
SA088786 | CA209025-138-1034 | CA209025-138-1034_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 10.152 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0154_Marios_PD1_Inhib2_HP-AF004062-9.raw |
SA088784 | CA209025-139-1015 | CA209025-139-1015_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 14.916 | Phase III_RCC_CA209025 | US/CANADA | 32 | F | OTHER | 0874_Marios_PD1_Inhib2_HP-AF048312-8.raw |
SA088787 | CA209025-139-665 | CA209025-139-665_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 22.505 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0837_Marios_PD1_Inhib2_HP-AE645252-7.raw |
SA088790 | CA209025-140-869 | CA209025-140-869_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 2.464 | Phase III_RCC_CA209025 | US/CANADA | 69 | M | WHITE | 0238_Marios_PD1_Inhib2_HP-AD828985-7.raw |
SA088768 | CA209025-1-417 | CA209025-1-417_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 20.271 | Phase III_RCC_CA209025 | US/CANADA | 66 | F | WHITE | 0888_Marios_PD1_Inhib2_HP-AD709256-6.raw |
SA088770 | CA209025-1-517 | CA209025-1-517_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 2.563 | Phase III_RCC_CA209025 | US/CANADA | 48 | M | OTHER | 0083_Marios_PD1_Inhib2_HP-AE471827-7.raw |
SA088777 | CA209025-159-114 | CA209025-159-114_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 39.228 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | F | OTHER | 0149_Marios_PD1_Inhib2_HP-S3472022-7.raw |
SA088776 | CA209025-159-750 | CA209025-159-750_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 27.433 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | OTHER | 1168_Marios_PD1_Inhib2_HP-S3681808-7.raw |
SA088775 | CA209025-159-91 | CA209025-159-91_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 33.249 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | F | OTHER | 0817_Marios_PD1_Inhib2_HP-S3472021-7.raw |
SA088779 | CA209025-159-945 | CA209025-159-945_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 26.842 | Phase III_RCC_CA209025 | REST OF WORLD | 57 | M | OTHER | 0549_Marios_PD1_Inhib2_HP-S4107208-9.raw |
SA088760 | CA209025-166-161 | CA209025-166-161_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 15.047 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | OTHER | 0161_Marios_PD1_Inhib2_HP-S3508687-7.raw |
SA088734 | CA209025-17-612 | CA209025-17-612_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 13.010 | Phase III_RCC_CA209025 | US/CANADA | 48 | M | WHITE | 0418_Marios_PD1_Inhib2_HP-AE522916-7.raw |
SA088738 | CA209025-21-442 | CA209025-21-442_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 19.877 | Phase III_RCC_CA209025 | US/CANADA | 50 | F | WHITE | 0056_Marios_PD1_Inhib2_HP-AE206902-7.raw |
SA088751 | CA209025-21-967 | CA209025-21-967_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 18.530 | Phase III_RCC_CA209025 | US/CANADA | 74 | F | WHITE | 0667_Marios_PD1_Inhib2_HP-AF063578-9.raw |
SA088736 | CA209025-2-24 | CA209025-2-24_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 12.452 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | F | WHITE | 0535_Marios_PD1_Inhib2_HP-E9101710-8.raw |
SA088753 | CA209025-23-124 | CA209025-23-124_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 29.470 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 0724_Marios_PD1_Inhib2_HP-AD490506-7.raw |
SA088752 | CA209025-23-684 | CA209025-23-684_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 13.963 | Phase III_RCC_CA209025 | US/CANADA | 60 | F | WHITE | 0736_Marios_PD1_Inhib2_HP-AE600725-7.raw |
SA088754 | CA209025-2-38 | CA209025-2-38_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 20.895 | Phase III_RCC_CA209025 | WESTERN EUROPE | 71 | F | WHITE | 0291_Marios_PD1_Inhib2_HP-E9130935-7.raw |
SA088749 | CA209025-2-477 | CA209025-2-477_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 30.062 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | M | WHITE | 0308_Marios_PD1_Inhib2_HP-E9618953-7.raw |
SA088741 | CA209025-24-887 | CA209025-24-887_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 27.696 | Phase III_RCC_CA209025 | US/CANADA | 44 | M | WHITE | 0385_Marios_PD1_Inhib2_HP-AF009311-9.raw |
SA088740 | CA209025-25-165 | CA209025-25-165_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 1.906 | Phase III_RCC_CA209025 | US/CANADA | 57 | F | WHITE | 0642_Marios_PD1_Inhib2_HP-AD610056-7.raw |
SA088748 | CA209025-2-793 | CA209025-2-793_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 31.179 | Phase III_RCC_CA209025 | WESTERN EUROPE | 45 | M | WHITE | 0943_Marios_PD1_Inhib2_HP-EA495436-7.raw |
SA088742 | CA209025-29-1021 | CA209025-29-1021_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 7.097 | Phase III_RCC_CA209025 | US/CANADA | 49 | F | WHITE | 0031_Marios_PD1_Inhib2_HP-AF008967-9.raw |
SA088743 | CA209025-29-621 | CA209025-29-621_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 18.234 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0169_Marios_PD1_Inhib2_HP-AE294677-7.raw |
SA088745 | CA209025-29-626 | CA209025-29-626_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 8.608 | Phase III_RCC_CA209025 | US/CANADA | 48 | M | WHITE | 0359_Marios_PD1_Inhib2_HP-AE294680-7.raw |
SA088739 | CA209025-43-567 | CA209025-43-567_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 10.152 | Phase III_RCC_CA209025 | US/CANADA | 53 | F | WHITE | 0368_Marios_PD1_Inhib2_HP-AE427607-7.raw |
SA088744 | CA209025-4-759 | CA209025-4-759_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 6.472 | Phase III_RCC_CA209025 | WESTERN EUROPE | 51 | M | WHITE | 1140_Marios_PD1_Inhib2_HP-E9099304-2.raw |
SA088746 | CA209025-48-282 | CA209025-48-282_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 29.602 | Phase III_RCC_CA209025 | WESTERN EUROPE | 74 | M | WHITE | 0638_Marios_PD1_Inhib2_HP-EA044582-7.raw |
SA088747 | CA209025-48-285 | CA209025-48-285_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 15.836 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 0626_Marios_PD1_Inhib2_HP-E9674322-7.raw |
SA088750 | CA209025-50-902 | CA209025-50-902_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 35.581 | Phase III_RCC_CA209025 | WESTERN EUROPE | 49 | M | WHITE | 0278_Marios_PD1_Inhib2_HP-EA412067-10.raw |
SA088735 | CA209025-59-159 | CA209025-59-159_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 1.183 | Phase III_RCC_CA209025 | WESTERN EUROPE | 78 | F | WHITE | 1088_Marios_PD1_Inhib2_HP-E9172350-7.raw |
SA088737 | CA209025-65-301 | CA209025-65-301_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 30.784 | Phase III_RCC_CA209025 | WESTERN EUROPE | 72 | M | WHITE | 0032_Marios_PD1_Inhib2_HP-EA002605-7.raw |
SA088781 | CA209025-66-544 | CA209025-66-544_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 23.162 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0527_Marios_PD1_Inhib2_HP-E9241873-7.raw |
SA088783 | CA209025-73-447 | CA209025-73-447_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 33.643 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | M | WHITE | 0377_Marios_PD1_Inhib2_HP-E9073425-7.raw |
SA088755 | CA209025-75-113 | CA209025-75-113_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 21.355 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | F | WHITE | 0938_Marios_PD1_Inhib2_HP-E9104437-7.raw |
SA088785 | CA209025-75-615 | CA209025-75-615_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 31.047 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | F | WHITE | 0077_Marios_PD1_Inhib2_HP-E9479165-7.raw |
SA088773 | CA209025-79-373 | CA209025-79-373_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 38.209 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | M | WHITE | 0289_Marios_PD1_Inhib2_HP-L1352789-6.raw |
SA088764 | CA209025-80-728 | CA209025-80-728_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 25.988 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | F | WHITE | 0879_Marios_PD1_Inhib2_HP-EA083034-7.raw |
SA088767 | CA209025-82-378 | CA209025-82-378_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 16.789 | Phase III_RCC_CA209025 | WESTERN EUROPE | 47 | F | WHITE | 0311_Marios_PD1_Inhib2_HP-E9703897-7.raw |
SA088772 | CA209025-84-704 | CA209025-84-704_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 19.055 | Phase III_RCC_CA209025 | REST OF WORLD | 72 | M | WHITE | 0788_Marios_PD1_Inhib2_HP-L1381807-6.raw |
SA088759 | CA209025-8-677 | CA209025-8-677_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 37.815 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | WHITE | 0520_Marios_PD1_Inhib2_HP-E9125189-7.raw |
SA088756 | CA209025-8-69 | CA209025-8-69_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 24.148 | Phase III_RCC_CA209025 | WESTERN EUROPE | 71 | M | WHITE | 1012_Marios_PD1_Inhib2_HP-E9108732-7.raw |
SA088782 | CA209025-87-234 | CA209025-87-234_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 43.039 | Phase III_RCC_CA209025 | WESTERN EUROPE | 37 | M | WHITE | 0214_Marios_PD1_Inhib2_HP-E9103643-7.raw |
SA088778 | CA209025-87-267 | CA209025-87-267_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 14.883 | Phase III_RCC_CA209025 | WESTERN EUROPE | 68 | F | WHITE | 1147_Marios_PD1_Inhib2_HP-E9103642-7.raw |
SA088780 | CA209025-96-498 | CA209025-96-498_baseline | baseline | - | FAVORABLE | NIVOLUMAB | FALSE | 32.164 | Phase III_RCC_CA209025 | REST OF WORLD | 54 | M | WHITE | 0781_Marios_PD1_Inhib2_HP-S3740939-7.raw |
SA088801 | CA209025-139-784 | CA209025-139-784_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 43.499 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0620_Marios_PD1_Inhib2_HP-AE645251-7.raw |
SA088798 | CA209025-139-978 | CA209025-139-978_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 31.343 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | OTHER | 0151_Marios_PD1_Inhib2_HP-AF048313-9.raw |
SA088797 | CA209025-147-367 | CA209025-147-367_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 36.205 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | WHITE | 0085_Marios_PD1_Inhib2_HP-AD673732-7.raw |
SA088794 | CA209025-158-680 | CA209025-158-680_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 18.103 | Phase III_RCC_CA209025 | REST OF WORLD | 78 | M | OTHER | 0526_Marios_PD1_Inhib2_HP-S3746240-7.raw |
SA088800 | CA209025-1-618 | CA209025-1-618_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 15.376 | Phase III_RCC_CA209025 | US/CANADA | 53 | F | WHITE | 0454_Marios_PD1_Inhib2_HP-AE471830-6.raw |
SA088796 | CA209025-17-1066 | CA209025-17-1066_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 25.626 | Phase III_RCC_CA209025 | US/CANADA | 60 | F | WHITE | 0756_Marios_PD1_Inhib2_HP-AE613962-7.raw |
SA088803 | CA209025-17-328 | CA209025-17-328_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 27.828 | Phase III_RCC_CA209025 | US/CANADA | 63 | F | WHITE | 0803_Marios_PD1_Inhib2_HP-AD749688-7.raw |
SA088795 | CA209025-17-473 | CA209025-17-473_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 7.524 | Phase III_RCC_CA209025 | US/CANADA | 49 | M | OTHER | 0211_Marios_PD1_Inhib2_HP-AE302153-9.raw |
SA088793 | CA209025-22-935 | CA209025-22-935_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 24.772 | Phase III_RCC_CA209025 | US/CANADA | 45 | M | WHITE | 1165_Marios_PD1_Inhib2_HP-AE302091-6.raw |
SA088799 | CA209025-25-197 | CA209025-25-197_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 34.530 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0859_Marios_PD1_Inhib2_HP-AD775402-7.raw |
SA088802 | CA209025-26-693 | CA209025-26-693_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 31.343 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0491_Marios_PD1_Inhib2_HP-AE438256-7.raw |
SA088792 | CA209025-30-418 | CA209025-30-418_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 44.058 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0465_Marios_PD1_Inhib2_HP-AE355052-7.raw |
SA088791 | CA209025-3-871 | CA209025-3-871_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 7.064 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 0740_Marios_PD1_Inhib2_HP-E9064328-7.raw |
SA088805 | CA209025-63-607 | CA209025-63-607_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 12.518 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | F | WHITE | 0766_Marios_PD1_Inhib2_HP-E9528379-7.raw |
SA088806 | CA209025-74-194 | CA209025-74-194_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 13.799 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | M | WHITE | 0242_Marios_PD1_Inhib2_HP-E9103990-7.raw |
SA088807 | CA209025-75-191 | CA209025-75-191_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 42.185 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0953_Marios_PD1_Inhib2_HP-E9104438-7.raw |
SA088808 | CA209025-75-84 | CA209025-75-84_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 44.583 | Phase III_RCC_CA209025 | WESTERN EUROPE | 75 | M | WHITE | 0985_Marios_PD1_Inhib2_HP-E9064315-7.raw |
SA088804 | CA209025-90-703 | CA209025-90-703_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 14.259 | Phase III_RCC_CA209025 | WESTERN EUROPE | 45 | M | WHITE | 0402_Marios_PD1_Inhib2_HP-E9634499-7.raw |
SA088809 | CA209025-94-851 | CA209025-94-851_baseline | baseline | - | FAVORABLE | NIVOLUMAB | TRUE | 23.688 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | WHITE | 0422_Marios_PD1_Inhib2_HP-S3884097-7.raw |
SA088817 | CA209025-102-279 | CA209025-102-279_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 10.349 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 1151_Marios_PD1_Inhib2_HP-E9172289-6.raw |
SA088863 | CA209025-111-304 | CA209025-111-304_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 7.819 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | F | WHITE | 0902_Marios_PD1_Inhib2_HP-EA003802-7.raw |
SA088895 | CA209025-112-175 | CA209025-112-175_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 5.881 | Phase III_RCC_CA209025 | WESTERN EUROPE | 38 | M | WHITE | 0159_Marios_PD1_Inhib2_HP-E9123049-7.raw |
SA088890 | CA209025-114-60 | CA209025-114-60_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 1.938 | Phase III_RCC_CA209025 | WESTERN EUROPE | 68 | M | WHITE | 1090_Marios_PD1_Inhib2_HP-E9123055-7.raw |
SA088875 | CA209025-11-829 | CA209025-11-829_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 6.834 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0328_Marios_PD1_Inhib2_HP-AE330678-6.raw |
SA088842 | CA209025-118-446 | CA209025-118-446_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 3.417 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0975_Marios_PD1_Inhib2_HP-E9712823-7.raw |
SA088849 | CA209025-119-246 | CA209025-119-246_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 3.581 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | M | WHITE | 0168_Marios_PD1_Inhib2_HP-E9754089-7.raw |
SA088866 | CA209025-1-201 | CA209025-1-201_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 8.049 | Phase III_RCC_CA209025 | US/CANADA | 69 | M | WHITE | 0217_Marios_PD1_Inhib2_HP-AD424476-7.raw |
SA088889 | CA209025-124-763 | CA209025-124-763_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 12.780 | Phase III_RCC_CA209025 | REST OF WORLD | 60 | M | WHITE | 0863_Marios_PD1_Inhib2_HP-L1387364-10.raw |
SA088898 | CA209025-125-508 | CA209025-125-508_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 11.006 | Phase III_RCC_CA209025 | REST OF WORLD | 69 | M | WHITE | 0333_Marios_PD1_Inhib2_HP-L1366503-6.raw |
SA088879 | CA209025-126-230 | CA209025-126-230_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 1.347 | Phase III_RCC_CA209025 | WESTERN EUROPE | 84 | M | WHITE | 1056_Marios_PD1_Inhib2_HP-E9474282-7.raw |
SA088845 | CA209025-1-28 | CA209025-1-28_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 16.131 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 0877_Marios_PD1_Inhib2_HP-AD185797-7.raw |
SA088850 | CA209025-1-326 | CA209025-1-326_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 19.253 | Phase III_RCC_CA209025 | US/CANADA | 69 | F | WHITE | 0744_Marios_PD1_Inhib2_HP-AD424472-7.raw |
SA088894 | CA209025-13-526 | CA209025-13-526_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 35.088 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 1110_Marios_PD1_Inhib2_HP-AD827407-7.raw |
SA088825 | CA209025-137-55 | CA209025-137-55_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 23.064 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | M | WHITE | 0613_Marios_PD1_Inhib2_HP-E9073336-7.raw |
SA088841 | CA209025-138-1069 | CA209025-138-1069_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 7.359 | Phase III_RCC_CA209025 | US/CANADA | 76 | M | WHITE | 0895_Marios_PD1_Inhib2_HP-AF004064-9.raw |
SA088839 | CA209025-138-398 | CA209025-138-398_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 29.733 | Phase III_RCC_CA209025 | US/CANADA | 71 | M | WHITE | 0660_Marios_PD1_Inhib2_HP-AE133962-7.raw |
SA088810 | CA209025-139-764 | CA209025-139-764_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 18.826 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | OTHER | 0409_Marios_PD1_Inhib2_HP-AF048315-9.raw |
SA088858 | CA209025-139-796 | CA209025-139-796_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 3.121 | Phase III_RCC_CA209025 | US/CANADA | 69 | F | WHITE | 0644_Marios_PD1_Inhib2_HP-AE853232-7.raw |
SA088818 | CA209025-139-950 | CA209025-139-950_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 11.860 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0250_Marios_PD1_Inhib2_HP-AF048314-9.raw |
SA088855 | CA209025-141-370 | CA209025-141-370_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 8.016 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 1113_Marios_PD1_Inhib2_HP-AD780393-7.raw |
SA088813 | CA209025-143-565 | CA209025-143-565_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 2.760 | Phase III_RCC_CA209025 | US/CANADA | 79 | M | WHITE | 0682_Marios_PD1_Inhib2_HP-AE459920-7.raw |
SA088811 | CA209025-145-391 | CA209025-145-391_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 47.113 | Phase III_RCC_CA209025 | US/CANADA | 85 | F | WHITE | 1204_Marios_PD1_Inhib2_HP-AD780353-7.raw |
SA088872 | CA209025-149-748 | CA209025-149-748_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 7.425 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | WHITE | 0147_Marios_PD1_Inhib2_HP-EA039694-7.raw |
SA088815 | CA209025-14-996 | CA209025-14-996_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 15.212 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0670_Marios_PD1_Inhib2_HP-AE902413-6.raw |
SA088881 | CA209025-154-119 | CA209025-154-119_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 17.708 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | OTHER | 0013_Marios_PD1_Inhib2_HP-S3470296-7.raw |
SA088864 | CA209025-155-858 | CA209025-155-858_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 17.478 | Phase III_RCC_CA209025 | REST OF WORLD | 58 | F | OTHER | 0846_Marios_PD1_Inhib2_HP-S4071079-7.raw |
SA088847 | CA209025-156-744 | CA209025-156-744_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 25.199 | Phase III_RCC_CA209025 | REST OF WORLD | 72 | M | OTHER | 0442_Marios_PD1_Inhib2_HP-S3877147-6.raw |
SA088900 | CA209025-1-71 | CA209025-1-71_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 30.916 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0917_Marios_PD1_Inhib2_HP-AD424471-8.raw |
SA088826 | CA209025-174-863 | CA209025-174-863_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 4.632 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | OTHER | 1206_Marios_PD1_Inhib2_HP-S3949116-7.raw |
SA088834 | CA209025-180-1053 | CA209025-180-1053_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 6.571 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | F | WHITE | 0529_Marios_PD1_Inhib2_HP-EB335372-8.raw |
SA088844 | CA209025-18-148 | CA209025-18-148_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 10.513 | Phase III_RCC_CA209025 | US/CANADA | 74 | M | WHITE | 0273_Marios_PD1_Inhib2_HP-AD498710-7.raw |
SA088851 | CA209025-182-701 | CA209025-182-701_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 19.975 | Phase III_RCC_CA209025 | US/CANADA | 82 | M | WHITE | 0747_Marios_PD1_Inhib2_HP-AE283064-7.raw |
SA088827 | CA209025-1-972 | CA209025-1-972_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 14.686 | Phase III_RCC_CA209025 | US/CANADA | 50 | F | OTHER | 1078_Marios_PD1_Inhib2_HP-AF002676-10.raw |
SA088891 | CA209025-20-1075 | CA209025-20-1075_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 8.509 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 1127_Marios_PD1_Inhib2_HP-AF252767-9.raw |
SA088888 | CA209025-2-103 | CA209025-2-103_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 10.119 | Phase III_RCC_CA209025 | WESTERN EUROPE | 61 | M | WHITE | 0223_Marios_PD1_Inhib2_HP-E9425294-7.raw |
SA088848 | CA209025-21-380 | CA209025-21-380_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 36.797 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0684_Marios_PD1_Inhib2_HP-AD601336-7.raw |
SA088836 | CA209025-22-344 | CA209025-22-344_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 11.860 | Phase III_RCC_CA209025 | US/CANADA | 40 | M | WHITE | 0020_Marios_PD1_Inhib2_HP-AE198219-6.raw |
SA088833 | CA209025-23-196 | CA209025-23-196_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 16.230 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0799_Marios_PD1_Inhib2_HP-AD461613-7.raw |
SA088860 | CA209025-2-440 | CA209025-2-440_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 7.589 | Phase III_RCC_CA209025 | WESTERN EUROPE | 51 | F | WHITE | 0132_Marios_PD1_Inhib2_HP-E9618950-7.raw |
SA088814 | CA209025-25-135 | CA209025-25-135_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 7.392 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 0981_Marios_PD1_Inhib2_HP-AD610058-7.raw |
SA088821 | CA209025-2-573 | CA209025-2-573_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 20.041 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | M | WHITE | 0300_Marios_PD1_Inhib2_HP-E9618948-7.raw |
SA088830 | CA209025-27-513 | CA209025-27-513_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 7.655 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 1082_Marios_PD1_Inhib2_HP-AE302625-7.raw |
SA088887 | CA209025-29-486 | CA209025-29-486_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 19.910 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0375_Marios_PD1_Inhib2_HP-AE294669-7.raw |
SA088897 | CA209025-29-51 | CA209025-29-51_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 17.643 | Phase III_RCC_CA209025 | US/CANADA | 67 | F | WHITE | 0912_Marios_PD1_Inhib2_HP-AD176340-6.raw |
SA088893 | CA209025-29-601 | CA209025-29-601_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 6.965 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | WHITE | 0340_Marios_PD1_Inhib2_HP-AE294679-7.raw |
SA088886 | CA209025-33-29 | CA209025-33-29_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 29.963 | Phase III_RCC_CA209025 | WESTERN EUROPE | 58 | M | WHITE | 0353_Marios_PD1_Inhib2_HP-E9101786-7.raw |
SA088823 | CA209025-35-332 | CA209025-35-332_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 19.910 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 0088_Marios_PD1_Inhib2_HP-E9103732-7.raw |
SA088829 | CA209025-38-514 | CA209025-38-514_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 26.185 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 1041_Marios_PD1_Inhib2_HP-E9133655-7.raw |
SA088831 | CA209025-39-749 | CA209025-39-749_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 17.906 | Phase III_RCC_CA209025 | WESTERN EUROPE | 76 | M | WHITE | 0128_Marios_PD1_Inhib2_HP-E9432886-7.raw |
SA088822 | CA209025-41-980 | CA209025-41-980_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 18.891 | Phase III_RCC_CA209025 | US/CANADA | 54 | M | OTHER | 1128_Marios_PD1_Inhib2_HP-AF008938-9.raw |
SA088856 | CA209025-42-1051 | CA209025-42-1051_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 5.322 | Phase III_RCC_CA209025 | US/CANADA | 47 | M | WHITE | 0811_Marios_PD1_Inhib2_HP-AF126072-9.raw |
SA088865 | CA209025-42-959 | CA209025-42-959_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 2.201 | Phase III_RCC_CA209025 | US/CANADA | 54 | F | WHITE | 0839_Marios_PD1_Inhib2_HP-AF126071-9.raw |
SA088835 | CA209025-49-975 | CA209025-49-975_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 22.078 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | WHITE | 0604_Marios_PD1_Inhib2_HP-AE673154-6.raw |
SA088838 | CA209025-50-825 | CA209025-50-825_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 23.754 | Phase III_RCC_CA209025 | WESTERN EUROPE | 58 | M | WHITE | 0855_Marios_PD1_Inhib2_HP-EA412066-6.raw |
SA088824 | CA209025-53-1003 | CA209025-53-1003_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 5.355 | Phase III_RCC_CA209025 | US/CANADA | 57 | F | WHITE | 1091_Marios_PD1_Inhib2_HP-AF016229-9.raw |
SA088840 | CA209025-56-592 | CA209025-56-592_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 1.544 | Phase III_RCC_CA209025 | WESTERN EUROPE | 72 | M | WHITE | 0102_Marios_PD1_Inhib2_HP-E9096038-7.raw |
SA088880 | CA209025-58-545 | CA209025-58-545_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 25.725 | Phase III_RCC_CA209025 | WESTERN EUROPE | 58 | M | OTHER | 0058_Marios_PD1_Inhib2_HP-EA103410-7.raw |
SA088878 | CA209025-59-412 | CA209025-59-412_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 18.497 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | F | WHITE | 0236_Marios_PD1_Inhib2_HP-E9172349-7.raw |
SA088877 | CA209025-59-691 | CA209025-59-691_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 6.932 | Phase III_RCC_CA209025 | WESTERN EUROPE | 76 | M | WHITE | 0106_Marios_PD1_Inhib2_HP-EA185598-6.raw |
SA088861 | CA209025-61-189 | CA209025-61-189_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 41.922 | Phase III_RCC_CA209025 | WESTERN EUROPE | 78 | M | WHITE | 0190_Marios_PD1_Inhib2_HP-E9240778-6.raw |
SA088868 | CA209025-61-218 | CA209025-61-218_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 6.374 | Phase III_RCC_CA209025 | WESTERN EUROPE | 83 | M | WHITE | 0367_Marios_PD1_Inhib2_HP-E9667539-6.raw |
SA088867 | CA209025-62-108 | CA209025-62-108_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 6.209 | Phase III_RCC_CA209025 | WESTERN EUROPE | 71 | M | WHITE | 0068_Marios_PD1_Inhib2_HP-E9241306-7.raw |
SA088882 | CA209025-62-315 | CA209025-62-315_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 5.750 | Phase III_RCC_CA209025 | WESTERN EUROPE | 47 | M | WHITE | 1154_Marios_PD1_Inhib2_HP-EA015432-7.raw |
SA088899 | CA209025-62-78 | CA209025-62-78_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 2.924 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | F | WHITE | 0089_Marios_PD1_Inhib2_HP-E9241305-7.raw |
SA088883 | CA209025-64-846 | CA209025-64-846_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 11.663 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | F | WHITE | 0552_Marios_PD1_Inhib2_HP-E9485322-7.raw |
SA088892 | CA209025-65-437 | CA209025-65-437_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 7.064 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 0067_Marios_PD1_Inhib2_HP-EA048753-6.raw |
SA088857 | CA209025-65-438 | CA209025-65-438_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 9.856 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | F | WHITE | 0502_Marios_PD1_Inhib2_HP-E9778359-7.raw |
SA088819 | CA209025-70-414 | CA209025-70-414_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 23.951 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | WHITE | 0751_Marios_PD1_Inhib2_HP-EA088437-7.raw |
SA088812 | CA209025-73-92 | CA209025-73-92_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 17.971 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 1159_Marios_PD1_Inhib2_HP-E9106364-6.raw |
SA088854 | CA209025-75-675 | CA209025-75-675_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 8.214 | Phase III_RCC_CA209025 | WESTERN EUROPE | 76 | M | WHITE | 0072_Marios_PD1_Inhib2_HP-EA040851-7.raw |
SA088853 | CA209025-77-492 | CA209025-77-492_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 15.212 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | WHITE | 0313_Marios_PD1_Inhib2_HP-L1381859-7.raw |
SA088843 | CA209025-78-1007 | CA209025-78-1007_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 4.337 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | M | WHITE | 0797_Marios_PD1_Inhib2_HP-L1376090-7.raw |
SA088832 | CA209025-78-1014 | CA209025-78-1014_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 5.618 | Phase III_RCC_CA209025 | REST OF WORLD | 52 | M | WHITE | 0618_Marios_PD1_Inhib2_HP-L1479322-12.raw |
SA088837 | CA209025-78-627 | CA209025-78-627_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 4.961 | Phase III_RCC_CA209025 | REST OF WORLD | 71 | M | WHITE | 0894_Marios_PD1_Inhib2_HP-L1376089-6.raw |
SA088828 | CA209025-79-705 | CA209025-79-705_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 13.405 | Phase III_RCC_CA209025 | REST OF WORLD | 77 | M | WHITE | 0124_Marios_PD1_Inhib2_HP-L1381834-6.raw |
SA088896 | CA209025-80-19 | CA209025-80-19_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 21.552 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | M | WHITE | 1164_Marios_PD1_Inhib2_HP-E9097389-7.raw |
SA088884 | CA209025-80-37 | CA209025-80-37_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 26.218 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 0243_Marios_PD1_Inhib2_HP-E9097391-7.raw |
SA088873 | CA209025-84-349 | CA209025-84-349_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 16.953 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | F | WHITE | 0681_Marios_PD1_Inhib2_HP-L1357305-7.raw |
SA088846 | CA209025-84-933 | CA209025-84-933_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 25.528 | Phase III_RCC_CA209025 | REST OF WORLD | 71 | M | WHITE | 0592_Marios_PD1_Inhib2_HP-L1443424-9.raw |
SA088852 | CA209025-85-971 | CA209025-85-971_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 20.862 | Phase III_RCC_CA209025 | REST OF WORLD | 76 | M | WHITE | 0556_Marios_PD1_Inhib2_HP-L1453006-10.raw |
SA088820 | CA209025-8-676 | CA209025-8-676_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 22.801 | Phase III_RCC_CA209025 | WESTERN EUROPE | 47 | M | WHITE | 0576_Marios_PD1_Inhib2_HP-E9108730-7.raw |
SA088816 | CA209025-89-336 | CA209025-89-336_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 4.370 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | M | WHITE | 0064_Marios_PD1_Inhib2_HP-E9656483-7.raw |
SA088885 | CA209025-89-740 | CA209025-89-740_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 25.758 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | M | WHITE | 0729_Marios_PD1_Inhib2_HP-EA511887-7.raw |
SA088869 | CA209025-90-799 | CA209025-90-799_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 15.836 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | M | WHITE | 0123_Marios_PD1_Inhib2_HP-E9665082-7.raw |
SA088874 | CA209025-94-877 | CA209025-94-877_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 19.187 | Phase III_RCC_CA209025 | REST OF WORLD | 57 | M | WHITE | 1219_Marios_PD1_Inhib2_HP-S4102905-9.raw |
SA088871 | CA209025-95-707 | CA209025-95-707_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 15.573 | Phase III_RCC_CA209025 | REST OF WORLD | 52 | M | WHITE | 0677_Marios_PD1_Inhib2_HP-S3792613-7.raw |
SA088901 | CA209025-9-575 | CA209025-9-575_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 3.318 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 1098_Marios_PD1_Inhib2_HP-AD611931-7.raw |
SA088876 | CA209025-96-819 | CA209025-96-819_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 35.910 | Phase III_RCC_CA209025 | REST OF WORLD | 68 | M | WHITE | 0175_Marios_PD1_Inhib2_HP-S3740940-7.raw |
SA088870 | CA209025-97-688 | CA209025-97-688_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 2.760 | Phase III_RCC_CA209025 | REST OF WORLD | 49 | F | WHITE | 0683_Marios_PD1_Inhib2_HP-S3722551-7.raw |
SA088862 | CA209025-98-527 | CA209025-98-527_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 3.975 | Phase III_RCC_CA209025 | REST OF WORLD | 68 | M | WHITE | 0376_Marios_PD1_Inhib2_HP-S3862085-7.raw |
SA088859 | CA209025-9-984 | CA209025-9-984_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | FALSE | 22.341 | Phase III_RCC_CA209025 | US/CANADA | 74 | F | WHITE | 0958_Marios_PD1_Inhib2_HP-AF002779-9.raw |
SA088919 | CA209025-11-145 | CA209025-11-145_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 18.431 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | OTHER | 0794_Marios_PD1_Inhib2_HP-AD604106-7.raw |
SA088903 | CA209025-121-540 | CA209025-121-540_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 6.505 | Phase III_RCC_CA209025 | REST OF WORLD | 44 | F | WHITE | 0553_Marios_PD1_Inhib2_HP-L1370587-6.raw |
SA088909 | CA209025-126-222 | CA209025-126-222_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 18.431 | Phase III_RCC_CA209025 | WESTERN EUROPE | 75 | M | WHITE | 0438_Marios_PD1_Inhib2_HP-E9474281-7.raw |
SA088925 | CA209025-138-479 | CA209025-138-479_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 25.856 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0258_Marios_PD1_Inhib2_HP-AE133961-7.raw |
SA088906 | CA209025-139-808 | CA209025-139-808_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 4.830 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0408_Marios_PD1_Inhib2_HP-AE861579-7.raw |
SA088922 | CA209025-147-620 | CA209025-147-620_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 13.996 | Phase III_RCC_CA209025 | US/CANADA | 71 | F | WHITE | 0339_Marios_PD1_Inhib2_HP-AD673733-6.raw |
SA088910 | CA209025-159-722 | CA209025-159-722_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 22.998 | Phase III_RCC_CA209025 | REST OF WORLD | 72 | M | OTHER | 0327_Marios_PD1_Inhib2_HP-S3781279-7.raw |
SA088924 | CA209025-183-874 | CA209025-183-874_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 41.561 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 0910_Marios_PD1_Inhib2_HP-AE606326-6.raw |
SA088917 | CA209025-20-122 | CA209025-20-122_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 19.745 | Phase III_RCC_CA209025 | US/CANADA | 72 | M | WHITE | 0240_Marios_PD1_Inhib2_HP-AD612902-7.raw |
SA088914 | CA209025-20-782 | CA209025-20-782_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 16.427 | Phase III_RCC_CA209025 | US/CANADA | 72 | M | WHITE | 0370_Marios_PD1_Inhib2_HP-AE710607-7.raw |
SA088904 | CA209025-23-898 | CA209025-23-898_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 20.994 | Phase III_RCC_CA209025 | US/CANADA | 73 | F | WHITE | 1049_Marios_PD1_Inhib2_HP-AF002747-9.raw |
SA088905 | CA209025-25-1028 | CA209025-25-1028_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 2.103 | Phase III_RCC_CA209025 | US/CANADA | 67 | F | WHITE | 0202_Marios_PD1_Inhib2_HP-AF185748-9.raw |
SA088907 | CA209025-25-947 | CA209025-25-947_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 11.368 | Phase III_RCC_CA209025 | US/CANADA | 69 | F | WHITE | 0090_Marios_PD1_Inhib2_HP-AF009252-9.raw |
SA088908 | CA209025-33-6 | CA209025-33-6_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 10.053 | Phase III_RCC_CA209025 | WESTERN EUROPE | 73 | M | WHITE | 0208_Marios_PD1_Inhib2_HP-E9070703-27.raw |
SA088902 | CA209025-37-18 | CA209025-37-18_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 4.731 | Phase III_RCC_CA209025 | WESTERN EUROPE | 58 | M | WHITE | 0447_Marios_PD1_Inhib2_HP-E9103769-7.raw |
SA088916 | CA209025-42-89 | CA209025-42-89_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 12.879 | Phase III_RCC_CA209025 | US/CANADA | 46 | M | WHITE | 0548_Marios_PD1_Inhib2_HP-AD452684-7.raw |
SA088913 | CA209025-53-595 | CA209025-53-595_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 39.655 | Phase III_RCC_CA209025 | US/CANADA | 43 | F | WHITE | 0575_Marios_PD1_Inhib2_HP-AE436649-7.raw |
SA088912 | CA209025-53-885 | CA209025-53-885_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 3.614 | Phase III_RCC_CA209025 | US/CANADA | 54 | M | OTHER | 0392_Marios_PD1_Inhib2_HP-AF016230-9.raw |
SA088918 | CA209025-56-532 | CA209025-56-532_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 30.719 | Phase III_RCC_CA209025 | WESTERN EUROPE | 43 | M | WHITE | 0691_Marios_PD1_Inhib2_HP-E9106982-11.raw |
SA088921 | CA209025-62-652 | CA209025-62-652_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 10.875 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 0897_Marios_PD1_Inhib2_HP-EA297778-7.raw |
SA088915 | CA209025-89-563 | CA209025-89-563_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 5.421 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | M | WHITE | 0569_Marios_PD1_Inhib2_HP-E9656485-7.raw |
SA088923 | CA209025-89-63 | CA209025-89-63_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 15.836 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0026_Marios_PD1_Inhib2_HP-E9103841-7.raw |
SA088920 | CA209025-90-87 | CA209025-90-87_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 17.610 | Phase III_RCC_CA209025 | WESTERN EUROPE | 51 | M | WHITE | 0055_Marios_PD1_Inhib2_HP-E9103088-7.raw |
SA088911 | CA209025-9-361 | CA209025-9-361_baseline | baseline | - | INTERMEDIATE | EVEROLIMUS | TRUE | 35.910 | Phase III_RCC_CA209025 | US/CANADA | 51 | M | OTHER | 0105_Marios_PD1_Inhib2_HP-AD611930-7.raw |
SA088957 | CA209025-108-510 | CA209025-108-510_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 3.910 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | WHITE | 0432_Marios_PD1_Inhib2_HP-EA185078-17.raw |
SA088939 | CA209025-1-1024 | CA209025-1-1024_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 5.651 | Phase III_RCC_CA209025 | US/CANADA | 78 | F | WHITE | 0814_Marios_PD1_Inhib2_HP-AE663608-7.raw |
SA088932 | CA209025-1-1071 | CA209025-1-1071_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.567 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 0051_Marios_PD1_Inhib2_HP-AF439756-9.raw |
SA088959 | CA209025-11-1073 | CA209025-11-1073_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 38.571 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 0867_Marios_PD1_Inhib2_HP-AF015814-9.raw |
SA088947 | CA209025-113-206 | CA209025-113-206_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 18.267 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 1046_Marios_PD1_Inhib2_HP-E9414567-7.raw |
SA088948 | CA209025-113-280 | CA209025-113-280_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 39.261 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | M | WHITE | 0792_Marios_PD1_Inhib2_HP-E9717740-7.raw |
SA088949 | CA209025-113-570 | CA209025-113-570_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 27.893 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | F | WHITE | 0197_Marios_PD1_Inhib2_HP-E9717742-7.raw |
SA088950 | CA209025-118-163 | CA209025-118-163_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 41.232 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 0710_Marios_PD1_Inhib2_HP-E9314438-7.raw |
SA088956 | CA209025-12-131 | CA209025-12-131_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 12.715 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | M | WHITE | 0543_Marios_PD1_Inhib2_HP-E9124672-7.raw |
SA088929 | CA209025-126-101 | CA209025-126-101_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 4.534 | Phase III_RCC_CA209025 | WESTERN EUROPE | 56 | M | WHITE | 0949_Marios_PD1_Inhib2_HP-E9123120-7.raw |
SA088937 | CA209025-135-694 | CA209025-135-694_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 38.407 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | WHITE | 0198_Marios_PD1_Inhib2_HP-L1379647-7.raw |
SA088958 | CA209025-135-884 | CA209025-135-884_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 26.809 | Phase III_RCC_CA209025 | REST OF WORLD | 49 | M | WHITE | 0049_Marios_PD1_Inhib2_HP-L1366489-10.raw |
SA088955 | CA209025-138-814 | CA209025-138-814_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 26.842 | Phase III_RCC_CA209025 | US/CANADA | 71 | M | WHITE | 0247_Marios_PD1_Inhib2_HP-AF004066-9.raw |
SA088954 | CA209025-138-847 | CA209025-138-847_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 25.134 | Phase III_RCC_CA209025 | US/CANADA | 76 | M | WHITE | 0967_Marios_PD1_Inhib2_HP-AE726338-7.raw |
SA088936 | CA209025-143-115 | CA209025-143-115_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.228 | Phase III_RCC_CA209025 | US/CANADA | 45 | M | WHITE | 0458_Marios_PD1_Inhib2_HP-AD645853-7.raw |
SA088951 | CA209025-143-423 | CA209025-143-423_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 24.181 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0191_Marios_PD1_Inhib2_HP-AD645855-7.raw |
SA088977 | CA209025-143-794 | CA209025-143-794_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.370 | Phase III_RCC_CA209025 | US/CANADA | 85 | M | WHITE | 0112_Marios_PD1_Inhib2_HP-AE794343-7.raw |
SA089012 | CA209025-149-646 | CA209025-149-646_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 0.296 | Phase III_RCC_CA209025 | REST OF WORLD | 71 | M | WHITE | 0987_Marios_PD1_Inhib2_HP-EA039696-7.raw |
SA089015 | CA209025-151-351 | CA209025-151-351_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 35.121 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | F | WHITE | 0304_Marios_PD1_Inhib2_HP-E9540922-7.raw |
SA089013 | CA209025-15-379 | CA209025-15-379_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 21.750 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0698_Marios_PD1_Inhib2_HP-AE091504-7.raw |
SA089014 | CA209025-155-266 | CA209025-155-266_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.622 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | OTHER | 1202_Marios_PD1_Inhib2_HP-S3578238-7.raw |
SA089009 | CA209025-155-632 | CA209025-155-632_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 15.606 | Phase III_RCC_CA209025 | REST OF WORLD | 42 | M | OTHER | 0388_Marios_PD1_Inhib2_HP-S3578236-7.raw |
SA089008 | CA209025-156-136 | CA209025-156-136_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 45.897 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | M | OTHER | 1029_Marios_PD1_Inhib2_HP-S3509147-7.raw |
SA088927 | CA209025-1-5 | CA209025-1-5_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 16.460 | Phase III_RCC_CA209025 | US/CANADA | 78 | F | WHITE | 0749_Marios_PD1_Inhib2_HP-AD176328-7.raw |
SA088926 | CA209025-1-604 | CA209025-1-604_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.889 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 1024_Marios_PD1_Inhib2_HP-AE471829-6.raw |
SA089004 | CA209025-163-542 | CA209025-163-542_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 21.815 | Phase III_RCC_CA209025 | REST OF WORLD | 81 | M | OTHER | 0663_Marios_PD1_Inhib2_HP-S3675224-7.raw |
SA088933 | CA209025-1-682 | CA209025-1-682_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 35.975 | Phase III_RCC_CA209025 | US/CANADA | 60 | F | WHITE | 0742_Marios_PD1_Inhib2_HP-AE471831-6.raw |
SA088930 | CA209025-1-716 | CA209025-1-716_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 44.583 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 1072_Marios_PD1_Inhib2_HP-AE663606-7.raw |
SA089016 | CA209025-17-213 | CA209025-17-213_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 12.945 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0903_Marios_PD1_Inhib2_HP-AD749689-8.raw |
SA089019 | CA209025-17-327 | CA209025-17-327_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 30.324 | Phase III_RCC_CA209025 | US/CANADA | 47 | M | WHITE | 0062_Marios_PD1_Inhib2_HP-AD749690-7.raw |
SA089020 | CA209025-175-252 | CA209025-175-252_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 0.887 | Phase III_RCC_CA209025 | WESTERN EUROPE | 74 | M | WHITE | 0856_Marios_PD1_Inhib2_HP-E9123327-7.raw |
SA088999 | CA209025-179-484 | CA209025-179-484_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.396 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 1213_Marios_PD1_Inhib2_HP-E9758912-7.raw |
SA088974 | CA209025-180-936 | CA209025-180-936_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.195 | Phase III_RCC_CA209025 | REST OF WORLD | 53 | M | WHITE | 0373_Marios_PD1_Inhib2_HP-E9784759-7.raw |
SA088973 | CA209025-185-983 | CA209025-185-983_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.008 | Phase III_RCC_CA209025 | US/CANADA | 53 | F | WHITE | 1007_Marios_PD1_Inhib2_HP-AF016204-8.raw |
SA088931 | CA209025-1-920 | CA209025-1-920_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 14.029 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 1162_Marios_PD1_Inhib2_HP-AE846130-7.raw |
SA088943 | CA209025-1-932 | CA209025-1-932_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 2.136 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0107_Marios_PD1_Inhib2_HP-AE846131-7.raw |
SA088953 | CA209025-1-997 | CA209025-1-997_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.534 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0801_Marios_PD1_Inhib2_HP-AF002673-9.raw |
SA088971 | CA209025-20-59 | CA209025-20-59_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 12.747 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | OTHER | 0861_Marios_PD1_Inhib2_HP-AD452646-6.raw |
SA088970 | CA209025-20-914 | CA209025-20-914_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.725 | Phase III_RCC_CA209025 | US/CANADA | 54 | M | WHITE | 0509_Marios_PD1_Inhib2_HP-AE062796-7.raw |
SA088962 | CA209025-21-307 | CA209025-21-307_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 3.318 | Phase III_RCC_CA209025 | US/CANADA | 61 | F | WHITE | 0216_Marios_PD1_Inhib2_HP-AD601337-7.raw |
SA088972 | CA209025-2-134 | CA209025-2-134_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 21.914 | Phase III_RCC_CA209025 | WESTERN EUROPE | 31 | M | OTHER | 1109_Marios_PD1_Inhib2_HP-E9425297-7.raw |
SA088975 | CA209025-2-199 | CA209025-2-199_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 10.448 | Phase III_RCC_CA209025 | WESTERN EUROPE | 36 | M | WHITE | 0009_Marios_PD1_Inhib2_HP-E9425293-7.raw |
SA088981 | CA209025-23-922 | CA209025-23-922_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 22.111 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0183_Marios_PD1_Inhib2_HP-AE886505-6.raw |
SA088994 | CA209025-25-1042 | CA209025-25-1042_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.429 | Phase III_RCC_CA209025 | US/CANADA | 75 | M | WHITE | 1210_Marios_PD1_Inhib2_HP-AF185746-9.raw |
SA089000 | CA209025-2-57 | CA209025-2-57_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 40.016 | Phase III_RCC_CA209025 | WESTERN EUROPE | 38 | M | WHITE | 0145_Marios_PD1_Inhib2_HP-E9130933-7.raw |
SA088992 | CA209025-26-559 | CA209025-26-559_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 10.645 | Phase III_RCC_CA209025 | US/CANADA | 51 | M | WHITE | 0997_Marios_PD1_Inhib2_HP-AE488971-7.raw |
SA088995 | CA209025-26-965 | CA209025-26-965_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 14.390 | Phase III_RCC_CA209025 | US/CANADA | 50 | M | WHITE | 0939_Marios_PD1_Inhib2_HP-AE588066-7.raw |
SA088996 | CA209025-27-915 | CA209025-27-915_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 8.706 | Phase III_RCC_CA209025 | US/CANADA | 74 | M | WHITE | 0230_Marios_PD1_Inhib2_HP-AE302624-7.raw |
SA088991 | CA209025-29-938 | CA209025-29-938_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.988 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 1004_Marios_PD1_Inhib2_HP-AF008966-9.raw |
SA088982 | CA209025-31-317 | CA209025-31-317_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 10.711 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 0900_Marios_PD1_Inhib2_HP-AD452570-7.raw |
SA088990 | CA209025-3-253 | CA209025-3-253_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 22.209 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | F | WHITE | 0730_Marios_PD1_Inhib2_HP-E9101839-7.raw |
SA088985 | CA209025-33-12 | CA209025-33-12_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 24.608 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | M | WHITE | 0293_Marios_PD1_Inhib2_HP-E9101785-7.raw |
SA088986 | CA209025-33-257 | CA209025-33-257_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 38.801 | Phase III_RCC_CA209025 | WESTERN EUROPE | 80 | M | WHITE | 0931_Marios_PD1_Inhib2_HP-E9102116-7.raw |
SA088984 | CA209025-3-346 | CA209025-3-346_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 14.423 | Phase III_RCC_CA209025 | WESTERN EUROPE | 68 | M | WHITE | 0605_Marios_PD1_Inhib2_HP-E9101838-7.raw |
SA088989 | CA209025-34-291 | CA209025-34-291_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.988 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 0602_Marios_PD1_Inhib2_HP-E9167415-7.raw |
SA088988 | CA209025-37-93 | CA209025-37-93_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 36.403 | Phase III_RCC_CA209025 | WESTERN EUROPE | 57 | M | WHITE | 0531_Marios_PD1_Inhib2_HP-E9103771-7.raw |
SA088987 | CA209025-38-800 | CA209025-38-800_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 15.212 | Phase III_RCC_CA209025 | WESTERN EUROPE | 42 | M | WHITE | 0775_Marios_PD1_Inhib2_HP-EA295651-7.raw |
SA088997 | CA209025-42-46 | CA209025-42-46_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 13.109 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 1152_Marios_PD1_Inhib2_HP-AD452686-7.raw |
SA088998 | CA209025-42-919 | CA209025-42-919_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.359 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 0245_Marios_PD1_Inhib2_HP-AF008952-9.raw |
SA088983 | CA209025-4-815 | CA209025-4-815_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 18.497 | Phase III_RCC_CA209025 | WESTERN EUROPE | 44 | M | WHITE | 0848_Marios_PD1_Inhib2_HP-EA532286-9.raw |
SA088980 | CA209025-48-501 | CA209025-48-501_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 12.813 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 0966_Marios_PD1_Inhib2_HP-EA044581-7.raw |
SA088967 | CA209025-48-582 | CA209025-48-582_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 3.548 | Phase III_RCC_CA209025 | WESTERN EUROPE | 61 | M | WHITE | 1194_Marios_PD1_Inhib2_HP-E9782204-7.raw |
SA088968 | CA209025-48-736 | CA209025-48-736_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.195 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | F | WHITE | 0276_Marios_PD1_Inhib2_HP-EA044583-7.raw |
SA088969 | CA209025-49-39 | CA209025-49-39_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 10.481 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 1047_Marios_PD1_Inhib2_HP-AD193615-7.raw |
SA088966 | CA209025-49-664 | CA209025-49-664_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 41.528 | Phase III_RCC_CA209025 | US/CANADA | 75 | M | WHITE | 0898_Marios_PD1_Inhib2_HP-AD577641-7.raw |
SA088964 | CA209025-49-79 | CA209025-49-79_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 13.339 | Phase III_RCC_CA209025 | US/CANADA | 39 | F | WHITE | 0143_Marios_PD1_Inhib2_HP-AD577640-7.raw |
SA088978 | CA209025-58-462 | CA209025-58-462_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 4.205 | Phase III_RCC_CA209025 | WESTERN EUROPE | 47 | M | OTHER | 0537_Marios_PD1_Inhib2_HP-E9097312-7.raw |
SA088979 | CA209025-58-739 | CA209025-58-739_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 16.953 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | F | OTHER | 0021_Marios_PD1_Inhib2_HP-E9630285-7.raw |
SA088976 | CA209025-58-74 | CA209025-58-74_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 15.376 | Phase III_RCC_CA209025 | WESTERN EUROPE | 85 | M | OTHER | 0653_Marios_PD1_Inhib2_HP-E9097314-7.raw |
SA089018 | CA209025-62-523 | CA209025-62-523_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 6.374 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 0652_Marios_PD1_Inhib2_HP-EA015429-8.raw |
SA089006 | CA209025-65-306 | CA209025-65-306_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.797 | Phase III_RCC_CA209025 | WESTERN EUROPE | 71 | M | WHITE | 0952_Marios_PD1_Inhib2_HP-EA002606-7.raw |
SA089007 | CA209025-65-553 | CA209025-65-553_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 12.123 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 0407_Marios_PD1_Inhib2_HP-E9778360-7.raw |
SA089017 | CA209025-69-810 | CA209025-69-810_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 17.084 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | F | WHITE | 0885_Marios_PD1_Inhib2_HP-EA350191-7.raw |
SA089001 | CA209025-70-617 | CA209025-70-617_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 3.943 | Phase III_RCC_CA209025 | REST OF WORLD | 78 | F | WHITE | 0476_Marios_PD1_Inhib2_HP-EA088439-7.raw |
SA089002 | CA209025-70-678 | CA209025-70-678_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 19.647 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | WHITE | 0979_Marios_PD1_Inhib2_HP-E9784263-7.raw |
SA089003 | CA209025-70-845 | CA209025-70-845_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 11.236 | Phase III_RCC_CA209025 | REST OF WORLD | 60 | M | WHITE | 0872_Marios_PD1_Inhib2_HP-E9784261-7.raw |
SA088961 | CA209025-70-883 | CA209025-70-883_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 25.528 | Phase III_RCC_CA209025 | REST OF WORLD | 77 | M | WHITE | 0700_Marios_PD1_Inhib2_HP-EA088435-7.raw |
SA089010 | CA209025-72-211 | CA209025-72-211_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 4.895 | Phase III_RCC_CA209025 | WESTERN EUROPE | 84 | M | WHITE | 0672_Marios_PD1_Inhib2_HP-E9145478-7.raw |
SA088941 | CA209025-73-512 | CA209025-73-512_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 11.565 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | WHITE | 0914_Marios_PD1_Inhib2_HP-E9717899-7.raw |
SA088934 | CA209025-73-645 | CA209025-73-645_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.166 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | M | WHITE | 0656_Marios_PD1_Inhib2_HP-E9073424-7.raw |
SA088942 | CA209025-73-789 | CA209025-73-789_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 3.943 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | WHITE | 0942_Marios_PD1_Inhib2_HP-E9717902-7.raw |
SA088945 | CA209025-75-321 | CA209025-75-321_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 15.113 | Phase III_RCC_CA209025 | WESTERN EUROPE | 36 | M | WHITE | 1160_Marios_PD1_Inhib2_HP-E9479160-7.raw |
SA088935 | CA209025-77-493 | CA209025-77-493_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 3.680 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | WHITE | 0650_Marios_PD1_Inhib2_HP-L1384333-7.raw |
SA088960 | CA209025-80-184 | CA209025-80-184_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 19.581 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0648_Marios_PD1_Inhib2_HP-E9433488-6.raw |
SA088944 | CA209025-80-265 | CA209025-80-265_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 16.920 | Phase III_RCC_CA209025 | WESTERN EUROPE | 58 | M | WHITE | 0578_Marios_PD1_Inhib2_HP-E9097390-7.raw |
SA088946 | CA209025-80-656 | CA209025-80-656_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 8.279 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 0808_Marios_PD1_Inhib2_HP-E9134600-7.raw |
SA088952 | CA209025-80-824 | CA209025-80-824_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 14.982 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | WHITE | 1000_Marios_PD1_Inhib2_HP-EA083036-7.raw |
SA088928 | CA209025-82-506 | CA209025-82-506_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.205 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 0675_Marios_PD1_Inhib2_HP-EA305475-6.raw |
SA088938 | CA209025-84-894 | CA209025-84-894_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 5.651 | Phase III_RCC_CA209025 | REST OF WORLD | 49 | M | WHITE | 0819_Marios_PD1_Inhib2_HP-L1381808-7.raw |
SA088940 | CA209025-90-247 | CA209025-90-247_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 8.871 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | F | WHITE | 0103_Marios_PD1_Inhib2_HP-E9665084-7.raw |
SA089011 | CA209025-93-460 | CA209025-93-460_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 13.865 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | F | WHITE | 0689_Marios_PD1_Inhib2_HP-E9791866-7.raw |
SA089005 | CA209025-95-318 | CA209025-95-318_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.764 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | WHITE | 0763_Marios_PD1_Inhib2_HP-S3713044-7.raw |
SA088963 | CA209025-95-706 | CA209025-95-706_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 2.004 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 1142_Marios_PD1_Inhib2_HP-S3792614-7.raw |
SA088965 | CA209025-95-721 | CA209025-95-721_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 5.684 | Phase III_RCC_CA209025 | REST OF WORLD | 49 | M | WHITE | 0572_Marios_PD1_Inhib2_HP-S3792616-7.raw |
SA088993 | CA209025-95-834 | CA209025-95-834_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | FALSE | 0.723 | Phase III_RCC_CA209025 | REST OF WORLD | 56 | F | WHITE | 0229_Marios_PD1_Inhib2_HP-S4025566-7.raw |
SA089021 | CA209025-114-597 | CA209025-114-597_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 43.105 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0561_Marios_PD1_Inhib2_HP-EA341119-7.raw |
SA089028 | CA209025-126-149 | CA209025-126-149_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 21.388 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | M | WHITE | 0310_Marios_PD1_Inhib2_HP-E9474280-7.raw |
SA089023 | CA209025-135-795 | CA209025-135-795_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 17.314 | Phase III_RCC_CA209025 | REST OF WORLD | 77 | F | OTHER | 1172_Marios_PD1_Inhib2_HP-L1379646-7.raw |
SA089040 | CA209025-138-480 | CA209025-138-480_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 28.255 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0611_Marios_PD1_Inhib2_HP-AE133960-7.raw |
SA089041 | CA209025-138-619 | CA209025-138-619_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 16.723 | Phase III_RCC_CA209025 | US/CANADA | 73 | M | WHITE | 0857_Marios_PD1_Inhib2_HP-AE428475-7.raw |
SA089049 | CA209025-139-864 | CA209025-139-864_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 16.624 | Phase III_RCC_CA209025 | US/CANADA | 68 | M | WHITE | 0936_Marios_PD1_Inhib2_HP-AF003920-9.raw |
SA089034 | CA209025-139-989 | CA209025-139-989_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 26.086 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0120_Marios_PD1_Inhib2_HP-AF003921-9.raw |
SA089030 | CA209025-158-183 | CA209025-158-183_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 19.023 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | F | OTHER | 0945_Marios_PD1_Inhib2_HP-S3653084-7.raw |
SA089048 | CA209025-160-786 | CA209025-160-786_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 8.904 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | F | OTHER | 0853_Marios_PD1_Inhib2_HP-S3717397-6.raw |
SA089037 | CA209025-164-901 | CA209025-164-901_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 25.823 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | F | OTHER | 0354_Marios_PD1_Inhib2_HP-S4093204-9.raw |
SA089038 | CA209025-166-957 | CA209025-166-957_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 13.963 | Phase III_RCC_CA209025 | REST OF WORLD | 68 | M | OTHER | 1031_Marios_PD1_Inhib2_HP-S4152606-9.raw |
SA089031 | CA209025-173-377 | CA209025-173-377_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 15.310 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | OTHER | 0419_Marios_PD1_Inhib2_HP-S3575911-7.raw |
SA089043 | CA209025-23-20 | CA209025-23-20_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 43.335 | Phase III_RCC_CA209025 | US/CANADA | 66 | F | WHITE | 0815_Marios_PD1_Inhib2_HP-AD195647-7.raw |
SA089046 | CA209025-23-72 | CA209025-23-72_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 13.175 | Phase III_RCC_CA209025 | US/CANADA | 77 | M | WHITE | 0516_Marios_PD1_Inhib2_HP-AD490505-6.raw |
SA089025 | CA209025-25-166 | CA209025-25-166_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 12.090 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0495_Marios_PD1_Inhib2_HP-AD775401-7.raw |
SA089032 | CA209025-27-906 | CA209025-27-906_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 17.150 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 1185_Marios_PD1_Inhib2_HP-AE302623-7.raw |
SA089036 | CA209025-39-150 | CA209025-39-150_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 14.324 | Phase III_RCC_CA209025 | WESTERN EUROPE | 53 | M | OTHER | 1134_Marios_PD1_Inhib2_HP-E9432887-7.raw |
SA089024 | CA209025-44-785 | CA209025-44-785_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 26.316 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0096_Marios_PD1_Inhib2_HP-AE837371-7.raw |
SA089045 | CA209025-48-284 | CA209025-48-284_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 15.836 | Phase III_RCC_CA209025 | WESTERN EUROPE | 74 | M | WHITE | 0157_Marios_PD1_Inhib2_HP-E9674323-7.raw |
SA089044 | CA209025-48-500 | CA209025-48-500_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 5.552 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | WHITE | 0027_Marios_PD1_Inhib2_HP-E9674321-7.raw |
SA089042 | CA209025-63-790 | CA209025-63-790_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 8.706 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | F | WHITE | 0266_Marios_PD1_Inhib2_HP-E9528382-8.raw |
SA089029 | CA209025-79-73 | CA209025-79-73_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 45.175 | Phase III_RCC_CA209025 | REST OF WORLD | 48 | F | WHITE | 0988_Marios_PD1_Inhib2_HP-L1293268-6.raw |
SA089047 | CA209025-82-139 | CA209025-82-139_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 4.370 | Phase III_RCC_CA209025 | WESTERN EUROPE | 56 | F | WHITE | 0371_Marios_PD1_Inhib2_HP-E9172456-7.raw |
SA089033 | CA209025-82-355 | CA209025-82-355_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 4.205 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 0100_Marios_PD1_Inhib2_HP-E9703900-6.raw |
SA089039 | CA209025-89-129 | CA209025-89-129_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 4.304 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | F | WHITE | 0865_Marios_PD1_Inhib2_HP-E9526839-7.raw |
SA089035 | CA209025-90-30 | CA209025-90-30_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 9.593 | Phase III_RCC_CA209025 | WESTERN EUROPE | 74 | F | WHITE | 0383_Marios_PD1_Inhib2_HP-E9103087-7.raw |
SA089026 | CA209025-9-754 | CA209025-9-754_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 34.037 | Phase III_RCC_CA209025 | US/CANADA | 71 | M | WHITE | 1099_Marios_PD1_Inhib2_HP-AE556392-7.raw |
SA089022 | CA209025-97-569 | CA209025-97-569_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 29.766 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | OTHER | 0499_Marios_PD1_Inhib2_HP-S3722553-7.raw |
SA089027 | CA209025-98-673 | CA209025-98-673_baseline | baseline | - | INTERMEDIATE | NIVOLUMAB | TRUE | 11.499 | Phase III_RCC_CA209025 | REST OF WORLD | 76 | F | WHITE | 0882_Marios_PD1_Inhib2_HP-S3862083-7.raw |
SA089078 | CA209025-116-530 | CA209025-116-530_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 15.639 | Phase III_RCC_CA209025 | REST OF WORLD | 57 | M | WHITE | 0473_Marios_PD1_Inhib2_HP-E9567515-9.raw |
SA089069 | CA209025-118-160 | CA209025-118-160_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 0.789 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 1067_Marios_PD1_Inhib2_HP-E9314436-7.raw |
SA089086 | CA209025-121-214 | CA209025-121-214_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 11.499 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | M | WHITE | 1089_Marios_PD1_Inhib2_HP-L1305559-7.raw |
SA089074 | CA209025-125-525 | CA209025-125-525_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 3.614 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | F | WHITE | 0092_Marios_PD1_Inhib2_HP-L1366505-7.raw |
SA089067 | CA209025-137-127 | CA209025-137-127_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 7.852 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | M | WHITE | 0594_Marios_PD1_Inhib2_HP-E9073335-7.raw |
SA089075 | CA209025-139-1033 | CA209025-139-1033_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 16.230 | Phase III_RCC_CA209025 | US/CANADA | 49 | M | WHITE | 0174_Marios_PD1_Inhib2_HP-AF337221-9.raw |
SA089077 | CA209025-144-435 | CA209025-144-435_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 14.522 | Phase III_RCC_CA209025 | US/CANADA | 61 | F | WHITE | 0562_Marios_PD1_Inhib2_HP-AD829004-7.raw |
SA089088 | CA209025-149-251 | CA209025-149-251_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 15.737 | Phase III_RCC_CA209025 | REST OF WORLD | 73 | M | WHITE | 0282_Marios_PD1_Inhib2_HP-E9540033-7.raw |
SA089051 | CA209025-149-783 | CA209025-149-783_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 2.661 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | F | WHITE | 0478_Marios_PD1_Inhib2_HP-E9540032-7.raw |
SA089056 | CA209025-151-490 | CA209025-151-490_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 9.495 | Phase III_RCC_CA209025 | REST OF WORLD | 67 | F | WHITE | 1036_Marios_PD1_Inhib2_HP-EA251051-7.raw |
SA089061 | CA209025-153-406 | CA209025-153-406_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 5.092 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0445_Marios_PD1_Inhib2_HP-AD780266-7.raw |
SA089054 | CA209025-15-555 | CA209025-15-555_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 7.162 | Phase III_RCC_CA209025 | US/CANADA | 41 | F | WHITE | 0444_Marios_PD1_Inhib2_HP-AE383168-7.raw |
SA089064 | CA209025-15-774 | CA209025-15-774_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 6.407 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0320_Marios_PD1_Inhib2_HP-AE383169-7.raw |
SA089068 | CA209025-172-354 | CA209025-172-354_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 5.060 | Phase III_RCC_CA209025 | REST OF WORLD | 81 | F | OTHER | 0366_Marios_PD1_Inhib2_HP-S3670415-7.raw |
SA089087 | CA209025-17-397 | CA209025-17-397_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 18.793 | Phase III_RCC_CA209025 | US/CANADA | 66 | F | WHITE | 0643_Marios_PD1_Inhib2_HP-AE104721-7.raw |
SA089072 | CA209025-22-1022 | CA209025-22-1022_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 7.918 | Phase III_RCC_CA209025 | US/CANADA | 36 | M | WHITE | 0023_Marios_PD1_Inhib2_HP-AF009294-9.raw |
SA089084 | CA209025-2-23 | CA209025-2-23_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 13.799 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | M | OTHER | 1173_Marios_PD1_Inhib2_HP-E9101709-7.raw |
SA089081 | CA209025-2-746 | CA209025-2-746_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 16.624 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | F | WHITE | 0462_Marios_PD1_Inhib2_HP-E9618952-7.raw |
SA089070 | CA209025-29-68 | CA209025-29-68_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 3.811 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0661_Marios_PD1_Inhib2_HP-AD176341-6.raw |
SA089083 | CA209025-36-310 | CA209025-36-310_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 11.203 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 0916_Marios_PD1_Inhib2_HP-E9103752-7.raw |
SA089085 | CA209025-39-220 | CA209025-39-220_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 12.090 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | M | WHITE | 1022_Marios_PD1_Inhib2_HP-E9432884-7.raw |
SA089071 | CA209025-42-1058 | CA209025-42-1058_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 2.990 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 0186_Marios_PD1_Inhib2_HP-AF439245-9.raw |
SA089079 | CA209025-4-313 | CA209025-4-313_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 22.768 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | M | WHITE | 0973_Marios_PD1_Inhib2_HP-E9099273-7.raw |
SA089062 | CA209025-43-917 | CA209025-43-917_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 2.727 | Phase III_RCC_CA209025 | US/CANADA | 55 | M | WHITE | 0754_Marios_PD1_Inhib2_HP-AF003941-9.raw |
SA089073 | CA209025-4-43 | CA209025-4-43_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 8.476 | Phase III_RCC_CA209025 | WESTERN EUROPE | 75 | M | WHITE | 1061_Marios_PD1_Inhib2_HP-E9108955-7.raw |
SA089076 | CA209025-4-731 | CA209025-4-731_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 1.019 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 0079_Marios_PD1_Inhib2_HP-E9099271-7.raw |
SA089063 | CA209025-47-860 | CA209025-47-860_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 2.826 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 1217_Marios_PD1_Inhib2_HP-AE679098-7.raw |
SA089058 | CA209025-5-35 | CA209025-5-35_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 5.848 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | F | WHITE | 0688_Marios_PD1_Inhib2_HP-E9108657-7.raw |
SA089053 | CA209025-5-538 | CA209025-5-538_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 5.191 | Phase III_RCC_CA209025 | WESTERN EUROPE | 74 | M | WHITE | 0905_Marios_PD1_Inhib2_HP-E9125254-7.raw |
SA089052 | CA209025-58-457 | CA209025-58-457_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 18.497 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | M | OTHER | 0349_Marios_PD1_Inhib2_HP-E9630287-7.raw |
SA089060 | CA209025-74-52 | CA209025-74-52_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 9.692 | Phase III_RCC_CA209025 | WESTERN EUROPE | 61 | M | WHITE | 0213_Marios_PD1_Inhib2_HP-E9103992-7.raw |
SA089059 | CA209025-75-520 | CA209025-75-520_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 13.339 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | F | WHITE | 1034_Marios_PD1_Inhib2_HP-E9479162-7.raw |
SA089065 | CA209025-75-529 | CA209025-75-529_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 5.027 | Phase III_RCC_CA209025 | WESTERN EUROPE | 76 | M | WHITE | 0719_Marios_PD1_Inhib2_HP-E9479163-7.raw |
SA089066 | CA209025-78-726 | CA209025-78-726_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 0.690 | Phase III_RCC_CA209025 | REST OF WORLD | 56 | M | WHITE | 1042_Marios_PD1_Inhib2_HP-L1376088-6.raw |
SA089055 | CA209025-82-217 | CA209025-82-217_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 4.403 | Phase III_RCC_CA209025 | WESTERN EUROPE | 31 | M | WHITE | 0557_Marios_PD1_Inhib2_HP-E9703899-8.raw |
SA089050 | CA209025-93-187 | CA209025-93-187_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 42.941 | Phase III_RCC_CA209025 | WESTERN EUROPE | 76 | M | WHITE | 0071_Marios_PD1_Inhib2_HP-E9123036-7.raw |
SA089057 | CA209025-9-531 | CA209025-9-531_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 9.002 | Phase III_RCC_CA209025 | US/CANADA | 60 | F | WHITE | 0468_Marios_PD1_Inhib2_HP-AD611932-7.raw |
SA089082 | CA209025-95-613 | CA209025-95-613_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 1.117 | Phase III_RCC_CA209025 | REST OF WORLD | 58 | M | WHITE | 0676_Marios_PD1_Inhib2_HP-S3713042-7.raw |
SA089080 | CA209025-97-788 | CA209025-97-788_baseline | baseline | - | POOR | EVEROLIMUS | FALSE | 1.380 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | WHITE | 0207_Marios_PD1_Inhib2_HP-S4038602-7.raw |
SA089091 | CA209025-113-75 | CA209025-113-75_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 7.129 | Phase III_RCC_CA209025 | WESTERN EUROPE | 74 | M | WHITE | 0314_Marios_PD1_Inhib2_HP-E9123068-7.raw |
SA089104 | CA209025-139-576 | CA209025-139-576_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 3.745 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 1104_Marios_PD1_Inhib2_HP-AD783001-7.raw |
SA089095 | CA209025-145-278 | CA209025-145-278_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 4.698 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 0361_Marios_PD1_Inhib2_HP-AD780352-7.raw |
SA089101 | CA209025-1-478 | CA209025-1-478_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 20.665 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 1180_Marios_PD1_Inhib2_HP-AD709259-7.raw |
SA089105 | CA209025-17-343 | CA209025-17-343_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 5.421 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | OTHER | 0414_Marios_PD1_Inhib2_HP-AE104720-7.raw |
SA089103 | CA209025-17-964 | CA209025-17-964_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 35.351 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0727_Marios_PD1_Inhib2_HP-AF015797-9.raw |
SA089096 | CA209025-180-1001 | CA209025-180-1001_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 24.246 | Phase III_RCC_CA209025 | REST OF WORLD | 80 | F | WHITE | 0962_Marios_PD1_Inhib2_HP-E9784758-7.raw |
SA089092 | CA209025-20-1031 | CA209025-20-1031_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 2.201 | Phase III_RCC_CA209025 | US/CANADA | 73 | F | WHITE | 0714_Marios_PD1_Inhib2_HP-AF002812-9.raw |
SA089094 | CA209025-20-715 | CA209025-20-715_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 4.731 | Phase III_RCC_CA209025 | US/CANADA | 73 | M | WHITE | 1055_Marios_PD1_Inhib2_HP-AE331982-7.raw |
SA089090 | CA209025-21-509 | CA209025-21-509_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 6.538 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0793_Marios_PD1_Inhib2_HP-AE206901-7.raw |
SA089093 | CA209025-2-32 | CA209025-2-32_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 7.195 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | M | WHITE | 1028_Marios_PD1_Inhib2_HP-E9130937-7.raw |
SA089098 | CA209025-29-312 | CA209025-29-312_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 1.938 | Phase III_RCC_CA209025 | US/CANADA | 60 | F | WHITE | 0401_Marios_PD1_Inhib2_HP-AD657189-7.raw |
SA089106 | CA209025-41-456 | CA209025-41-456_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 16.493 | Phase III_RCC_CA209025 | US/CANADA | 75 | F | WHITE | 0237_Marios_PD1_Inhib2_HP-AF008940-18.raw |
SA089100 | CA209025-41-924 | CA209025-41-924_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 3.581 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 1198_Marios_PD1_Inhib2_HP-AE525981-7.raw |
SA089097 | CA209025-78-53 | CA209025-78-53_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 12.550 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | WHITE | 0555_Marios_PD1_Inhib2_HP-L1293251-7.raw |
SA089089 | CA209025-82-369 | CA209025-82-369_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 7.918 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | M | WHITE | 0469_Marios_PD1_Inhib2_HP-EA305474-7.raw |
SA089099 | CA209025-8-524 | CA209025-8-524_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 15.212 | Phase III_RCC_CA209025 | WESTERN EUROPE | 48 | M | WHITE | 0341_Marios_PD1_Inhib2_HP-E9108731-7.raw |
SA089102 | CA209025-97-286 | CA209025-97-286_baseline | baseline | - | POOR | EVEROLIMUS | TRUE | 0.789 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | F | WHITE | 0956_Marios_PD1_Inhib2_HP-S3708671-7.raw |
SA089113 | CA209025-102-86 | CA209025-102-86_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 11.729 | Phase III_RCC_CA209025 | WESTERN EUROPE | 56 | M | WHITE | 0493_Marios_PD1_Inhib2_HP-E9172288-6.raw |
SA089144 | CA209025-113-50 | CA209025-113-50_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 3.614 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | M | WHITE | 0218_Marios_PD1_Inhib2_HP-E9123067-7.raw |
SA089129 | CA209025-11-482 | CA209025-11-482_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 4.501 | Phase III_RCC_CA209025 | US/CANADA | 66 | F | OTHER | 0460_Marios_PD1_Inhib2_HP-AE330679-6.raw |
SA089149 | CA209025-119-192 | CA209025-119-192_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 34.333 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | F | WHITE | 0685_Marios_PD1_Inhib2_HP-E9123042-7.raw |
SA089131 | CA209025-125-647 | CA209025-125-647_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 35.253 | Phase III_RCC_CA209025 | REST OF WORLD | 54 | M | WHITE | 0812_Marios_PD1_Inhib2_HP-L1392381-7.raw |
SA089141 | CA209025-12-65 | CA209025-12-65_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 28.058 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | M | WHITE | 0704_Marios_PD1_Inhib2_HP-E9124674-7.raw |
SA089133 | CA209025-12-723 | CA209025-12-723_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 18.234 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 0957_Marios_PD1_Inhib2_HP-E9108719-7.raw |
SA089135 | CA209025-13-111 | CA209025-13-111_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 25.002 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0570_Marios_PD1_Inhib2_HP-AD452590-7.raw |
SA089145 | CA209025-143-515 | CA209025-143-515_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 9.068 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0615_Marios_PD1_Inhib2_HP-AE459919-6.raw |
SA089138 | CA209025-144-451 | CA209025-144-451_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 22.439 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | WHITE | 0251_Marios_PD1_Inhib2_HP-AD829003-7.raw |
SA089139 | CA209025-144-596 | CA209025-144-596_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 22.867 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0639_Marios_PD1_Inhib2_HP-AE506716-7.raw |
SA089136 | CA209025-153-416 | CA209025-153-416_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 5.092 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 0963_Marios_PD1_Inhib2_HP-AD780265-7.raw |
SA089134 | CA209025-165-83 | CA209025-165-83_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 27.368 | Phase III_RCC_CA209025 | REST OF WORLD | 72 | M | OTHER | 0034_Marios_PD1_Inhib2_HP-S3475410-7.raw |
SA089142 | CA209025-17-541 | CA209025-17-541_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 0.821 | Phase III_RCC_CA209025 | US/CANADA | 79 | M | WHITE | 0790_Marios_PD1_Inhib2_HP-AG020731-2.raw |
SA089152 | CA209025-179-521 | CA209025-179-521_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 6.439 | Phase III_RCC_CA209025 | WESTERN EUROPE | 49 | M | WHITE | 1135_Marios_PD1_Inhib2_HP-E9758913-7.raw |
SA089150 | CA209025-17-981 | CA209025-17-981_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 27.926 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | WHITE | 0628_Marios_PD1_Inhib2_HP-AF015798-9.raw |
SA089146 | CA209025-20-781 | CA209025-20-781_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 36.961 | Phase III_RCC_CA209025 | US/CANADA | 48 | M | WHITE | 0285_Marios_PD1_Inhib2_HP-AE710608-7.raw |
SA089153 | CA209025-21-1050 | CA209025-21-1050_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 25.988 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0450_Marios_PD1_Inhib2_HP-AF002693-9.raw |
SA089114 | CA209025-21-308 | CA209025-21-308_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 18.300 | Phase III_RCC_CA209025 | US/CANADA | 55 | M | WHITE | 0133_Marios_PD1_Inhib2_HP-AE206903-7.raw |
SA089115 | CA209025-21-311 | CA209025-21-311_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 9.232 | Phase III_RCC_CA209025 | US/CANADA | 68 | M | WHITE | 0425_Marios_PD1_Inhib2_HP-AE206905-7.raw |
SA089111 | CA209025-23-671 | CA209025-23-671_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 1.774 | Phase III_RCC_CA209025 | US/CANADA | 82 | M | WHITE | 0041_Marios_PD1_Inhib2_HP-AE600728-7.raw |
SA089109 | CA209025-23-9 | CA209025-23-9_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 12.255 | Phase III_RCC_CA209025 | US/CANADA | 69 | M | WHITE | 0448_Marios_PD1_Inhib2_HP-AD195646-7.raw |
SA089110 | CA209025-25-130 | CA209025-25-130_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 13.602 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0316_Marios_PD1_Inhib2_HP-AD610057-7.raw |
SA089108 | CA209025-25-987 | CA209025-25-987_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 10.218 | Phase III_RCC_CA209025 | US/CANADA | 85 | M | WHITE | 0193_Marios_PD1_Inhib2_HP-AF009253-9.raw |
SA089117 | CA209025-27-566 | CA209025-27-566_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 9.593 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0456_Marios_PD1_Inhib2_HP-AD451701-6.raw |
SA089147 | CA209025-2-76 | CA209025-2-76_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 20.403 | Phase III_RCC_CA209025 | WESTERN EUROPE | 48 | F | WHITE | 0135_Marios_PD1_Inhib2_HP-E9425295-7.raw |
SA089127 | CA209025-30-695 | CA209025-30-695_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 9.528 | Phase III_RCC_CA209025 | US/CANADA | 62 | F | WHITE | 0233_Marios_PD1_Inhib2_HP-AE355053-6.raw |
SA089118 | CA209025-33-7 | CA209025-33-7_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 20.698 | Phase III_RCC_CA209025 | WESTERN EUROPE | 30 | F | WHITE | 0541_Marios_PD1_Inhib2_HP-E9070705-7.raw |
SA089119 | CA209025-37-711 | CA209025-37-711_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 1.741 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | M | WHITE | 1048_Marios_PD1_Inhib2_HP-E9774680-7.raw |
SA089120 | CA209025-39-102 | CA209025-39-102_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 11.663 | Phase III_RCC_CA209025 | WESTERN EUROPE | 68 | M | WHITE | 1010_Marios_PD1_Inhib2_HP-E9204600-7.raw |
SA089126 | CA209025-42-316 | CA209025-42-316_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 6.538 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0209_Marios_PD1_Inhib2_HP-AE155084-7.raw |
SA089124 | CA209025-42-622 | CA209025-42-622_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 2.661 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 1209_Marios_PD1_Inhib2_HP-AE601506-7.raw |
SA089122 | CA209025-4-732 | CA209025-4-732_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 1.577 | Phase III_RCC_CA209025 | WESTERN EUROPE | 49 | M | WHITE | 0427_Marios_PD1_Inhib2_HP-E9099303-2.raw |
SA089148 | CA209025-62-225 | CA209025-62-225_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 8.312 | Phase III_RCC_CA209025 | WESTERN EUROPE | 42 | M | WHITE | 0395_Marios_PD1_Inhib2_HP-E9589114-7.raw |
SA089132 | CA209025-70-347 | CA209025-70-347_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 42.382 | Phase III_RCC_CA209025 | REST OF WORLD | 71 | M | WHITE | 0296_Marios_PD1_Inhib2_HP-EA088436-7.raw |
SA089140 | CA209025-71-709 | CA209025-71-709_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 17.051 | Phase III_RCC_CA209025 | REST OF WORLD | 68 | M | WHITE | 1183_Marios_PD1_Inhib2_HP-E9337920-7.raw |
SA089137 | CA209025-73-178 | CA209025-73-178_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 15.343 | Phase III_RCC_CA209025 | WESTERN EUROPE | 51 | M | WHITE | 0918_Marios_PD1_Inhib2_HP-E9106365-8.raw |
SA089116 | CA209025-82-200 | CA209025-82-200_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 2.398 | Phase III_RCC_CA209025 | WESTERN EUROPE | 61 | F | WHITE | 1216_Marios_PD1_Inhib2_HP-E9703902-7.raw |
SA089107 | CA209025-82-302 | CA209025-82-302_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 5.027 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0786_Marios_PD1_Inhib2_HP-E9703901-7.raw |
SA089121 | CA209025-85-940 | CA209025-85-940_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 9.331 | Phase III_RCC_CA209025 | REST OF WORLD | 76 | M | WHITE | 1103_Marios_PD1_Inhib2_HP-L1497969-9.raw |
SA089130 | CA209025-85-992 | CA209025-85-992_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 13.339 | Phase III_RCC_CA209025 | REST OF WORLD | 58 | M | WHITE | 1014_Marios_PD1_Inhib2_HP-L1497968-10.raw |
SA089151 | CA209025-8-628 | CA209025-8-628_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 44.386 | Phase III_RCC_CA209025 | WESTERN EUROPE | 73 | M | WHITE | 0480_Marios_PD1_Inhib2_HP-E9125190-7.raw |
SA089125 | CA209025-89-34 | CA209025-89-34_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 48.526 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | M | WHITE | 0430_Marios_PD1_Inhib2_HP-E9103839-7.raw |
SA089143 | CA209025-95-320 | CA209025-95-320_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 1.150 | Phase III_RCC_CA209025 | REST OF WORLD | 80 | M | WHITE | 0961_Marios_PD1_Inhib2_HP-S3447249-7.raw |
SA089128 | CA209025-95-331 | CA209025-95-331_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 46.686 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | M | WHITE | 0118_Marios_PD1_Inhib2_HP-S3713043-7.raw |
SA089112 | CA209025-95-681 | CA209025-95-681_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 4.862 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | WHITE | 0521_Marios_PD1_Inhib2_HP-S3907393-7.raw |
SA089123 | CA209025-98-547 | CA209025-98-547_baseline | baseline | - | POOR | NIVOLUMAB | FALSE | 9.396 | Phase III_RCC_CA209025 | REST OF WORLD | 48 | F | WHITE | 0692_Marios_PD1_Inhib2_HP-S3862084-7.raw |
SA089164 | CA209025-139-1025 | CA209025-139-1025_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 6.209 | Phase III_RCC_CA209025 | US/CANADA | 72 | F | WHITE | 0850_Marios_PD1_Inhib2_HP-AF337224-9.raw |
SA089154 | CA209025-139-140 | CA209025-139-140_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 45.470 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0255_Marios_PD1_Inhib2_HP-AD585851-7.raw |
SA089155 | CA209025-139-359 | CA209025-139-359_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 32.723 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 0947_Marios_PD1_Inhib2_HP-AE052722-7.raw |
SA089161 | CA209025-153-407 | CA209025-153-407_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 32.230 | Phase III_RCC_CA209025 | US/CANADA | 45 | M | WHITE | 0607_Marios_PD1_Inhib2_HP-AD780267-7.raw |
SA089159 | CA209025-158-70 | CA209025-158-70_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 26.711 | Phase III_RCC_CA209025 | REST OF WORLD | 39 | F | OTHER | 0001_Marios_PD1_Inhib2_HP-S3473952-7.raw |
SA089166 | CA209025-20-371 | CA209025-20-371_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 5.257 | Phase III_RCC_CA209025 | US/CANADA | 43 | M | WHITE | 1196_Marios_PD1_Inhib2_HP-AE062797-7.raw |
SA089168 | CA209025-2-357 | CA209025-2-357_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 38.407 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | M | WHITE | 0241_Marios_PD1_Inhib2_HP-E9657509-7.raw |
SA089165 | CA209025-25-930 | CA209025-25-930_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 7.655 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0042_Marios_PD1_Inhib2_HP-AF009251-9.raw |
SA089167 | CA209025-41-485 | CA209025-41-485_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 7.491 | Phase III_RCC_CA209025 | US/CANADA | 71 | M | WHITE | 0344_Marios_PD1_Inhib2_HP-AD604553-11.raw |
SA089162 | CA209025-49-828 | CA209025-49-828_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 0.526 | Phase III_RCC_CA209025 | US/CANADA | 41 | F | WHITE | 0560_Marios_PD1_Inhib2_HP-AE354851-10.raw |
SA089163 | CA209025-56-522 | CA209025-56-522_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 4.731 | Phase III_RCC_CA209025 | WESTERN EUROPE | 40 | M | WHITE | 0829_Marios_PD1_Inhib2_HP-E9096039-7.raw |
SA089157 | CA209025-62-552 | CA209025-62-552_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 3.253 | Phase III_RCC_CA209025 | WESTERN EUROPE | 50 | M | WHITE | 1221_Marios_PD1_Inhib2_HP-EA039954-7.raw |
SA089158 | CA209025-69-539 | CA209025-69-539_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 18.136 | Phase III_RCC_CA209025 | REST OF WORLD | 54 | F | WHITE | 0280_Marios_PD1_Inhib2_HP-E9483500-7.raw |
SA089160 | CA209025-82-904 | CA209025-82-904_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 3.023 | Phase III_RCC_CA209025 | WESTERN EUROPE | 51 | F | WHITE | 0400_Marios_PD1_Inhib2_HP-EA305478-7.raw |
SA089156 | CA209025-89-132 | CA209025-89-132_baseline | baseline | - | POOR | NIVOLUMAB | TRUE | 10.218 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 0222_Marios_PD1_Inhib2_HP-E9526838-7.raw |
SA089498 | CA209025-1-1048 | CA209025-1-1048_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | FALSE | 38.275 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0226_Marios_PD1_Inhib2_HP-AF365618-8.raw |
SA089495 | CA209025-141-667 | CA209025-141-667_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | FALSE | 28.583 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0363_Marios_PD1_Inhib2_HP-AE462189-7.raw |
SA089492 | CA209025-141-730 | CA209025-141-730_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | FALSE | 34.793 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0713_Marios_PD1_Inhib2_HP-AE630797-8.raw |
SA089496 | CA209025-14-943 | CA209025-14-943_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | FALSE | 41.429 | Phase III_RCC_CA209025 | US/CANADA | 75 | F | WHITE | 0930_Marios_PD1_Inhib2_HP-AF015791-8.raw |
SA089493 | CA209025-154-1019 | CA209025-154-1019_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | FALSE | 39.754 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | OTHER | 0708_Marios_PD1_Inhib2_HP-S4107204-8.raw |
SA089500 | CA209025-159-994 | CA209025-159-994_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | FALSE | 24.476 | Phase III_RCC_CA209025 | REST OF WORLD | 60 | F | OTHER | 0318_Marios_PD1_Inhib2_HP-S4107214-8.raw |
SA089497 | CA209025-20-946 | CA209025-20-946_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | FALSE | 41.298 | Phase III_RCC_CA209025 | US/CANADA | 55 | M | WHITE | 0559_Marios_PD1_Inhib2_HP-AF002819-8.raw |
SA089494 | CA209025-84-861 | CA209025-84-861_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | FALSE | 27.466 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | WHITE | 0609_Marios_PD1_Inhib2_HP-L1448904-12.raw |
SA089499 | CA209025-92-806 | CA209025-92-806_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | FALSE | 27.236 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | WHITE | 1021_Marios_PD1_Inhib2_HP-EA716002-8.raw |
SA089502 | CA209025-1-1056 | CA209025-1-1056_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | TRUE | 22.801 | Phase III_RCC_CA209025 | US/CANADA | 76 | M | WHITE | 0201_Marios_PD1_Inhib2_HP-AF581650-8.raw |
SA089501 | CA209025-138-699 | CA209025-138-699_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | TRUE | 43.532 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0140_Marios_PD1_Inhib2_HP-AE726357-6.raw |
SA089503 | CA209025-47-1037 | CA209025-47-1037_week 4 | week 4 | 1 | FAVORABLE | EVEROLIMUS | TRUE | 40.476 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0568_Marios_PD1_Inhib2_HP-AF016172-8.raw |
SA089506 | CA209025-138-734 | CA209025-138-734_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.682 | Phase III_RCC_CA209025 | US/CANADA | 62 | F | WHITE | 1190_Marios_PD1_Inhib2_HP-AE726356-6.raw |
SA089520 | CA209025-139-1006 | CA209025-139-1006_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 39.589 | Phase III_RCC_CA209025 | US/CANADA | 46 | M | WHITE | 0921_Marios_PD1_Inhib2_HP-AF048325-8.raw |
SA089515 | CA209025-154-929 | CA209025-154-929_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 42.481 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | M | OTHER | 1156_Marios_PD1_Inhib2_HP-S4107203-8.raw |
SA089509 | CA209025-156-1017 | CA209025-156-1017_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 39.918 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | OTHER | 1052_Marios_PD1_Inhib2_HP-S4152615-7.raw |
SA089516 | CA209025-15-773 | CA209025-15-773_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.090 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0330_Marios_PD1_Inhib2_HP-AE091510-8.raw |
SA089507 | CA209025-161-974 | CA209025-161-974_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.936 | Phase III_RCC_CA209025 | REST OF WORLD | 69 | F | OTHER | 0518_Marios_PD1_Inhib2_HP-S4144272-8.raw |
SA089511 | CA209025-169-660 | CA209025-169-660_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.419 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 0844_Marios_PD1_Inhib2_HP-S4022646-7.raw |
SA089514 | CA209025-17-1044 | CA209025-17-1044_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 39.524 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0380_Marios_PD1_Inhib2_HP-AG392084-34.raw |
SA089510 | CA209025-173-757 | CA209025-173-757_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 22.111 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | M | OTHER | 0497_Marios_PD1_Inhib2_HP-S4097411-8.raw |
SA089513 | CA209025-174-1010 | CA209025-174-1010_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.049 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | OTHER | 0983_Marios_PD1_Inhib2_HP-S4107173-8.raw |
SA089512 | CA209025-17-928 | CA209025-17-928_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 42.283 | Phase III_RCC_CA209025 | US/CANADA | 77 | M | WHITE | 1059_Marios_PD1_Inhib2_HP-AF064095-8.raw |
SA089508 | CA209025-18-954 | CA209025-18-954_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 41.922 | Phase III_RCC_CA209025 | US/CANADA | 43 | M | OTHER | 0679_Marios_PD1_Inhib2_HP-AF008932-8.raw |
SA089522 | CA209025-21-1027 | CA209025-21-1027_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 34.267 | Phase III_RCC_CA209025 | US/CANADA | 69 | F | WHITE | 0935_Marios_PD1_Inhib2_HP-AF146084-8.raw |
SA089521 | CA209025-21-1039 | CA209025-21-1039_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 31.803 | Phase III_RCC_CA209025 | US/CANADA | 59 | F | WHITE | 0891_Marios_PD1_Inhib2_HP-AF002705-8.raw |
SA089517 | CA209025-21-849 | CA209025-21-849_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.312 | Phase III_RCC_CA209025 | US/CANADA | 52 | F | WHITE | 0784_Marios_PD1_Inhib2_HP-AF002704-8.raw |
SA089519 | CA209025-22-1000 | CA209025-22-1000_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.969 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 0440_Marios_PD1_Inhib2_HP-AF009300-8.raw |
SA089524 | CA209025-24-840 | CA209025-24-840_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 42.842 | Phase III_RCC_CA209025 | US/CANADA | 23 | F | WHITE | 0539_Marios_PD1_Inhib2_HP-AF009316-8.raw |
SA089505 | CA209025-29-1002 | CA209025-29-1002_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.674 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0483_Marios_PD1_Inhib2_HP-AF325370-8.raw |
SA089504 | CA209025-43-941 | CA209025-43-941_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 22.012 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | WHITE | 0600_Marios_PD1_Inhib2_HP-AF003952-8.raw |
SA089518 | CA209025-9-756 | CA209025-9-756_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 43.302 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0513_Marios_PD1_Inhib2_HP-AF002787-8.raw |
SA089523 | CA209025-9-892 | CA209025-9-892_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 43.072 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | WHITE | 1201_Marios_PD1_Inhib2_HP-AF032142-8.raw |
SA089527 | CA209025-114-813 | CA209025-114-813_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 43.926 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | M | WHITE | 0346_Marios_PD1_Inhib2_HP-E9124387-6.raw |
SA089526 | CA209025-139-1036 | CA209025-139-1036_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 38.571 | Phase III_RCC_CA209025 | US/CANADA | 72 | M | WHITE | 0769_Marios_PD1_Inhib2_HP-AF438567-8.raw |
SA089525 | CA209025-93-836 | CA209025-93-836_week 4 | week 4 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 42.743 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 0771_Marios_PD1_Inhib2_HP-EA716174-8.raw |
SA089529 | CA209025-131-1043 | CA209025-131-1043_week 4 | week 4 | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 40.312 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | F | WHITE | 0507_Marios_PD1_Inhib2_HP-EA720992-8.raw |
SA089530 | CA209025-131-939 | CA209025-131-939_week 4 | week 4 | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 18.628 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | WHITE | 0591_Marios_PD1_Inhib2_HP-EA720994-8.raw |
SA089531 | CA209025-14-1070 | CA209025-14-1070_week 4 | week 4 | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 38.505 | Phase III_RCC_CA209025 | US/CANADA | 59 | F | WHITE | 1177_Marios_PD1_Inhib2_HP-AF575413-8.raw |
SA089532 | CA209025-165-850 | CA209025-165-850_week 4 | week 4 | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 43.039 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | OTHER | 0061_Marios_PD1_Inhib2_HP-S4107194-8.raw |
SA089533 | CA209025-43-931 | CA209025-43-931_week 4 | week 4 | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 33.643 | Phase III_RCC_CA209025 | US/CANADA | 57 | F | WHITE | 0130_Marios_PD1_Inhib2_HP-AF003954-8.raw |
SA089528 | CA209025-9-896 | CA209025-9-896_week 4 | week 4 | 1 | INTERMEDIATE | EVEROLIMUS | FALSE | 42.842 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0421_Marios_PD1_Inhib2_HP-AF032141-8.raw |
SA089535 | CA209025-158-654 | CA209025-158-654_week 4 | week 4 | 1 | INTERMEDIATE | EVEROLIMUS | TRUE | 32.493 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 0382_Marios_PD1_Inhib2_HP-S4035153-7.raw |
SA089534 | CA209025-185-805 | CA209025-185-805_week 4 | week 4 | 1 | INTERMEDIATE | EVEROLIMUS | TRUE | 31.113 | Phase III_RCC_CA209025 | US/CANADA | 49 | M | WHITE | 1106_Marios_PD1_Inhib2_HP-AF016210-8.raw |
SA089538 | CA209025-125-855 | CA209025-125-855_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.762 | Phase III_RCC_CA209025 | REST OF WORLD | 54 | M | WHITE | 0993_Marios_PD1_Inhib2_HP-L1426707-9.raw |
SA089543 | CA209025-143-679 | CA209025-143-679_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 44.452 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 1145_Marios_PD1_Inhib2_HP-AE602895-16.raw |
SA089546 | CA209025-155-1020 | CA209025-155-1020_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 39.951 | Phase III_RCC_CA209025 | REST OF WORLD | 46 | M | OTHER | 0180_Marios_PD1_Inhib2_HP-S4103686-7.raw |
SA089537 | CA209025-159-777 | CA209025-159-777_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.598 | Phase III_RCC_CA209025 | REST OF WORLD | 73 | M | OTHER | 1096_Marios_PD1_Inhib2_HP-S4035170-7.raw |
SA089539 | CA209025-163-1012 | CA209025-163-1012_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 40.411 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | OTHER | 0971_Marios_PD1_Inhib2_HP-S4211195-8.raw |
SA089544 | CA209025-167-1011 | CA209025-167-1011_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 39.819 | Phase III_RCC_CA209025 | REST OF WORLD | 69 | F | OTHER | 0597_Marios_PD1_Inhib2_HP-S4251324-8.raw |
SA089536 | CA209025-1-961 | CA209025-1-961_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 41.725 | Phase III_RCC_CA209025 | US/CANADA | 69 | M | WHITE | 0271_Marios_PD1_Inhib2_HP-AF002687-9.raw |
SA089540 | CA209025-21-1065 | CA209025-21-1065_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 38.932 | Phase III_RCC_CA209025 | US/CANADA | 55 | M | WHITE | 0659_Marios_PD1_Inhib2_HP-AF146083-8.raw |
SA089541 | CA209025-23-953 | CA209025-23-953_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 41.363 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 1119_Marios_PD1_Inhib2_HP-AE795125-9.raw |
SA089545 | CA209025-29-988 | CA209025-29-988_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 40.772 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0005_Marios_PD1_Inhib2_HP-AF008971-8.raw |
SA089542 | CA209025-79-982 | CA209025-79-982_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 17.840 | Phase III_RCC_CA209025 | REST OF WORLD | 67 | M | WHITE | 0695_Marios_PD1_Inhib2_HP-L1443412-7.raw |
SA089548 | CA209025-84-1041 | CA209025-84-1041_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 39.031 | Phase III_RCC_CA209025 | REST OF WORLD | 57 | M | WHITE | 0488_Marios_PD1_Inhib2_HP-L1443430-8.raw |
SA089547 | CA209025-85-986 | CA209025-85-986_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 41.035 | Phase III_RCC_CA209025 | REST OF WORLD | 71 | M | WHITE | 0825_Marios_PD1_Inhib2_HP-L1497978-11.raw |
SA089549 | CA209025-14-1057 | CA209025-14-1057_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 39.129 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 0302_Marios_PD1_Inhib2_HP-AF015789-8.raw |
SA089550 | CA209025-20-1059 | CA209025-20-1059_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 38.899 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0907_Marios_PD1_Inhib2_HP-AF252786-8.raw |
SA089551 | CA209025-44-944 | CA209025-44-944_week 4 | week 4 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 41.265 | Phase III_RCC_CA209025 | US/CANADA | 54 | F | WHITE | 0126_Marios_PD1_Inhib2_HP-AF016224-8.raw |
SA089553 | CA209025-20-976 | CA209025-20-976_week 4 | week 4 | 1 | POOR | EVEROLIMUS | FALSE | 23.688 | Phase III_RCC_CA209025 | US/CANADA | 75 | F | WHITE | 0037_Marios_PD1_Inhib2_HP-AF252783-8.raw |
SA089554 | CA209025-21-1064 | CA209025-21-1064_week 4 | week 4 | 1 | POOR | EVEROLIMUS | FALSE | 27.006 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 1139_Marios_PD1_Inhib2_HP-AF146081-8.raw |
SA089552 | CA209025-79-1061 | CA209025-79-1061_week 4 | week 4 | 1 | POOR | EVEROLIMUS | FALSE | 24.246 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | WHITE | 1129_Marios_PD1_Inhib2_HP-L1443413-7.raw |
SA089559 | CA209025-141-666 | CA209025-141-666_week 4 | week 4 | 1 | POOR | NIVOLUMAB | FALSE | 43.959 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0833_Marios_PD1_Inhib2_HP-AE630795-6.raw |
SA089555 | CA209025-165-758 | CA209025-165-758_week 4 | week 4 | 1 | POOR | NIVOLUMAB | FALSE | 44.616 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | OTHER | 0268_Marios_PD1_Inhib2_HP-S4035312-7.raw |
SA089556 | CA209025-28-951 | CA209025-28-951_week 4 | week 4 | 1 | POOR | NIVOLUMAB | FALSE | 41.429 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0164_Marios_PD1_Inhib2_HP-AF015542-8.raw |
SA089557 | CA209025-29-921 | CA209025-29-921_week 4 | week 4 | 1 | POOR | NIVOLUMAB | FALSE | 42.053 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 0047_Marios_PD1_Inhib2_HP-AF008973-8.raw |
SA089558 | CA209025-9-1055 | CA209025-9-1055_week 4 | week 4 | 1 | POOR | NIVOLUMAB | FALSE | 39.097 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | OTHER | 1070_Marios_PD1_Inhib2_HP-AF032140-8.raw |
SA089560 | CA209025-9-870 | CA209025-9-870_week 4 | week 4 | 1 | POOR | NIVOLUMAB | TRUE | 43.039 | Phase III_RCC_CA209025 | US/CANADA | 73 | M | WHITE | 0717_Marios_PD1_Inhib2_HP-AF002790-8.raw |
SA089414 | CA209025-139-990 | CA209025-139-990_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | FALSE | 15.047 | Phase III_RCC_CA209025 | US/CANADA | 67 | F | WHITE | 0631_Marios_PD1_Inhib2_HP-AF048321-8.raw |
SA089409 | CA209025-161-973 | CA209025-161-973_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | FALSE | 32.526 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | OTHER | 0759_Marios_PD1_Inhib2_HP-S4103671-7.raw |
SA089413 | CA209025-1-948 | CA209025-1-948_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | FALSE | 12.550 | Phase III_RCC_CA209025 | US/CANADA | 71 | M | WHITE | 1150_Marios_PD1_Inhib2_HP-AF002686-8.raw |
SA089407 | CA209025-20-1040 | CA209025-20-1040_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | FALSE | 2.431 | Phase III_RCC_CA209025 | US/CANADA | 51 | F | WHITE | 0338_Marios_PD1_Inhib2_HP-AF252787-8.raw |
SA089406 | CA209025-21-907 | CA209025-21-907_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | FALSE | 14.292 | Phase III_RCC_CA209025 | US/CANADA | 56 | F | WHITE | 0094_Marios_PD1_Inhib2_HP-AF146086-8.raw |
SA089405 | CA209025-23-952 | CA209025-23-952_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | FALSE | 12.255 | Phase III_RCC_CA209025 | US/CANADA | 76 | M | WHITE | 0111_Marios_PD1_Inhib2_HP-AF002758-8.raw |
SA089408 | CA209025-30-639 | CA209025-30-639_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | FALSE | 32.756 | Phase III_RCC_CA209025 | US/CANADA | 66 | F | WHITE | 0807_Marios_PD1_Inhib2_HP-AD810805-4.raw |
SA089412 | CA209025-43-897 | CA209025-43-897_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | FALSE | 14.916 | Phase III_RCC_CA209025 | US/CANADA | 63 | F | WHITE | 1117_Marios_PD1_Inhib2_HP-AF003951-8.raw |
SA089411 | CA209025-44-1009 | CA209025-44-1009_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | FALSE | 4.074 | Phase III_RCC_CA209025 | US/CANADA | 23 | M | WHITE | 0066_Marios_PD1_Inhib2_HP-AF016223-8.raw |
SA089410 | CA209025-79-1062 | CA209025-79-1062_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | FALSE | 3.647 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | F | WHITE | 0365_Marios_PD1_Inhib2_HP-L1478158-8.raw |
SA089415 | CA209025-138-872 | CA209025-138-872_week 4 | week 4 | - | FAVORABLE | EVEROLIMUS | TRUE | 25.856 | Phase III_RCC_CA209025 | US/CANADA | 58 | F | WHITE | 1094_Marios_PD1_Inhib2_HP-AF004073-8.raw |
SA089421 | CA209025-1-1004 | CA209025-1-1004_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | FALSE | 32.657 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0417_Marios_PD1_Inhib2_HP-AF365619-8.raw |
SA089416 | CA209025-1-1030 | CA209025-1-1030_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | FALSE | 23.951 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 0398_Marios_PD1_Inhib2_HP-AF439760-8.raw |
SA089418 | CA209025-11-910 | CA209025-11-910_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | FALSE | 8.674 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0471_Marios_PD1_Inhib2_HP-AF015820-8.raw |
SA089422 | CA209025-138-1034 | CA209025-138-1034_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | FALSE | 10.152 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0155_Marios_PD1_Inhib2_HP-AF004072-8.raw |
SA089425 | CA209025-139-1015 | CA209025-139-1015_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | FALSE | 14.916 | Phase III_RCC_CA209025 | US/CANADA | 32 | F | OTHER | 0875_Marios_PD1_Inhib2_HP-AF048323-8.raw |
SA089417 | CA209025-159-750 | CA209025-159-750_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | FALSE | 27.433 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | OTHER | 1169_Marios_PD1_Inhib2_HP-S4035169-6.raw |
SA089423 | CA209025-159-945 | CA209025-159-945_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | FALSE | 26.842 | Phase III_RCC_CA209025 | REST OF WORLD | 57 | M | OTHER | 0550ri_Marios_PD1_Inhib2_HP-S4107213-8.raw |
SA089424 | CA209025-24-887 | CA209025-24-887_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | FALSE | 27.696 | Phase III_RCC_CA209025 | US/CANADA | 44 | M | WHITE | 0386_Marios_PD1_Inhib2_HP-AF009315-8.raw |
SA089419 | CA209025-29-621 | CA209025-29-621_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | FALSE | 18.234 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0170_Marios_PD1_Inhib2_HP-AE294697-2.raw |
SA089420 | CA209025-29-626 | CA209025-29-626_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | FALSE | 8.608 | Phase III_RCC_CA209025 | US/CANADA | 48 | M | WHITE | 0360_Marios_PD1_Inhib2_HP-AE294698-2.raw |
SA089429 | CA209025-139-978 | CA209025-139-978_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | TRUE | 31.343 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | OTHER | 0152_Marios_PD1_Inhib2_HP-AF048322-8.raw |
SA089427 | CA209025-17-1066 | CA209025-17-1066_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | TRUE | 25.626 | Phase III_RCC_CA209025 | US/CANADA | 60 | F | WHITE | 0757_Marios_PD1_Inhib2_HP-AF015802-8.raw |
SA089426 | CA209025-22-935 | CA209025-22-935_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | TRUE | 24.772 | Phase III_RCC_CA209025 | US/CANADA | 45 | M | WHITE | 1166_Marios_PD1_Inhib2_HP-AF009299-8.raw |
SA089428 | CA209025-3-871 | CA209025-3-871_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | TRUE | 7.064 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 0741_Marios_PD1_Inhib2_HP-EA716458-8.raw |
SA089430 | CA209025-94-851 | CA209025-94-851_week 4 | week 4 | - | FAVORABLE | NIVOLUMAB | TRUE | 23.688 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | WHITE | 0423_Marios_PD1_Inhib2_HP-S4102912-8.raw |
SA089443 | CA209025-11-829 | CA209025-11-829_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 6.834 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0329_Marios_PD1_Inhib2_HP-AE487824-2.raw |
SA089445 | CA209025-138-1069 | CA209025-138-1069_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 7.359 | Phase III_RCC_CA209025 | US/CANADA | 76 | M | WHITE | 0896_Marios_PD1_Inhib2_HP-AF004074-8.raw |
SA089438 | CA209025-14-996 | CA209025-14-996_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 15.212 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0671_Marios_PD1_Inhib2_HP-AF015790-8.raw |
SA089446 | CA209025-155-858 | CA209025-155-858_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 17.478 | Phase III_RCC_CA209025 | REST OF WORLD | 58 | F | OTHER | 0845_Marios_PD1_Inhib2_HP-S3947232-6.raw |
SA089439 | CA209025-156-744 | CA209025-156-744_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 25.199 | Phase III_RCC_CA209025 | REST OF WORLD | 72 | M | OTHER | 0443_Marios_PD1_Inhib2_HP-S4035151-7.raw |
SA089437 | CA209025-174-863 | CA209025-174-863_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 4.632 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | OTHER | 1207_Marios_PD1_Inhib2_HP-S4107175-8.raw |
SA089436 | CA209025-180-1053 | CA209025-180-1053_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 6.571 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | F | WHITE | 0530_Marios_PD1_Inhib2_HP-EB335385-8.raw |
SA089440 | CA209025-182-701 | CA209025-182-701_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 19.975 | Phase III_RCC_CA209025 | US/CANADA | 82 | M | WHITE | 0748_Marios_PD1_Inhib2_HP-AE283074-7.raw |
SA089435 | CA209025-1-972 | CA209025-1-972_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 14.686 | Phase III_RCC_CA209025 | US/CANADA | 50 | F | OTHER | 1079_Marios_PD1_Inhib2_HP-AF002683-8.raw |
SA089441 | CA209025-20-1075 | CA209025-20-1075_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 8.509 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 1126_Marios_PD1_Inhib2_HP-AF002821-8.raw |
SA089444 | CA209025-42-1051 | CA209025-42-1051_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 5.322 | Phase III_RCC_CA209025 | US/CANADA | 47 | M | WHITE | 0810_Marios_PD1_Inhib2_HP-AF008957-8.raw |
SA089442 | CA209025-53-1003 | CA209025-53-1003_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 5.355 | Phase III_RCC_CA209025 | US/CANADA | 57 | F | WHITE | 1092_Marios_PD1_Inhib2_HP-AF016234-8.raw |
SA089432 | CA209025-78-1007 | CA209025-78-1007_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 4.337 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | M | WHITE | 0798_Marios_PD1_Inhib2_HP-L1479331-12.raw |
SA089431 | CA209025-78-1014 | CA209025-78-1014_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 5.618 | Phase III_RCC_CA209025 | REST OF WORLD | 52 | M | WHITE | 0619_Marios_PD1_Inhib2_HP-L1479330-11.raw |
SA089434 | CA209025-84-933 | CA209025-84-933_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 25.528 | Phase III_RCC_CA209025 | REST OF WORLD | 71 | M | WHITE | 0593_Marios_PD1_Inhib2_HP-L1448902-11.raw |
SA089433 | CA209025-9-984 | CA209025-9-984_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | FALSE | 22.341 | Phase III_RCC_CA209025 | US/CANADA | 74 | F | WHITE | 0959_Marios_PD1_Inhib2_HP-AF002788-8.raw |
SA089449 | CA209025-183-874 | CA209025-183-874_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | TRUE | 41.561 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 0911_Marios_PD1_Inhib2_HP-AF016138-8.raw |
SA089448 | CA209025-25-947 | CA209025-25-947_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | TRUE | 11.368 | Phase III_RCC_CA209025 | US/CANADA | 69 | F | WHITE | 0091_Marios_PD1_Inhib2_HP-AF009257-8.raw |
SA089447 | CA209025-53-885 | CA209025-53-885_week 4 | week 4 | - | INTERMEDIATE | EVEROLIMUS | TRUE | 3.614 | Phase III_RCC_CA209025 | US/CANADA | 54 | M | OTHER | 0393_Marios_PD1_Inhib2_HP-AF016235-8.raw |
SA089456 | CA209025-1-1071 | CA209025-1-1071_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.567 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 0052_Marios_PD1_Inhib2_HP-AF581651-8.raw |
SA089455 | CA209025-11-1073 | CA209025-11-1073_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 38.571 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 0868_Marios_PD1_Inhib2_HP-AF015819-8.raw |
SA089453 | CA209025-138-814 | CA209025-138-814_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 26.842 | Phase III_RCC_CA209025 | US/CANADA | 71 | M | WHITE | 0248_Marios_PD1_Inhib2_HP-AF004075-8.raw |
SA089454 | CA209025-138-847 | CA209025-138-847_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 25.134 | Phase III_RCC_CA209025 | US/CANADA | 76 | M | WHITE | 0968_Marios_PD1_Inhib2_HP-AF004076-8.raw |
SA089450 | CA209025-143-794 | CA209025-143-794_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.370 | Phase III_RCC_CA209025 | US/CANADA | 85 | M | WHITE | 0113_Marios_PD1_Inhib2_HP-AF015778-8.raw |
SA089465 | CA209025-185-983 | CA209025-185-983_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.008 | Phase III_RCC_CA209025 | US/CANADA | 53 | F | WHITE | 1008_Marios_PD1_Inhib2_HP-AF016211-8.raw |
SA089451 | CA209025-1-920 | CA209025-1-920_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 14.029 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 1163_Marios_PD1_Inhib2_HP-AF002684-9.raw |
SA089452 | CA209025-1-932 | CA209025-1-932_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 2.136 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0108_Marios_PD1_Inhib2_HP-AF002685-9.raw |
SA089463 | CA209025-23-922 | CA209025-23-922_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 22.111 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0182_Marios_PD1_Inhib2_HP-AE795128-4.raw |
SA089462 | CA209025-25-1042 | CA209025-25-1042_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.429 | Phase III_RCC_CA209025 | US/CANADA | 75 | M | WHITE | 1211_Marios_PD1_Inhib2_HP-AF233273-8.raw |
SA089469 | CA209025-26-965 | CA209025-26-965_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 14.390 | Phase III_RCC_CA209025 | US/CANADA | 50 | M | WHITE | 0940_Marios_PD1_Inhib2_HP-AF003892-8.raw |
SA089464 | CA209025-27-915 | CA209025-27-915_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 8.706 | Phase III_RCC_CA209025 | US/CANADA | 74 | M | WHITE | 0231_Marios_PD1_Inhib2_HP-AF009271-7.raw |
SA089457 | CA209025-29-938 | CA209025-29-938_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.988 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 1005_Marios_PD1_Inhib2_HP-AF008972-8.raw |
SA089468 | CA209025-42-919 | CA209025-42-919_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.359 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 0246_Marios_PD1_Inhib2_HP-AF008959-8.raw |
SA089467 | CA209025-4-815 | CA209025-4-815_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 18.497 | Phase III_RCC_CA209025 | WESTERN EUROPE | 44 | M | WHITE | 0849_Marios_PD1_Inhib2_HP-EA677535-8.raw |
SA089459 | CA209025-69-810 | CA209025-69-810_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 17.084 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | F | WHITE | 0886_Marios_PD1_Inhib2_HP-EA715962-8.raw |
SA089460 | CA209025-70-883 | CA209025-70-883_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 25.528 | Phase III_RCC_CA209025 | REST OF WORLD | 77 | M | WHITE | 0701_Marios_PD1_Inhib2_HP-EA715505-8.raw |
SA089461 | CA209025-84-894 | CA209025-84-894_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 5.651 | Phase III_RCC_CA209025 | REST OF WORLD | 49 | M | WHITE | 0820_Marios_PD1_Inhib2_HP-L1448903-11.raw |
SA089466 | CA209025-95-706 | CA209025-95-706_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 2.004 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 1143_Marios_PD1_Inhib2_HP-S3907410-7.raw |
SA089458 | CA209025-95-721 | CA209025-95-721_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 5.684 | Phase III_RCC_CA209025 | REST OF WORLD | 49 | M | WHITE | 0573_Marios_PD1_Inhib2_HP-S3907411-7.raw |
SA089470 | CA209025-139-989 | CA209025-139-989_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 26.086 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0121_Marios_PD1_Inhib2_HP-AF003934-8.raw |
SA089476 | CA209025-164-901 | CA209025-164-901_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 25.823 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | F | OTHER | 0355_Marios_PD1_Inhib2_HP-S4093208-8.raw |
SA089474 | CA209025-166-957 | CA209025-166-957_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 13.963 | Phase III_RCC_CA209025 | REST OF WORLD | 68 | M | OTHER | 1032_Marios_PD1_Inhib2_HP-S4152610-8.raw |
SA089472 | CA209025-27-906 | CA209025-27-906_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 17.150 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 1186_Marios_PD1_Inhib2_HP-AF009273-8.raw |
SA089473 | CA209025-44-785 | CA209025-44-785_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 26.316 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0097_Marios_PD1_Inhib2_HP-AF016222-8.raw |
SA089471 | CA209025-97-569 | CA209025-97-569_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 29.766 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | OTHER | 0501_Marios_PD1_Inhib2_HP-S4008628-7.raw |
SA089475 | CA209025-98-673 | CA209025-98-673_week 4 | week 4 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 11.499 | Phase III_RCC_CA209025 | REST OF WORLD | 76 | F | WHITE | 0884_Marios_PD1_Inhib2_HP-S4008444-7.raw |
SA089479 | CA209025-22-1022 | CA209025-22-1022_week 4 | week 4 | - | POOR | EVEROLIMUS | FALSE | 7.918 | Phase III_RCC_CA209025 | US/CANADA | 36 | M | WHITE | 0024_Marios_PD1_Inhib2_HP-AF009298-8.raw |
SA089477 | CA209025-42-1058 | CA209025-42-1058_week 4 | week 4 | - | POOR | EVEROLIMUS | FALSE | 2.990 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 0185_Marios_PD1_Inhib2_HP-AF008958-8.raw |
SA089478 | CA209025-43-917 | CA209025-43-917_week 4 | week 4 | - | POOR | EVEROLIMUS | FALSE | 2.727 | Phase III_RCC_CA209025 | US/CANADA | 55 | M | WHITE | 0755_Marios_PD1_Inhib2_HP-AF132622-8.raw |
SA089480 | CA209025-17-964 | CA209025-17-964_week 4 | week 4 | - | POOR | EVEROLIMUS | TRUE | 35.351 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0728_Marios_PD1_Inhib2_HP-AF064096-8.raw |
SA089481 | CA209025-20-1031 | CA209025-20-1031_week 4 | week 4 | - | POOR | EVEROLIMUS | TRUE | 2.201 | Phase III_RCC_CA209025 | US/CANADA | 73 | F | WHITE | 0715_Marios_PD1_Inhib2_HP-AF252784-8.raw |
SA089489 | CA209025-143-515 | CA209025-143-515_week 4 | week 4 | - | POOR | NIVOLUMAB | FALSE | 9.068 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0614_Marios_PD1_Inhib2_HP-AD645863-9.raw |
SA089482 | CA209025-144-596 | CA209025-144-596_week 4 | week 4 | - | POOR | NIVOLUMAB | FALSE | 22.867 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0640_Marios_PD1_Inhib2_HP-AE506727-9.raw |
SA089484 | CA209025-17-981 | CA209025-17-981_week 4 | week 4 | - | POOR | NIVOLUMAB | FALSE | 27.926 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | WHITE | 0629_Marios_PD1_Inhib2_HP-AF015803-8.raw |
SA089486 | CA209025-21-1050 | CA209025-21-1050_week 4 | week 4 | - | POOR | NIVOLUMAB | FALSE | 25.988 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0451_Marios_PD1_Inhib2_HP-AF146082-8.raw |
SA089487 | CA209025-25-987 | CA209025-25-987_week 4 | week 4 | - | POOR | NIVOLUMAB | FALSE | 10.218 | Phase III_RCC_CA209025 | US/CANADA | 85 | M | WHITE | 0194_Marios_PD1_Inhib2_HP-AF009258-8.raw |
SA089483 | CA209025-30-695 | CA209025-30-695_week 4 | week 4 | - | POOR | NIVOLUMAB | FALSE | 9.528 | Phase III_RCC_CA209025 | US/CANADA | 62 | F | WHITE | 0234_Marios_PD1_Inhib2_HP-AE622838-6.raw |
SA089485 | CA209025-85-992 | CA209025-85-992_week 4 | week 4 | - | POOR | NIVOLUMAB | FALSE | 13.339 | Phase III_RCC_CA209025 | REST OF WORLD | 58 | M | WHITE | 1015_Marios_PD1_Inhib2_HP-L1497981-11.raw |
SA089488 | CA209025-95-681 | CA209025-95-681_week 4 | week 4 | - | POOR | NIVOLUMAB | FALSE | 4.862 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | WHITE | 0522_Marios_PD1_Inhib2_HP-S4025567-7.raw |
SA089491 | CA209025-139-1025 | CA209025-139-1025_week 4 | week 4 | - | POOR | NIVOLUMAB | TRUE | 6.209 | Phase III_RCC_CA209025 | US/CANADA | 72 | F | WHITE | 0851_Marios_PD1_Inhib2_HP-AF438569-8.raw |
SA089490 | CA209025-25-930 | CA209025-25-930_week 4 | week 4 | - | POOR | NIVOLUMAB | TRUE | 7.655 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0043_Marios_PD1_Inhib2_HP-AF009259-8.raw |
SA089804 | CA209025-101-142 | CA209025-101-142_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 51.187 | Phase III_RCC_CA209025 | WESTERN EUROPE | 73 | M | WHITE | 0635_Marios_PD1_Inhib2_HP-E9124069-3.raw |
SA089798 | CA209025-118-255 | CA209025-118-255_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 49.380 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | F | WHITE | 0413_Marios_PD1_Inhib2_HP-EA044208-6.raw |
SA089785 | CA209025-13-181 | CA209025-13-181_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.234 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 0467_Marios_PD1_Inhib2_HP-AD827415-6.raw |
SA089775 | CA209025-138-734 | CA209025-138-734_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.682 | Phase III_RCC_CA209025 | US/CANADA | 62 | F | WHITE | 1191_Marios_PD1_Inhib2_HP-AF004078-8.raw |
SA089777 | CA209025-139-1006 | CA209025-139-1006_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 39.589 | Phase III_RCC_CA209025 | US/CANADA | 46 | M | WHITE | 0922_Marios_PD1_Inhib2_HP-AF268551-8.raw |
SA089769 | CA209025-154-929 | CA209025-154-929_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 42.481 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | M | OTHER | 1157_Marios_PD1_Inhib2_HP-S4107205-8.raw |
SA089788 | CA209025-156-1017 | CA209025-156-1017_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 39.918 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | OTHER | 1051_Marios_PD1_Inhib2_HP-S4124108-8.raw |
SA089767 | CA209025-15-773 | CA209025-15-773_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.090 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0332_Marios_PD1_Inhib2_HP-AF015893-8.raw |
SA089765 | CA209025-15-99 | CA209025-15-99_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 51.515 | Phase III_RCC_CA209025 | US/CANADA | 51 | M | WHITE | 0735_Marios_PD1_Inhib2_HP-AD267750-5.raw |
SA089799 | CA209025-161-577 | CA209025-161-577_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 45.339 | Phase III_RCC_CA209025 | REST OF WORLD | 46 | M | OTHER | 0288_Marios_PD1_Inhib2_HP-S3977260-6.raw |
SA089792 | CA209025-161-974 | CA209025-161-974_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.936 | Phase III_RCC_CA209025 | REST OF WORLD | 69 | F | OTHER | 0519_Marios_PD1_Inhib2_HP-S4144273-8.raw |
SA089791 | CA209025-162-171 | CA209025-162-171_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.037 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | F | OTHER | 1175_Marios_PD1_Inhib2_HP-S3667134-6.raw |
SA089796 | CA209025-169-660 | CA209025-169-660_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.419 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 0843_Marios_PD1_Inhib2_HP-S3606424-7.raw |
SA089794 | CA209025-170-221 | CA209025-170-221_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.201 | Phase III_RCC_CA209025 | REST OF WORLD | 45 | M | OTHER | 0778_Marios_PD1_Inhib2_HP-S3474759-6.raw |
SA089795 | CA209025-17-1044 | CA209025-17-1044_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 39.524 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0379_Marios_PD1_Inhib2_HP-AF565735-8.raw |
SA089800 | CA209025-173-757 | CA209025-173-757_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 22.111 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | M | OTHER | 0498_Marios_PD1_Inhib2_HP-S4107189-8.raw |
SA089790 | CA209025-174-1010 | CA209025-174-1010_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.049 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | OTHER | 0984_Marios_PD1_Inhib2_HP-S4107176-8.raw |
SA089797 | CA209025-17-928 | CA209025-17-928_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 42.283 | Phase III_RCC_CA209025 | US/CANADA | 77 | M | WHITE | 1058_Marios_PD1_Inhib2_HP-AF015807-8.raw |
SA089801 | CA209025-18-954 | CA209025-18-954_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 41.922 | Phase III_RCC_CA209025 | US/CANADA | 43 | M | OTHER | 0680_Marios_PD1_Inhib2_HP-AF008936-8.raw |
SA089802 | CA209025-2-10 | CA209025-2-10_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 53.848 | Phase III_RCC_CA209025 | WESTERN EUROPE | 71 | F | WHITE | 0254_Marios_PD1_Inhib2_HP-E9101725-5.raw |
SA089772 | CA209025-21-1027 | CA209025-21-1027_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 34.267 | Phase III_RCC_CA209025 | US/CANADA | 69 | F | WHITE | 0933_Marios_PD1_Inhib2_HP-AF002710-8.raw |
SA089773 | CA209025-21-1039 | CA209025-21-1039_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 31.803 | Phase III_RCC_CA209025 | US/CANADA | 59 | F | WHITE | 0893_Marios_PD1_Inhib2_HP-AF412017-8.raw |
SA089764 | CA209025-21-849 | CA209025-21-849_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.312 | Phase III_RCC_CA209025 | US/CANADA | 52 | F | WHITE | 0785_Marios_PD1_Inhib2_HP-AF002709-8.raw |
SA089787 | CA209025-22-1000 | CA209025-22-1000_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.969 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 0441_Marios_PD1_Inhib2_HP-AF009301-8.raw |
SA089782 | CA209025-23-8 | CA209025-23-8_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 12.485 | Phase III_RCC_CA209025 | US/CANADA | 46 | M | WHITE | 1003_Marios_PD1_Inhib2_HP-AD195657-6.raw |
SA089786 | CA209025-24-840 | CA209025-24-840_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 42.842 | Phase III_RCC_CA209025 | US/CANADA | 23 | F | WHITE | 0540_Marios_PD1_Inhib2_HP-AF009320-8.raw |
SA089778 | CA209025-29-1002 | CA209025-29-1002_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 40.674 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0484_Marios_PD1_Inhib2_HP-AF360077-8.raw |
SA089774 | CA209025-39-147 | CA209025-39-147_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.201 | Phase III_RCC_CA209025 | WESTERN EUROPE | 56 | M | WHITE | 1017_Marios_PD1_Inhib2_HP-E9210503-6.raw |
SA089768 | CA209025-41-979 | CA209025-41-979_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 41.035 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | OTHER | 0584_Marios_PD1_Inhib2_HP-AF008949-8.raw |
SA089771 | CA209025-43-743 | CA209025-43-743_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 22.965 | Phase III_RCC_CA209025 | US/CANADA | 44 | M | WHITE | 1077_Marios_PD1_Inhib2_HP-AF003959-8.raw |
SA089770 | CA209025-43-941 | CA209025-43-941_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 22.012 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | WHITE | 0601_Marios_PD1_Inhib2_HP-AF132628-8.raw |
SA089803 | CA209025-44-643 | CA209025-44-643_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 45.043 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0722_Marios_PD1_Inhib2_HP-AF016226-8.raw |
SA089783 | CA209025-65-329 | CA209025-65-329_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 48.066 | Phase III_RCC_CA209025 | WESTERN EUROPE | 83 | F | WHITE | 0069_Marios_PD1_Inhib2_HP-E9778373-6.raw |
SA089805 | CA209025-6-586 | CA209025-6-586_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 45.273 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0746_Marios_PD1_Inhib2_HP-E9125363-6.raw |
SA089793 | CA209025-72-394 | CA209025-72-394_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 47.934 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 0625_Marios_PD1_Inhib2_HP-E9145492-6.raw |
SA089806 | CA209025-73-511 | CA209025-73-511_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 46.324 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | M | OTHER | 1114_Marios_PD1_Inhib2_HP-E9106381-6.raw |
SA089807 | CA209025-75-112 | CA209025-75-112_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 51.220 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | M | WHITE | 0669_Marios_PD1_Inhib2_HP-E9479246-6.raw |
SA089789 | CA209025-82-338 | CA209025-82-338_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 47.901 | Phase III_RCC_CA209025 | WESTERN EUROPE | 68 | M | WHITE | 0585_Marios_PD1_Inhib2_HP-E9190486-6.raw |
SA089766 | CA209025-89-174 | CA209025-89-174_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.398 | Phase III_RCC_CA209025 | WESTERN EUROPE | 48 | M | WHITE | 0116_Marios_PD1_Inhib2_HP-E9656500-6.raw |
SA089784 | CA209025-89-725 | CA209025-89-725_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 43.926 | Phase III_RCC_CA209025 | WESTERN EUROPE | 45 | M | WHITE | 0343_Marios_PD1_Inhib2_HP-EA563624-6.raw |
SA089776 | CA209025-90-105 | CA209025-90-105_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 50.727 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | F | WHITE | 0647_Marios_PD1_Inhib2_HP-E9103106-6.raw |
SA089781 | CA209025-9-756 | CA209025-9-756_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 43.302 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0514_Marios_PD1_Inhib2_HP-AF032147-8.raw |
SA089779 | CA209025-97-765 | CA209025-97-765_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 44.058 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | F | WHITE | 0262_Marios_PD1_Inhib2_HP-S4110448-8.raw |
SA089780 | CA209025-9-892 | CA209025-9-892_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | FALSE | 43.072 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | WHITE | 1200_Marios_PD1_Inhib2_HP-AF002793-8.raw |
SA089819 | CA209025-111-299 | CA209025-111-299_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 47.639 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | WHITE | 0995_Marios_PD1_Inhib2_HP-E9720055-8.raw |
SA089808 | CA209025-114-813 | CA209025-114-813_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 43.926 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | M | WHITE | 0347_Marios_PD1_Inhib2_HP-E9124391-5.raw |
SA089813 | CA209025-139-1036 | CA209025-139-1036_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 38.571 | Phase III_RCC_CA209025 | US/CANADA | 72 | M | WHITE | 0768_Marios_PD1_Inhib2_HP-AF268546-8.raw |
SA089809 | CA209025-139-610 | CA209025-139-610_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 44.649 | Phase III_RCC_CA209025 | US/CANADA | 58 | F | WHITE | 0976_Marios_PD1_Inhib2_HP-AD783027-6.raw |
SA089817 | CA209025-161-518 | CA209025-161-518_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 45.667 | Phase III_RCC_CA209025 | REST OF WORLD | 69 | F | OTHER | 0283_Marios_PD1_Inhib2_HP-S3474403-6.raw |
SA089810 | CA209025-17-154 | CA209025-17-154_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 51.055 | Phase III_RCC_CA209025 | US/CANADA | 40 | M | WHITE | 0733_Marios_PD1_Inhib2_HP-AE104730-6.raw |
SA089814 | CA209025-17-94 | CA209025-17-94_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 51.220 | Phase III_RCC_CA209025 | US/CANADA | 75 | F | WHITE | 0486_Marios_PD1_Inhib2_HP-AD577697-6.raw |
SA089818 | CA209025-2-401 | CA209025-2-401_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 46.719 | Phase III_RCC_CA209025 | WESTERN EUROPE | 29 | M | WHITE | 0795_Marios_PD1_Inhib2_HP-E9130957-6.raw |
SA089815 | CA209025-33-466 | CA209025-33-466_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 47.146 | Phase III_RCC_CA209025 | WESTERN EUROPE | 57 | M | WHITE | 0525_Marios_PD1_Inhib2_HP-E9811948-6.raw |
SA089816 | CA209025-93-836 | CA209025-93-836_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 42.743 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 0772_Marios_PD1_Inhib2_HP-EA716175-8.raw |
SA089811 | CA209025-95-167 | CA209025-95-167_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 49.807 | Phase III_RCC_CA209025 | REST OF WORLD | 53 | M | WHITE | 0871_Marios_PD1_Inhib2_HP-S3713049-6.raw |
SA089812 | CA209025-97-264 | CA209025-97-264_week 8 | week 8 | 1 | FAVORABLE | NIVOLUMAB | TRUE | 48.197 | Phase III_RCC_CA209025 | REST OF WORLD | 56 | M | WHITE | 0205_Marios_PD1_Inhib2_HP-S3447041-6.raw |
SA089824 | CA209025-108-362 | CA209025-108-362_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 48.427 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | F | WHITE | 0505_Marios_PD1_Inhib2_HP-EA175154-6.raw |
SA089823 | CA209025-111-778 | CA209025-111-778_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.992 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | WHITE | 0220_Marios_PD1_Inhib2_HP-EA717427-8.raw |
SA089822 | CA209025-11-687 | CA209025-11-687_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 45.602 | Phase III_RCC_CA209025 | US/CANADA | 43 | M | WHITE | 0011_Marios_PD1_Inhib2_HP-AE330691-6.raw |
SA089826 | CA209025-125-855 | CA209025-125-855_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.762 | Phase III_RCC_CA209025 | REST OF WORLD | 54 | M | WHITE | 0994_Marios_PD1_Inhib2_HP-L1443357-23.raw |
SA089827 | CA209025-12-64 | CA209025-12-64_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 51.745 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | M | WHITE | 0581_Marios_PD1_Inhib2_HP-E9124688-6.raw |
SA089828 | CA209025-137-503 | CA209025-137-503_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.949 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | F | WHITE | 1063_Marios_PD1_Inhib2_HP-E9106244-6.raw |
SA089820 | CA209025-138-700 | CA209025-138-700_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 3.844 | Phase III_RCC_CA209025 | US/CANADA | 72 | M | WHITE | 0823_Marios_PD1_Inhib2_HP-AE726358-6.raw |
SA089835 | CA209025-139-1049 | CA209025-139-1049_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 38.637 | Phase III_RCC_CA209025 | US/CANADA | 50 | M | WHITE | 0081_Marios_PD1_Inhib2_HP-AF268550-8.raw |
SA089853 | CA209025-139-152 | CA209025-139-152_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 50.234 | Phase III_RCC_CA209025 | US/CANADA | 48 | M | WHITE | 1066_Marios_PD1_Inhib2_HP-AD783024-6.raw |
SA089855 | CA209025-139-554 | CA209025-139-554_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.062 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0040_Marios_PD1_Inhib2_HP-AE490136-6.raw |
SA089854 | CA209025-139-776 | CA209025-139-776_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.138 | Phase III_RCC_CA209025 | US/CANADA | 73 | M | WHITE | 0411_Marios_PD1_Inhib2_HP-AF003939-8.raw |
SA089858 | CA209025-143-679 | CA209025-143-679_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 44.452 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 1146_Marios_PD1_Inhib2_HP-AF015782-8.raw |
SA089856 | CA209025-144-372 | CA209025-144-372_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 47.770 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 0204_Marios_PD1_Inhib2_HP-AD829014-6.raw |
SA089852 | CA209025-153-718 | CA209025-153-718_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 44.682 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 0004_Marios_PD1_Inhib2_HP-AF015773-8.raw |
SA089851 | CA209025-155-1020 | CA209025-155-1020_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 39.951 | Phase III_RCC_CA209025 | REST OF WORLD | 46 | M | OTHER | 0181_Marios_PD1_Inhib2_HP-S4103687-8.raw |
SA089860 | CA209025-157-237 | CA209025-157-237_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 4.403 | Phase III_RCC_CA209025 | REST OF WORLD | 79 | F | OTHER | 1124_Marios_PD1_Inhib2_HP-S3510232-6.raw |
SA089859 | CA209025-157-436 | CA209025-157-436_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.324 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 0534_Marios_PD1_Inhib2_HP-S3797351-6.raw |
SA089857 | CA209025-159-777 | CA209025-159-777_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.598 | Phase III_RCC_CA209025 | REST OF WORLD | 73 | M | OTHER | 1097_Marios_PD1_Inhib2_HP-S4107216-8.raw |
SA089849 | CA209025-163-1012 | CA209025-163-1012_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 40.411 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | OTHER | 0972_Marios_PD1_Inhib2_HP-S4211196-8.raw |
SA089836 | CA209025-163-425 | CA209025-163-425_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 47.606 | Phase III_RCC_CA209025 | REST OF WORLD | 63 | M | OTHER | 0263_Marios_PD1_Inhib2_HP-S3472425-6.raw |
SA089837 | CA209025-167-1011 | CA209025-167-1011_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 39.819 | Phase III_RCC_CA209025 | REST OF WORLD | 69 | F | OTHER | 0598_Marios_PD1_Inhib2_HP-S4251325-7.raw |
SA089838 | CA209025-174-203 | CA209025-174-203_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 49.840 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | M | OTHER | 1132_Marios_PD1_Inhib2_HP-S3733291-6.raw |
SA089825 | CA209025-1-82 | CA209025-1-82_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 51.581 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0841_Marios_PD1_Inhib2_HP-AD709268-6.raw |
SA089821 | CA209025-1-961 | CA209025-1-961_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 41.725 | Phase III_RCC_CA209025 | US/CANADA | 69 | M | WHITE | 0272_Marios_PD1_Inhib2_HP-AF365620-8.raw |
SA089850 | CA209025-20-116 | CA209025-20-116_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 50.858 | Phase III_RCC_CA209025 | US/CANADA | 88 | F | WHITE | 0323_Marios_PD1_Inhib2_HP-AE062808-6.raw |
SA089834 | CA209025-23-953 | CA209025-23-953_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 41.363 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 1121_Marios_PD1_Inhib2_HP-AF002760-7.raw |
SA089830 | CA209025-26-491 | CA209025-26-491_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.423 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0173_Marios_PD1_Inhib2_HP-AE588070-6.raw |
SA089831 | CA209025-29-988 | CA209025-29-988_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 40.772 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0006_Marios_PD1_Inhib2_HP-AF008975-8.raw |
SA089832 | CA209025-55-172 | CA209025-55-172_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 50.858 | Phase III_RCC_CA209025 | WESTERN EUROPE | 73 | M | WHITE | 0739_Marios_PD1_Inhib2_HP-E9106097-6.raw |
SA089833 | CA209025-56-791 | CA209025-56-791_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 43.696 | Phase III_RCC_CA209025 | WESTERN EUROPE | 37 | M | WHITE | 0406_Marios_PD1_Inhib2_HP-E9106999-6.raw |
SA089839 | CA209025-66-488 | CA209025-66-488_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.883 | Phase III_RCC_CA209025 | WESTERN EUROPE | 44 | M | WHITE | 0325_Marios_PD1_Inhib2_HP-E9241889-6.raw |
SA089840 | CA209025-70-405 | CA209025-70-405_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 47.869 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | WHITE | 0352_Marios_PD1_Inhib2_HP-EA088460-6.raw |
SA089846 | CA209025-71-635 | CA209025-71-635_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 45.667 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | WHITE | 0404_Marios_PD1_Inhib2_HP-E9337930-6.raw |
SA089847 | CA209025-76-507 | CA209025-76-507_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.456 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0260_Marios_PD1_Inhib2_HP-AE442058-6.raw |
SA089848 | CA209025-79-465 | CA209025-79-465_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 46.456 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | WHITE | 1108_Marios_PD1_Inhib2_HP-L1381844-5.raw |
SA089845 | CA209025-79-982 | CA209025-79-982_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 17.840 | Phase III_RCC_CA209025 | REST OF WORLD | 67 | M | WHITE | 0696_Marios_PD1_Inhib2_HP-L1443415-8.raw |
SA089844 | CA209025-82-208 | CA209025-82-208_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 50.103 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | F | WHITE | 1193_Marios_PD1_Inhib2_HP-E9190488-6.raw |
SA089841 | CA209025-84-1041 | CA209025-84-1041_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 39.031 | Phase III_RCC_CA209025 | REST OF WORLD | 57 | M | WHITE | 0489_Marios_PD1_Inhib2_HP-L1448925-10.raw |
SA089842 | CA209025-84-535 | CA209025-84-535_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 5.520 | Phase III_RCC_CA209025 | REST OF WORLD | 50 | M | WHITE | 0167_Marios_PD1_Inhib2_HP-L1381827-7.raw |
SA089829 | CA209025-85-986 | CA209025-85-986_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 41.035 | Phase III_RCC_CA209025 | REST OF WORLD | 71 | M | WHITE | 0826_Marios_PD1_Inhib2_HP-L1497987-11.raw |
SA089843 | CA209025-9-589 | CA209025-9-589_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | FALSE | 45.536 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0564_Marios_PD1_Inhib2_HP-AE556402-6.raw |
SA089869 | CA209025-126-31 | CA209025-126-31_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 53.947 | Phase III_RCC_CA209025 | WESTERN EUROPE | 46 | F | WHITE | 1081_Marios_PD1_Inhib2_HP-E9124110-6.raw |
SA089867 | CA209025-139-143 | CA209025-139-143_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 50.366 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 1027_Marios_PD1_Inhib2_HP-AD783025-6.raw |
SA089862 | CA209025-14-1057 | CA209025-14-1057_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 39.129 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 0303_Marios_PD1_Inhib2_HP-AF015792-8.raw |
SA089868 | CA209025-142-593 | CA209025-142-593_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 46.029 | Phase III_RCC_CA209025 | US/CANADA | 69 | M | WHITE | 0753_Marios_PD1_Inhib2_HP-AE691891-6.raw |
SA089865 | CA209025-156-606 | CA209025-156-606_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 45.207 | Phase III_RCC_CA209025 | REST OF WORLD | 73 | M | OTHER | 0030_Marios_PD1_Inhib2_HP-S4035150-7.raw |
SA089866 | CA209025-20-1059 | CA209025-20-1059_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 38.899 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0908_Marios_PD1_Inhib2_HP-AF273575-8.raw |
SA089864 | CA209025-29-1045 | CA209025-29-1045_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 38.735 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0475_Marios_PD1_Inhib2_HP-AF616669-8.raw |
SA089861 | CA209025-44-944 | CA209025-44-944_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 41.265 | Phase III_RCC_CA209025 | US/CANADA | 54 | F | WHITE | 0127_Marios_PD1_Inhib2_HP-AF261222-8.raw |
SA089863 | CA209025-49-66 | CA209025-49-66_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 52.074 | Phase III_RCC_CA209025 | US/CANADA | 62 | M | WHITE | 1179_Marios_PD1_Inhib2_HP-AD577644-10.raw |
SA089870 | CA209025-84-384 | CA209025-84-384_week 8 | week 8 | 1 | INTERMEDIATE | NIVOLUMAB | TRUE | 47.244 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | F | WHITE | 0588_Marios_PD1_Inhib2_HP-L1357316-6.raw |
SA089881 | CA209025-12-428 | CA209025-12-428_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 46.982 | Phase III_RCC_CA209025 | WESTERN EUROPE | 78 | M | WHITE | 0177_Marios_PD1_Inhib2_HP-EA246338-6.raw |
SA089880 | CA209025-131-640 | CA209025-131-640_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 3.680 | Phase III_RCC_CA209025 | REST OF WORLD | 48 | M | WHITE | 0762_Marios_PD1_Inhib2_HP-E9786657-6.raw |
SA089873 | CA209025-139-324 | CA209025-139-324_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 11.006 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0828_Marios_PD1_Inhib2_HP-AE490133-6.raw |
SA089871 | CA209025-141-666 | CA209025-141-666_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 43.959 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0834_Marios_PD1_Inhib2_HP-AF003916-8.raw |
SA089877 | CA209025-165-758 | CA209025-165-758_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 44.616 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | OTHER | 0269_Marios_PD1_Inhib2_HP-S4107197-8.raw |
SA089876 | CA209025-25-396 | CA209025-25-396_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 47.376 | Phase III_RCC_CA209025 | US/CANADA | 51 | M | WHITE | 0138_Marios_PD1_Inhib2_HP-AE435301-6.raw |
SA089875 | CA209025-28-951 | CA209025-28-951_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 41.429 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0165_Marios_PD1_Inhib2_HP-AF015543-8.raw |
SA089878 | CA209025-29-921 | CA209025-29-921_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 42.053 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 0048_Marios_PD1_Inhib2_HP-AF008974-13.raw |
SA089879 | CA209025-39-467 | CA209025-39-467_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 46.982 | Phase III_RCC_CA209025 | WESTERN EUROPE | 53 | M | WHITE | 0016_Marios_PD1_Inhib2_HP-EA217029-6.raw |
SA089882 | CA209025-4-26 | CA209025-4-26_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 53.980 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 0546_Marios_PD1_Inhib2_HP-E9099289-6.raw |
SA089874 | CA209025-4-468 | CA209025-4-468_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 47.310 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | M | WHITE | 1181_Marios_PD1_Inhib2_HP-E9099290-6.raw |
SA089872 | CA209025-9-1055 | CA209025-9-1055_week 8 | week 8 | 1 | POOR | NIVOLUMAB | FALSE | 39.097 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | OTHER | 1071_Marios_PD1_Inhib2_HP-AF032149-8.raw |
SA089884 | CA209025-13-360 | CA209025-13-360_week 8 | week 8 | 1 | POOR | NIVOLUMAB | TRUE | 47.212 | Phase III_RCC_CA209025 | US/CANADA | 75 | M | WHITE | 1083_Marios_PD1_Inhib2_HP-AD827416-6.raw |
SA089883 | CA209025-9-870 | CA209025-9-870_week 8 | week 8 | 1 | POOR | NIVOLUMAB | TRUE | 43.039 | Phase III_RCC_CA209025 | US/CANADA | 73 | M | WHITE | 0718_Marios_PD1_Inhib2_HP-AF002792-8.raw |
SA089594 | CA209025-1-1004 | CA209025-1-1004_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 32.657 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0416_Marios_PD1_Inhib2_HP-AF002690-12.raw |
SA089591 | CA209025-1-1030 | CA209025-1-1030_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 23.951 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 0399_Marios_PD1_Inhib2_HP-AF581653-8.raw |
SA089599 | CA209025-111-811 | CA209025-111-811_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 11.302 | Phase III_RCC_CA209025 | REST OF WORLD | 34 | F | WHITE | 1040_Marios_PD1_Inhib2_HP-EA717425-8.raw |
SA089561 | CA209025-11-240 | CA209025-11-240_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 38.768 | Phase III_RCC_CA209025 | US/CANADA | 51 | M | WHITE | 0436_Marios_PD1_Inhib2_HP-AD604118-7.raw |
SA089588 | CA209025-113-669 | CA209025-113-669_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 6.604 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0990_Marios_PD1_Inhib2_HP-E9123616-6.raw |
SA089577 | CA209025-118-207 | CA209025-118-207_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 19.778 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 1111_Marios_PD1_Inhib2_HP-E9314447-6.raw |
SA089595 | CA209025-11-910 | CA209025-11-910_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 8.674 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0472_Marios_PD1_Inhib2_HP-AF015821-8.raw |
SA089567 | CA209025-1-205 | CA209025-1-205_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 29.865 | Phase III_RCC_CA209025 | US/CANADA | 45 | M | WHITE | 0188_Marios_PD1_Inhib2_HP-AD185807-6.raw |
SA089572 | CA209025-121-272 | CA209025-121-272_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 31.836 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | WHITE | 1044_Marios_PD1_Inhib2_HP-L1370589-6.raw |
SA089597 | CA209025-135-450 | CA209025-135-450_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 17.971 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | WHITE | 0299_Marios_PD1_Inhib2_HP-L1379655-6.raw |
SA089592 | CA209025-138-1034 | CA209025-138-1034_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 10.152 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0156_Marios_PD1_Inhib2_HP-AF004077-8.raw |
SA089601 | CA209025-139-1015 | CA209025-139-1015_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 14.916 | Phase III_RCC_CA209025 | US/CANADA | 32 | F | OTHER | 0876_Marios_PD1_Inhib2_HP-AF438575-8.raw |
SA089593 | CA209025-139-665 | CA209025-139-665_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 22.505 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0838_Marios_PD1_Inhib2_HP-AF048328-8.raw |
SA089569 | CA209025-1-417 | CA209025-1-417_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 20.271 | Phase III_RCC_CA209025 | US/CANADA | 66 | F | WHITE | 0889_Marios_PD1_Inhib2_HP-AE471842-6.raw |
SA089570 | CA209025-159-114 | CA209025-159-114_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 39.228 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | F | OTHER | 0150_Marios_PD1_Inhib2_HP-S3681816-6.raw |
SA089589 | CA209025-159-750 | CA209025-159-750_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 27.433 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | OTHER | 1170_Marios_PD1_Inhib2_HP-S4107215-8.raw |
SA089585 | CA209025-159-91 | CA209025-159-91_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 33.249 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | F | OTHER | 0818_Marios_PD1_Inhib2_HP-S3472031-6.raw |
SA089586 | CA209025-159-945 | CA209025-159-945_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 26.842 | Phase III_RCC_CA209025 | REST OF WORLD | 57 | M | OTHER | 0551_Marios_PD1_Inhib2_HP-S4107217-8.raw |
SA089582 | CA209025-166-161 | CA209025-166-161_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 15.047 | Phase III_RCC_CA209025 | REST OF WORLD | 64 | M | OTHER | 0162_Marios_PD1_Inhib2_HP-S3508698-6.raw |
SA089584 | CA209025-21-442 | CA209025-21-442_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 19.877 | Phase III_RCC_CA209025 | US/CANADA | 50 | F | WHITE | 0057_Marios_PD1_Inhib2_HP-AE206928-6.raw |
SA089564 | CA209025-21-967 | CA209025-21-967_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 18.530 | Phase III_RCC_CA209025 | US/CANADA | 74 | F | WHITE | 0666_Marios_PD1_Inhib2_HP-AF002708-8.raw |
SA089575 | CA209025-2-24 | CA209025-2-24_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 12.452 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | F | WHITE | 0536_Marios_PD1_Inhib2_HP-E9101728-6.raw |
SA089573 | CA209025-23-124 | CA209025-23-124_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 29.470 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 0725_Marios_PD1_Inhib2_HP-AE070746-6.raw |
SA089571 | CA209025-23-684 | CA209025-23-684_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 13.963 | Phase III_RCC_CA209025 | US/CANADA | 60 | F | WHITE | 0737_Marios_PD1_Inhib2_HP-AE822134-6.raw |
SA089581 | CA209025-2-38 | CA209025-2-38_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 20.895 | Phase III_RCC_CA209025 | WESTERN EUROPE | 71 | F | WHITE | 0292_Marios_PD1_Inhib2_HP-E9130958-5.raw |
SA089587 | CA209025-2-477 | CA209025-2-477_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 30.062 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | M | WHITE | 0307_Marios_PD1_Inhib2_HP-E9130956-5.raw |
SA089590 | CA209025-24-887 | CA209025-24-887_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 27.696 | Phase III_RCC_CA209025 | US/CANADA | 44 | M | WHITE | 0387_Marios_PD1_Inhib2_HP-AF009319-8.raw |
SA089596 | CA209025-29-621 | CA209025-29-621_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 18.234 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0171_Marios_PD1_Inhib2_HP-AE613362-6.raw |
SA089563 | CA209025-4-759 | CA209025-4-759_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 6.472 | Phase III_RCC_CA209025 | WESTERN EUROPE | 51 | M | WHITE | 1141_Marios_PD1_Inhib2_HP-EA677539-8.raw |
SA089576 | CA209025-48-285 | CA209025-48-285_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 15.836 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 0627_Marios_PD1_Inhib2_HP-EA344249-6.raw |
SA089580 | CA209025-50-902 | CA209025-50-902_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 35.581 | Phase III_RCC_CA209025 | WESTERN EUROPE | 49 | M | WHITE | 0279_Marios_PD1_Inhib2_HP-EA722886-8.raw |
SA089579 | CA209025-65-301 | CA209025-65-301_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 30.784 | Phase III_RCC_CA209025 | WESTERN EUROPE | 72 | M | WHITE | 0033_Marios_PD1_Inhib2_HP-EA002609-6.raw |
SA089578 | CA209025-66-544 | CA209025-66-544_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 23.162 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0528_Marios_PD1_Inhib2_HP-E9241890-6.raw |
SA089574 | CA209025-75-615 | CA209025-75-615_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 31.047 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | F | WHITE | 0078_Marios_PD1_Inhib2_HP-EA040892-6.raw |
SA089583 | CA209025-79-373 | CA209025-79-373_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 38.209 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | M | WHITE | 0290_Marios_PD1_Inhib2_HP-L1381843-5.raw |
SA089565 | CA209025-80-728 | CA209025-80-728_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 25.988 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | F | WHITE | 0880_Marios_PD1_Inhib2_HP-EA083054-6.raw |
SA089566 | CA209025-82-378 | CA209025-82-378_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 16.789 | Phase III_RCC_CA209025 | WESTERN EUROPE | 47 | F | WHITE | 0312_Marios_PD1_Inhib2_HP-E9703918-6.raw |
SA089568 | CA209025-84-704 | CA209025-84-704_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 19.055 | Phase III_RCC_CA209025 | REST OF WORLD | 72 | M | WHITE | 0789_Marios_PD1_Inhib2_HP-L1443435-8.raw |
SA089562 | CA209025-8-69 | CA209025-8-69_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 24.148 | Phase III_RCC_CA209025 | WESTERN EUROPE | 71 | M | WHITE | 1013_Marios_PD1_Inhib2_HP-E9125205-6.raw |
SA089602 | CA209025-87-234 | CA209025-87-234_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 43.039 | Phase III_RCC_CA209025 | WESTERN EUROPE | 37 | M | WHITE | 0215_Marios_PD1_Inhib2_HP-E9774340-6.raw |
SA089600 | CA209025-87-267 | CA209025-87-267_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 14.883 | Phase III_RCC_CA209025 | WESTERN EUROPE | 68 | F | WHITE | 1148_Marios_PD1_Inhib2_HP-E9774341-19.raw |
SA089598 | CA209025-96-498 | CA209025-96-498_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | FALSE | 32.164 | Phase III_RCC_CA209025 | REST OF WORLD | 54 | M | WHITE | 0780_Marios_PD1_Inhib2_HP-S3447224-6.raw |
SA089611 | CA209025-139-784 | CA209025-139-784_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 43.499 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0621_Marios_PD1_Inhib2_HP-AF003938-8.raw |
SA089606 | CA209025-139-978 | CA209025-139-978_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 31.343 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | OTHER | 0153_Marios_PD1_Inhib2_HP-AF048329-8.raw |
SA089615 | CA209025-147-367 | CA209025-147-367_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 36.205 | Phase III_RCC_CA209025 | US/CANADA | 67 | M | WHITE | 0086_Marios_PD1_Inhib2_HP-AD673742-6.raw |
SA089617 | CA209025-1-618 | CA209025-1-618_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 15.376 | Phase III_RCC_CA209025 | US/CANADA | 53 | F | WHITE | 0455_Marios_PD1_Inhib2_HP-AE471844-6.raw |
SA089612 | CA209025-17-1066 | CA209025-17-1066_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 25.626 | Phase III_RCC_CA209025 | US/CANADA | 60 | F | WHITE | 0758_Marios_PD1_Inhib2_HP-AF692201-8.raw |
SA089607 | CA209025-17-328 | CA209025-17-328_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 27.828 | Phase III_RCC_CA209025 | US/CANADA | 63 | F | WHITE | 0804_Marios_PD1_Inhib2_HP-AE104728-6.raw |
SA089605 | CA209025-17-473 | CA209025-17-473_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 7.524 | Phase III_RCC_CA209025 | US/CANADA | 49 | M | OTHER | 0212_Marios_PD1_Inhib2_HP-AE302162-8.raw |
SA089616 | CA209025-22-935 | CA209025-22-935_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 24.772 | Phase III_RCC_CA209025 | US/CANADA | 45 | M | WHITE | 1167_Marios_PD1_Inhib2_HP-AF009303-8.raw |
SA089609 | CA209025-25-197 | CA209025-25-197_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 34.530 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0860_Marios_PD1_Inhib2_HP-AE371901-6.raw |
SA089610 | CA209025-26-693 | CA209025-26-693_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 31.343 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0492_Marios_PD1_Inhib2_HP-AF003894-8.raw |
SA089614 | CA209025-30-418 | CA209025-30-418_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 44.058 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0464_Marios_PD1_Inhib2_HP-AD810806-5.raw |
SA089608 | CA209025-63-607 | CA209025-63-607_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 12.518 | Phase III_RCC_CA209025 | WESTERN EUROPE | 55 | F | WHITE | 0765_Marios_PD1_Inhib2_HP-E9241182-6.raw |
SA089613 | CA209025-75-191 | CA209025-75-191_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 42.185 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0954_Marios_PD1_Inhib2_HP-E9479242-8.raw |
SA089603 | CA209025-75-84 | CA209025-75-84_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 44.583 | Phase III_RCC_CA209025 | WESTERN EUROPE | 75 | M | WHITE | 0986_Marios_PD1_Inhib2_HP-E9479245-6.raw |
SA089604 | CA209025-94-851 | CA209025-94-851_week 8 | week 8 | - | FAVORABLE | NIVOLUMAB | TRUE | 23.688 | Phase III_RCC_CA209025 | REST OF WORLD | 61 | M | WHITE | 0424_Marios_PD1_Inhib2_HP-S4102914-8.raw |
SA089650 | CA209025-1-1071 | CA209025-1-1071_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.567 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 0050_Marios_PD1_Inhib2_HP-AF002688-13.raw |
SA089642 | CA209025-11-1073 | CA209025-11-1073_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 38.571 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 0866_Marios_PD1_Inhib2_HP-AE487826-6.raw |
SA089633 | CA209025-113-206 | CA209025-113-206_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 18.267 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 1045_Marios_PD1_Inhib2_HP-E9123619-6.raw |
SA089634 | CA209025-113-280 | CA209025-113-280_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 39.261 | Phase III_RCC_CA209025 | WESTERN EUROPE | 70 | M | WHITE | 0791_Marios_PD1_Inhib2_HP-E9123618-6.raw |
SA089631 | CA209025-113-570 | CA209025-113-570_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 27.893 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | F | WHITE | 0196_Marios_PD1_Inhib2_HP-E9123617-6.raw |
SA089688 | CA209025-118-163 | CA209025-118-163_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 41.232 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 0711_Marios_PD1_Inhib2_HP-EA044209-6.raw |
SA089653 | CA209025-126-101 | CA209025-126-101_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 4.534 | Phase III_RCC_CA209025 | WESTERN EUROPE | 56 | M | WHITE | 0950_Marios_PD1_Inhib2_HP-E9124113-6.raw |
SA089670 | CA209025-135-694 | CA209025-135-694_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 38.407 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | WHITE | 0199_Marios_PD1_Inhib2_HP-L1379654-6.raw |
SA089665 | CA209025-138-814 | CA209025-138-814_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 26.842 | Phase III_RCC_CA209025 | US/CANADA | 71 | M | WHITE | 0249_Marios_PD1_Inhib2_HP-AF004081-8.raw |
SA089664 | CA209025-138-847 | CA209025-138-847_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 25.134 | Phase III_RCC_CA209025 | US/CANADA | 76 | M | WHITE | 0969_Marios_PD1_Inhib2_HP-AF004079-8.raw |
SA089649 | CA209025-143-115 | CA209025-143-115_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.228 | Phase III_RCC_CA209025 | US/CANADA | 45 | M | WHITE | 0459_Marios_PD1_Inhib2_HP-AD645865-6.raw |
SA089669 | CA209025-143-423 | CA209025-143-423_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 24.181 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0192_Marios_PD1_Inhib2_HP-AE077157-6.raw |
SA089668 | CA209025-143-794 | CA209025-143-794_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.370 | Phase III_RCC_CA209025 | US/CANADA | 85 | M | WHITE | 0114_Marios_PD1_Inhib2_HP-AF015781-8.raw |
SA089660 | CA209025-151-351 | CA209025-151-351_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 35.121 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | F | WHITE | 0305_Marios_PD1_Inhib2_HP-EA251059-6.raw |
SA089661 | CA209025-15-379 | CA209025-15-379_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 21.750 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0699_Marios_PD1_Inhib2_HP-AE562616-6.raw |
SA089652 | CA209025-155-266 | CA209025-155-266_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.622 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | OTHER | 1203_Marios_PD1_Inhib2_HP-S3795568-6.raw |
SA089655 | CA209025-155-632 | CA209025-155-632_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 15.606 | Phase III_RCC_CA209025 | REST OF WORLD | 42 | M | OTHER | 0389_Marios_PD1_Inhib2_HP-S3947233-6.raw |
SA089659 | CA209025-156-136 | CA209025-156-136_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 45.897 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | M | OTHER | 1030_Marios_PD1_Inhib2_HP-S3509157-6.raw |
SA089658 | CA209025-1-5 | CA209025-1-5_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 16.460 | Phase III_RCC_CA209025 | US/CANADA | 78 | F | WHITE | 0750_Marios_PD1_Inhib2_HP-AD375474-6.raw |
SA089689 | CA209025-163-542 | CA209025-163-542_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 21.815 | Phase III_RCC_CA209025 | REST OF WORLD | 81 | M | OTHER | 0664_Marios_PD1_Inhib2_HP-S3940117-6.raw |
SA089686 | CA209025-1-682 | CA209025-1-682_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 35.975 | Phase III_RCC_CA209025 | US/CANADA | 60 | F | WHITE | 0743_Marios_PD1_Inhib2_HP-AE724953-6.raw |
SA089685 | CA209025-1-716 | CA209025-1-716_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 44.583 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 1073_Marios_PD1_Inhib2_HP-AE724955-6.raw |
SA089679 | CA209025-17-213 | CA209025-17-213_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 12.945 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0904_Marios_PD1_Inhib2_HP-AE104726-6.raw |
SA089678 | CA209025-17-327 | CA209025-17-327_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 30.324 | Phase III_RCC_CA209025 | US/CANADA | 47 | M | WHITE | 0063_Marios_PD1_Inhib2_HP-AE302160-7.raw |
SA089684 | CA209025-179-484 | CA209025-179-484_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.396 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | M | WHITE | 1214_Marios_PD1_Inhib2_HP-EA277677-6.raw |
SA089627 | CA209025-179-598 | CA209025-179-598_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 6.045 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0566_Marios_PD1_Inhib2_HP-E9758923-6.raw |
SA089626 | CA209025-180-936 | CA209025-180-936_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.195 | Phase III_RCC_CA209025 | REST OF WORLD | 53 | M | WHITE | 0374_Marios_PD1_Inhib2_HP-E9784769-6.raw |
SA089628 | CA209025-185-983 | CA209025-185-983_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.008 | Phase III_RCC_CA209025 | US/CANADA | 53 | F | WHITE | 1009_Marios_PD1_Inhib2_HP-AF016215-8.raw |
SA089680 | CA209025-1-997 | CA209025-1-997_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.534 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | WHITE | 0802_Marios_PD1_Inhib2_HP-AF365621-8.raw |
SA089646 | CA209025-20-59 | CA209025-20-59_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 12.747 | Phase III_RCC_CA209025 | US/CANADA | 64 | M | OTHER | 0862_Marios_PD1_Inhib2_HP-AD612912-6.raw |
SA089639 | CA209025-20-914 | CA209025-20-914_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.725 | Phase III_RCC_CA209025 | US/CANADA | 54 | M | WHITE | 0510_Marios_PD1_Inhib2_HP-AE710626-6.raw |
SA089620 | CA209025-2-199 | CA209025-2-199_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 10.448 | Phase III_RCC_CA209025 | WESTERN EUROPE | 36 | M | WHITE | 0008_Marios_PD1_Inhib2_HP-E9130960-6.raw |
SA089621 | CA209025-23-922 | CA209025-23-922_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 22.111 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0184_Marios_PD1_Inhib2_HP-AF002762-8.raw |
SA089638 | CA209025-25-1042 | CA209025-25-1042_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.429 | Phase III_RCC_CA209025 | US/CANADA | 75 | M | WHITE | 1212_Marios_PD1_Inhib2_HP-AF565867-8.raw |
SA089647 | CA209025-2-57 | CA209025-2-57_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 40.016 | Phase III_RCC_CA209025 | WESTERN EUROPE | 38 | M | WHITE | 0146_Marios_PD1_Inhib2_HP-E9657535-6.raw |
SA089648 | CA209025-26-559 | CA209025-26-559_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 10.645 | Phase III_RCC_CA209025 | US/CANADA | 51 | M | WHITE | 0998_Marios_PD1_Inhib2_HP-AE488975-6.raw |
SA089618 | CA209025-26-965 | CA209025-26-965_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 14.390 | Phase III_RCC_CA209025 | US/CANADA | 50 | M | WHITE | 0941_Marios_PD1_Inhib2_HP-AF003898-8.raw |
SA089643 | CA209025-27-915 | CA209025-27-915_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 8.706 | Phase III_RCC_CA209025 | US/CANADA | 74 | M | WHITE | 0232_Marios_PD1_Inhib2_HP-AF009274-8.raw |
SA089637 | CA209025-29-938 | CA209025-29-938_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.988 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 1006_Marios_PD1_Inhib2_HP-AF008976-8.raw |
SA089636 | CA209025-31-317 | CA209025-31-317_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 10.711 | Phase III_RCC_CA209025 | US/CANADA | 64 | F | WHITE | 0901_Marios_PD1_Inhib2_HP-AE467065-6.raw |
SA089641 | CA209025-3-253 | CA209025-3-253_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 22.209 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | F | WHITE | 0731_Marios_PD1_Inhib2_HP-E9101854-6.raw |
SA089625 | CA209025-33-12 | CA209025-33-12_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 24.608 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | M | WHITE | 0294_Marios_PD1_Inhib2_HP-E9101801-6.raw |
SA089629 | CA209025-33-257 | CA209025-33-257_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 38.801 | Phase III_RCC_CA209025 | WESTERN EUROPE | 80 | M | WHITE | 0932_Marios_PD1_Inhib2_HP-E9811947-6.raw |
SA089622 | CA209025-3-346 | CA209025-3-346_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 14.423 | Phase III_RCC_CA209025 | WESTERN EUROPE | 68 | M | WHITE | 0606_Marios_PD1_Inhib2_HP-E9101855-6.raw |
SA089644 | CA209025-37-93 | CA209025-37-93_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 36.403 | Phase III_RCC_CA209025 | WESTERN EUROPE | 57 | M | WHITE | 0532_Marios_PD1_Inhib2_HP-E9135875-6.raw |
SA089645 | CA209025-38-800 | CA209025-38-800_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 15.212 | Phase III_RCC_CA209025 | WESTERN EUROPE | 42 | M | WHITE | 0774_Marios_PD1_Inhib2_HP-E9134933-6.raw |
SA089635 | CA209025-42-46 | CA209025-42-46_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 13.109 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 1153_Marios_PD1_Inhib2_HP-AD452695-6.raw |
SA089640 | CA209025-42-919 | CA209025-42-919_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.359 | Phase III_RCC_CA209025 | US/CANADA | 59 | M | WHITE | 0244_Marios_PD1_Inhib2_HP-AE601514-6.raw |
SA089630 | CA209025-48-582 | CA209025-48-582_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 3.548 | Phase III_RCC_CA209025 | WESTERN EUROPE | 61 | M | WHITE | 1195_Marios_PD1_Inhib2_HP-EA344251-6.raw |
SA089623 | CA209025-48-736 | CA209025-48-736_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 23.195 | Phase III_RCC_CA209025 | WESTERN EUROPE | 54 | F | WHITE | 0277_Marios_PD1_Inhib2_HP-EA344250-6.raw |
SA089619 | CA209025-49-664 | CA209025-49-664_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 41.528 | Phase III_RCC_CA209025 | US/CANADA | 75 | M | WHITE | 0899_Marios_PD1_Inhib2_HP-AE673153-6.raw |
SA089632 | CA209025-49-79 | CA209025-49-79_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 13.339 | Phase III_RCC_CA209025 | US/CANADA | 39 | F | WHITE | 0144_Marios_PD1_Inhib2_HP-AE354856-10.raw |
SA089624 | CA209025-58-739 | CA209025-58-739_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 16.953 | Phase III_RCC_CA209025 | WESTERN EUROPE | 65 | F | OTHER | 0022_Marios_PD1_Inhib2_HP-EA395245-6.raw |
SA089657 | CA209025-58-74 | CA209025-58-74_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 15.376 | Phase III_RCC_CA209025 | WESTERN EUROPE | 85 | M | OTHER | 0654_Marios_PD1_Inhib2_HP-E9425623-5.raw |
SA089682 | CA209025-62-523 | CA209025-62-523_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 6.374 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 0651_Marios_PD1_Inhib2_HP-E9241323-6.raw |
SA089690 | CA209025-65-306 | CA209025-65-306_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.797 | Phase III_RCC_CA209025 | WESTERN EUROPE | 71 | M | WHITE | 0951_Marios_PD1_Inhib2_HP-E9778372-6.raw |
SA089681 | CA209025-69-810 | CA209025-69-810_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 17.084 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | F | WHITE | 0887_Marios_PD1_Inhib2_HP-EA715964-8.raw |
SA089677 | CA209025-70-617 | CA209025-70-617_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 3.943 | Phase III_RCC_CA209025 | REST OF WORLD | 78 | F | WHITE | 0477_Marios_PD1_Inhib2_HP-EA088456-6.raw |
SA089673 | CA209025-70-678 | CA209025-70-678_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 19.647 | Phase III_RCC_CA209025 | REST OF WORLD | 59 | M | WHITE | 0980_Marios_PD1_Inhib2_HP-E9784272-6.raw |
SA089675 | CA209025-70-845 | CA209025-70-845_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 11.236 | Phase III_RCC_CA209025 | REST OF WORLD | 60 | M | WHITE | 0873_Marios_PD1_Inhib2_HP-EA715508-8.raw |
SA089676 | CA209025-70-883 | CA209025-70-883_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 25.528 | Phase III_RCC_CA209025 | REST OF WORLD | 77 | M | WHITE | 0702_Marios_PD1_Inhib2_HP-EA715506-8.raw |
SA089683 | CA209025-72-211 | CA209025-72-211_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 4.895 | Phase III_RCC_CA209025 | WESTERN EUROPE | 84 | M | WHITE | 0673_Marios_PD1_Inhib2_HP-E9145496-6.raw |
SA089691 | CA209025-73-512 | CA209025-73-512_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 11.565 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | WHITE | 0913_Marios_PD1_Inhib2_HP-E9106383-6.raw |
SA089687 | CA209025-73-645 | CA209025-73-645_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 9.166 | Phase III_RCC_CA209025 | WESTERN EUROPE | 67 | M | WHITE | 0657_Marios_PD1_Inhib2_HP-EA474551-6.raw |
SA089674 | CA209025-80-184 | CA209025-80-184_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 19.581 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0649_Marios_PD1_Inhib2_HP-E9433499-6.raw |
SA089671 | CA209025-80-265 | CA209025-80-265_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 16.920 | Phase III_RCC_CA209025 | WESTERN EUROPE | 58 | M | WHITE | 0579_Marios_PD1_Inhib2_HP-EA083058-6.raw |
SA089656 | CA209025-80-656 | CA209025-80-656_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 8.279 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 0809_Marios_PD1_Inhib2_HP-EA456769-5.raw |
SA089672 | CA209025-80-824 | CA209025-80-824_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 14.982 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | WHITE | 1001_Marios_PD1_Inhib2_HP-EA813062-6.raw |
SA089654 | CA209025-82-506 | CA209025-82-506_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.205 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 0674_Marios_PD1_Inhib2_HP-E9703917-6.raw |
SA089651 | CA209025-84-894 | CA209025-84-894_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 5.651 | Phase III_RCC_CA209025 | REST OF WORLD | 49 | M | WHITE | 0821_Marios_PD1_Inhib2_HP-L1448910-11.raw |
SA089667 | CA209025-90-247 | CA209025-90-247_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 8.871 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | F | WHITE | 0104_Marios_PD1_Inhib2_HP-E9792547-6.raw |
SA089666 | CA209025-93-460 | CA209025-93-460_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 13.865 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | F | WHITE | 0690_Marios_PD1_Inhib2_HP-EA214041-6.raw |
SA089662 | CA209025-95-318 | CA209025-95-318_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 20.764 | Phase III_RCC_CA209025 | REST OF WORLD | 70 | M | WHITE | 0764_Marios_PD1_Inhib2_HP-S3792628-6.raw |
SA089663 | CA209025-95-721 | CA209025-95-721_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | FALSE | 5.684 | Phase III_RCC_CA209025 | REST OF WORLD | 49 | M | WHITE | 0574_Marios_PD1_Inhib2_HP-S4110491-8.raw |
SA089694 | CA209025-126-149 | CA209025-126-149_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 21.388 | Phase III_RCC_CA209025 | WESTERN EUROPE | 59 | M | WHITE | 0309_Marios_PD1_Inhib2_HP-E9124112-6.raw |
SA089693 | CA209025-138-480 | CA209025-138-480_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 28.255 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0612_Marios_PD1_Inhib2_HP-AE428483-6.raw |
SA089692 | CA209025-138-619 | CA209025-138-619_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 16.723 | Phase III_RCC_CA209025 | US/CANADA | 73 | M | WHITE | 0858_Marios_PD1_Inhib2_HP-AE428482-6.raw |
SA089701 | CA209025-139-989 | CA209025-139-989_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 26.086 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0122_Marios_PD1_Inhib2_HP-AF438577-8.raw |
SA089696 | CA209025-158-183 | CA209025-158-183_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 19.023 | Phase III_RCC_CA209025 | REST OF WORLD | 51 | F | OTHER | 0946_Marios_PD1_Inhib2_HP-S3653087-6.raw |
SA089698 | CA209025-160-786 | CA209025-160-786_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 8.904 | Phase III_RCC_CA209025 | REST OF WORLD | 74 | F | OTHER | 0854_Marios_PD1_Inhib2_HP-S4103654-7.raw |
SA089700 | CA209025-164-901 | CA209025-164-901_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 25.823 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | F | OTHER | 0356_Marios_PD1_Inhib2_HP-S4093211-8.raw |
SA089699 | CA209025-166-957 | CA209025-166-957_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 13.963 | Phase III_RCC_CA209025 | REST OF WORLD | 68 | M | OTHER | 1033_Marios_PD1_Inhib2_HP-S4152611-8.raw |
SA089695 | CA209025-23-20 | CA209025-23-20_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 43.335 | Phase III_RCC_CA209025 | US/CANADA | 66 | F | WHITE | 0816_Marios_PD1_Inhib2_HP-AD490513-6.raw |
SA089697 | CA209025-23-72 | CA209025-23-72_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 13.175 | Phase III_RCC_CA209025 | US/CANADA | 77 | M | WHITE | 0515_Marios_PD1_Inhib2_HP-AD461620-6.raw |
SA089711 | CA209025-27-906 | CA209025-27-906_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 17.150 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 1187_Marios_PD1_Inhib2_HP-AF009275-8.raw |
SA089713 | CA209025-39-150 | CA209025-39-150_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 14.324 | Phase III_RCC_CA209025 | WESTERN EUROPE | 53 | M | OTHER | 1133_Marios_PD1_Inhib2_HP-E9210504-6.raw |
SA089715 | CA209025-44-785 | CA209025-44-785_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 26.316 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0098_Marios_PD1_Inhib2_HP-AF016227-8.raw |
SA089705 | CA209025-48-284 | CA209025-48-284_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 15.836 | Phase III_RCC_CA209025 | WESTERN EUROPE | 74 | M | WHITE | 0158_Marios_PD1_Inhib2_HP-EA344248-6.raw |
SA089706 | CA209025-48-500 | CA209025-48-500_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 5.552 | Phase III_RCC_CA209025 | WESTERN EUROPE | 69 | M | WHITE | 0028_Marios_PD1_Inhib2_HP-EA344247-6.raw |
SA089714 | CA209025-63-790 | CA209025-63-790_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 8.706 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | F | WHITE | 0265_Marios_PD1_Inhib2_HP-E9241183-6.raw |
SA089704 | CA209025-79-73 | CA209025-79-73_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 45.175 | Phase III_RCC_CA209025 | REST OF WORLD | 48 | F | WHITE | 0989_Marios_PD1_Inhib2_HP-L1293277-5.raw |
SA089707 | CA209025-82-139 | CA209025-82-139_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 4.370 | Phase III_RCC_CA209025 | WESTERN EUROPE | 56 | F | WHITE | 0372_Marios_PD1_Inhib2_HP-E9190484-6.raw |
SA089712 | CA209025-82-355 | CA209025-82-355_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 4.205 | Phase III_RCC_CA209025 | WESTERN EUROPE | 62 | M | WHITE | 0099_Marios_PD1_Inhib2_HP-E9190485-6.raw |
SA089709 | CA209025-89-129 | CA209025-89-129_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 4.304 | Phase III_RCC_CA209025 | WESTERN EUROPE | 52 | F | WHITE | 0864_Marios_PD1_Inhib2_HP-E9103856-6.raw |
SA089708 | CA209025-90-30 | CA209025-90-30_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 9.593 | Phase III_RCC_CA209025 | WESTERN EUROPE | 74 | F | WHITE | 0384_Marios_PD1_Inhib2_HP-E9103104-6.raw |
SA089703 | CA209025-9-754 | CA209025-9-754_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 34.037 | Phase III_RCC_CA209025 | US/CANADA | 71 | M | WHITE | 1100_Marios_PD1_Inhib2_HP-AF002794-8.raw |
SA089702 | CA209025-97-569 | CA209025-97-569_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 29.766 | Phase III_RCC_CA209025 | REST OF WORLD | 65 | M | OTHER | 0500_Marios_PD1_Inhib2_HP-S3722563-6.raw |
SA089710 | CA209025-98-673 | CA209025-98-673_week 8 | week 8 | - | INTERMEDIATE | NIVOLUMAB | TRUE | 11.499 | Phase III_RCC_CA209025 | REST OF WORLD | 76 | F | WHITE | 0883_Marios_PD1_Inhib2_HP-S3862099-7.raw |
SA089720 | CA209025-102-86 | CA209025-102-86_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 11.729 | Phase III_RCC_CA209025 | WESTERN EUROPE | 56 | M | WHITE | 0494_Marios_PD1_Inhib2_HP-E9191097-6.raw |
SA089745 | CA209025-11-482 | CA209025-11-482_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 4.501 | Phase III_RCC_CA209025 | US/CANADA | 66 | F | OTHER | 0461_Marios_PD1_Inhib2_HP-AE487827-6.raw |
SA089731 | CA209025-119-192 | CA209025-119-192_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 34.333 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | F | WHITE | 0686_Marios_PD1_Inhib2_HP-E9124259-6.raw |
SA089719 | CA209025-125-647 | CA209025-125-647_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 35.253 | Phase III_RCC_CA209025 | REST OF WORLD | 54 | M | WHITE | 0813_Marios_PD1_Inhib2_HP-L1426709-6.raw |
SA089732 | CA209025-12-65 | CA209025-12-65_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 28.058 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | M | WHITE | 0705_Marios_PD1_Inhib2_HP-E9124691-6.raw |
SA089736 | CA209025-13-111 | CA209025-13-111_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 25.002 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0571_Marios_PD1_Inhib2_HP-AE059528-6.raw |
SA089738 | CA209025-143-515 | CA209025-143-515_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 9.068 | Phase III_RCC_CA209025 | US/CANADA | 60 | M | WHITE | 0616_Marios_PD1_Inhib2_HP-AF015780-8.raw |
SA089744 | CA209025-144-451 | CA209025-144-451_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 22.439 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | WHITE | 0252_Marios_PD1_Inhib2_HP-AE506729-6.raw |
SA089753 | CA209025-144-596 | CA209025-144-596_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 22.867 | Phase III_RCC_CA209025 | US/CANADA | 53 | M | WHITE | 0641_Marios_PD1_Inhib2_HP-AE673812-6.raw |
SA089751 | CA209025-153-416 | CA209025-153-416_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 5.092 | Phase III_RCC_CA209025 | US/CANADA | 66 | M | WHITE | 0964_Marios_PD1_Inhib2_HP-AE613294-6.raw |
SA089722 | CA209025-165-83 | CA209025-165-83_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 27.368 | Phase III_RCC_CA209025 | REST OF WORLD | 72 | M | OTHER | 0035_Marios_PD1_Inhib2_HP-S3475421-6.raw |
SA089721 | CA209025-179-521 | CA209025-179-521_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 6.439 | Phase III_RCC_CA209025 | WESTERN EUROPE | 49 | M | WHITE | 1136_Marios_PD1_Inhib2_HP-EA277675-6.raw |
SA089726 | CA209025-17-981 | CA209025-17-981_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 27.926 | Phase III_RCC_CA209025 | US/CANADA | 57 | M | WHITE | 0630_Marios_PD1_Inhib2_HP-AF015805-8.raw |
SA089748 | CA209025-20-781 | CA209025-20-781_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 36.961 | Phase III_RCC_CA209025 | US/CANADA | 48 | M | WHITE | 0286_Marios_PD1_Inhib2_HP-AF002825-8.raw |
SA089746 | CA209025-21-1050 | CA209025-21-1050_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 25.988 | Phase III_RCC_CA209025 | US/CANADA | 65 | M | WHITE | 0452_Marios_PD1_Inhib2_HP-AF667456-8.raw |
SA089750 | CA209025-21-308 | CA209025-21-308_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 18.300 | Phase III_RCC_CA209025 | US/CANADA | 55 | M | WHITE | 0134_Marios_PD1_Inhib2_HP-AE206924-6.raw |
SA089735 | CA209025-23-9 | CA209025-23-9_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 12.255 | Phase III_RCC_CA209025 | US/CANADA | 69 | M | WHITE | 0449_Marios_PD1_Inhib2_HP-AD461621-6.raw |
SA089743 | CA209025-25-130 | CA209025-25-130_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 13.602 | Phase III_RCC_CA209025 | US/CANADA | 63 | M | WHITE | 0317_Marios_PD1_Inhib2_HP-AD610067-6.raw |
SA089740 | CA209025-25-987 | CA209025-25-987_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 10.218 | Phase III_RCC_CA209025 | US/CANADA | 85 | M | WHITE | 0195_Marios_PD1_Inhib2_HP-AF009262-8.raw |
SA089723 | CA209025-27-566 | CA209025-27-566_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 9.593 | Phase III_RCC_CA209025 | US/CANADA | 58 | M | WHITE | 0457_Marios_PD1_Inhib2_HP-AE302635-6.raw |
SA089718 | CA209025-2-76 | CA209025-2-76_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 20.403 | Phase III_RCC_CA209025 | WESTERN EUROPE | 48 | F | WHITE | 0136_Marios_PD1_Inhib2_HP-E9657534-6.raw |
SA089739 | CA209025-30-695 | CA209025-30-695_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 9.528 | Phase III_RCC_CA209025 | US/CANADA | 62 | F | WHITE | 0235_Marios_PD1_Inhib2_HP-AE817161-6.raw |
SA089734 | CA209025-33-7 | CA209025-33-7_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 20.698 | Phase III_RCC_CA209025 | WESTERN EUROPE | 30 | F | WHITE | 0542_Marios_PD1_Inhib2_HP-E9101803-6.raw |
SA089737 | CA209025-39-102 | CA209025-39-102_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 11.663 | Phase III_RCC_CA209025 | WESTERN EUROPE | 68 | M | WHITE | 1011_Marios_PD1_Inhib2_HP-E9210506-6.raw |
SA089733 | CA209025-42-316 | CA209025-42-316_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 6.538 | Phase III_RCC_CA209025 | US/CANADA | 52 | M | WHITE | 0210_Marios_PD1_Inhib2_HP-AE155091-6.raw |
SA089729 | CA209025-61-146 | CA209025-61-146_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 13.437 | Phase III_RCC_CA209025 | WESTERN EUROPE | 66 | M | WHITE | 0706_Marios_PD1_Inhib2_HP-E9240792-6.raw |
SA089724 | CA209025-62-225 | CA209025-62-225_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 8.312 | Phase III_RCC_CA209025 | WESTERN EUROPE | 42 | M | WHITE | 0394_Marios_PD1_Inhib2_HP-E9241321-6.raw |
SA089725 | CA209025-70-347 | CA209025-70-347_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 42.382 | Phase III_RCC_CA209025 | REST OF WORLD | 71 | M | WHITE | 0297_Marios_PD1_Inhib2_HP-EA088461-6.raw |
SA089727 | CA209025-71-709 | CA209025-71-709_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 17.051 | Phase III_RCC_CA209025 | REST OF WORLD | 68 | M | WHITE | 1184_Marios_PD1_Inhib2_HP-EA444380-6.raw |
SA089728 | CA209025-73-178 | CA209025-73-178_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 15.343 | Phase III_RCC_CA209025 | WESTERN EUROPE | 51 | M | WHITE | 0919_Marios_PD1_Inhib2_HP-E9106380-6.raw |
SA089717 | CA209025-82-302 | CA209025-82-302_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 5.027 | Phase III_RCC_CA209025 | WESTERN EUROPE | 63 | M | WHITE | 0787_Marios_PD1_Inhib2_HP-E9703915-6.raw |
SA089749 | CA209025-85-940 | CA209025-85-940_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 9.331 | Phase III_RCC_CA209025 | REST OF WORLD | 76 | M | WHITE | 1102_Marios_PD1_Inhib2_HP-L1453016-8.raw |
SA089747 | CA209025-85-992 | CA209025-85-992_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 13.339 | Phase III_RCC_CA209025 | REST OF WORLD | 58 | M | WHITE | 1016_Marios_PD1_Inhib2_HP-L1497984-11.raw |
SA089716 | CA209025-8-628 | CA209025-8-628_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 44.386 | Phase III_RCC_CA209025 | WESTERN EUROPE | 73 | M | WHITE | 0481_Marios_PD1_Inhib2_HP-E9125208-6.raw |
SA089752 | CA209025-89-34 | CA209025-89-34_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 48.526 | Phase III_RCC_CA209025 | WESTERN EUROPE | 60 | M | WHITE | 0431_Marios_PD1_Inhib2_HP-E9103858-6.raw |
SA089742 | CA209025-95-331 | CA209025-95-331_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 46.686 | Phase III_RCC_CA209025 | REST OF WORLD | 62 | M | WHITE | 0119_Marios_PD1_Inhib2_HP-S3792627-6.raw |
SA089741 | CA209025-95-681 | CA209025-95-681_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 4.862 | Phase III_RCC_CA209025 | REST OF WORLD | 66 | M | WHITE | 0523_Marios_PD1_Inhib2_HP-S4110494-8.raw |
SA089730 | CA209025-98-547 | CA209025-98-547_week 8 | week 8 | - | POOR | NIVOLUMAB | FALSE | 9.396 | Phase III_RCC_CA209025 | REST OF WORLD | 48 | F | WHITE | 0693_Marios_PD1_Inhib2_HP-S4110018-8.raw |
SA089763 | CA209025-139-1025 | CA209025-139-1025_week 8 | week 8 | - | POOR | NIVOLUMAB | TRUE | 6.209 | Phase III_RCC_CA209025 | US/CANADA | 72 | F | WHITE | 0852_Marios_PD1_Inhib2_HP-AF438576-8.raw |
SA089757 | CA209025-139-140 | CA209025-139-140_week 8 | week 8 | - | POOR | NIVOLUMAB | TRUE | 45.470 | Phase III_RCC_CA209025 | US/CANADA | 70 | M | WHITE | 0256_Marios_PD1_Inhib2_HP-AD783023-6.raw |
SA089754 | CA209025-139-359 | CA209025-139-359_week 8 | week 8 | - | POOR | NIVOLUMAB | TRUE | 32.723 | Phase III_RCC_CA209025 | US/CANADA | 61 | M | WHITE | 0948_Marios_PD1_Inhib2_HP-AE490137-6.raw |
SA089755 | CA209025-158-70 | CA209025-158-70_week 8 | week 8 | - | POOR | NIVOLUMAB | TRUE | 26.711 | Phase III_RCC_CA209025 | REST OF WORLD | 39 | F | OTHER | 0002_Marios_PD1_Inhib2_HP-S3473963-6.raw |
SA089762 | CA209025-25-930 | CA209025-25-930_week 8 | week 8 | - | POOR | NIVOLUMAB | TRUE | 7.655 | Phase III_RCC_CA209025 | US/CANADA | 56 | M | WHITE | 0044_Marios_PD1_Inhib2_HP-AF009261-8.raw |
SA089759 | CA209025-41-485 | CA209025-41-485_week 8 | week 8 | - | POOR | NIVOLUMAB | TRUE | 7.491 | Phase III_RCC_CA209025 | US/CANADA | 71 | M | WHITE | 0345_Marios_PD1_Inhib2_HP-AE525983-24.raw |
SA089761 | CA209025-56-522 | CA209025-56-522_week 8 | week 8 | - | POOR | NIVOLUMAB | TRUE | 4.731 | Phase III_RCC_CA209025 | WESTERN EUROPE | 40 | M | WHITE | 0830_Marios_PD1_Inhib2_HP-E9106996-6.raw |
SA089760 | CA209025-62-552 | CA209025-62-552_week 8 | week 8 | - | POOR | NIVOLUMAB | TRUE | 3.253 | Phase III_RCC_CA209025 | WESTERN EUROPE | 50 | M | WHITE | 1220_Marios_PD1_Inhib2_HP-E9241319-6.raw |
SA089758 | CA209025-69-539 | CA209025-69-539_week 8 | week 8 | - | POOR | NIVOLUMAB | TRUE | 18.136 | Phase III_RCC_CA209025 | REST OF WORLD | 54 | F | WHITE | 0281_Marios_PD1_Inhib2_HP-EA350205-6.raw |
SA089756 | CA209025-89-132 | CA209025-89-132_week 8 | week 8 | - | POOR | NIVOLUMAB | TRUE | 10.218 | Phase III_RCC_CA209025 | WESTERN EUROPE | 64 | M | WHITE | 0221_Marios_PD1_Inhib2_HP-E9103859-6.raw |